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Abstract 
 
The cardiac sodium/calcium exchanger (NCX1) regulates intracellular Ca2+ in cardiac 
muscle. Inappropriate NCX1 function contributes to cardiac contractile abnormalities 
and heart failure; reduced NCX1 activity reduces Ca removal therefore impairing 
relaxation, whereas overactive NCX1 unloads intracellular Ca stores and impairs 
systolic function. Although the structure-function relationship is well characterised, 
dynamic regulation of NCX1 function by post-translational modifications is 
controversial.  
 
The dynamic reversible post-translational modification of cysteine residues with the 16-
carbon fatty acid palmitate in proteins is an important and common post-translational 
modification in a variety of tissues. The cardiac palmitoyl proteome is largely 
uncharacterised. Few proteins have been identified as palmitoylated, for example the 
sodium pump regulator, phospholemman (Tulloch et al. 2011). 
 
Palmitoylation of NCX1 was investigated in isolated adult rat ventricular myocytes 
(ARVM), using site-specific resin assisted capture (Acyl Rac). Acyl rac purified 100% 
of the constitutively palmitoylated protein, caveolin-3 from ARVM lysates, and 60% of 
NCX1, indicating a biologically meaningful fraction of NCX1 is palmitoylated in 
ventricular muscle. Mutagenesis of selected cysteine residues revealed that Cys739, 
which is located in the large intracellular loop domain, is the principal palmitoylation 
site in NCX1. Palmitoylation is required to anchor this domain to membranes, and 
occurs in the secretory pathway. Co-immunoprecipitation of NCX1 with Golgi resident 
DHHC-containing enzymes revealed DHHC5, DHHC9, DHHC12 and DHHC18 are 
associated with NCX1 in HEK293 cells. Mutation of the active cysteine in DHHC5, 9, 
12 and 18 to serine revealed that DHHC9 and DHHC18 are important for NCX1 
palmitoylation.  
 
Measurement of NCX1 cell surface localisation using membrane impermeable 
biotinylation reagents revealed that palmitoylation was not required for trafficking of 
NCX1 to the cell surface membrane. The effect of palmitoylation on NCX1 exchange 
activity was measured using whole cell electrophysiology. Measurement of the current-
voltage relationship of NCX1 revealed that palmitoylation significantly reduced 
outward current measured at positive membrane potentials. Finally, NCX1 
! xxi 
palmitoylation was not significantly changed in in vivo models of left ventricular heart 
failure and cardiac hypertrophy. In conclusion, palmitoylation of NCX1 influences its 
transport function and occurs in the secretory pathway. 
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Chapter 1 Introduction 
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1.1 Cardiac Ion Transport 
 
The appropriate regulation of the ion transporters present in cardiac muscle is vital for 
the maintenance of normal electrical activity, ion gradients and thus cardiac output. 
There are several ion transport systems present in cardiac tissue that contribute to the 
maintenance of ion gradients. The Na+-Ca2+ exchanger is just one of these transport 
systems. 
 
 
 
Figure 1.1: The Transport Of Ca2+ In Ventricular Myocytes. Membrane 
depolarisation due to the influx of Na+ via voltage-gated Na+ channels, results in the 
influx of Ca2+ via the activation of voltage-senstive Ca2+ channels. This triggers Ca2+ 
release from intracellular stores, which binds to the contractile machinery to initiate 
contraction. This Ca2+ is then exported out of the cell by the Na+-Ca2+ exchanger, into 
the SR by the sarcoplasmic reticulum Ca2+ ATPase and into the mitochondria by the 
mitochondrial Ca2+ uniporter. The inset shows the action potential, Ca2+ transient and 
contraction in a rabbit myocytes at 37˚C. Modified from (Bers 2002). 
 
As shown in figure 1.1, the contraction cycle of the cardiac myocyte is a complex 
process, depending entirely on the unique interaction of a variety of ion transporters and 
channels to maintain correct Ca2+ homeostasis during the action potential and 
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afterwards to initiate relaxation. The Na+-Ca2+ exchanger is predominantly involved in 
extruding Ca2+ from the cell following a rise in cytoplasmic levels after an action 
potential. The action potential initiates in the sinoatrial node and propagates through the 
atria then to the ventricles. This activates Na+ channels and the influx of Na+ results in 
membrane depolarisation, thus activating voltage-gated Ca2+ channels and allowing 
Ca2+ to enter the cell. Ca2+ binds to ryanodine receptors located on the sarcoplasmic 
reticulum, and yet more Ca2+ is released into the cytoplasm. This free Ca2+ binds to the 
contractile machinery within the myocytes and initiates contraction. The Na+/Ca2+ 
exchanger works together with the sarcoplasmic reticulum Ca2+-ATPase (SERCA) to 
remove Ca2+ from the cytoplasm triggers relaxation. Na+ brought in by the exchanger is 
removed via the Na+ pump. 
 
1.1.1 SLC8 – Na+-Ca2+ Exchanger Family 
 
The Na+-Ca2+ exchanger, NCX1, present in cardiac cells, is a member of the Na+-Ca2+ 
exchanger family. All members of this family share a large percentage of homology, 
particularly in the transmembrane domains (Philipson & Nicoll 2000). There is 68% 
identity between NCX1 and 2, 73% between 1 and 3 and 75% between 2 and 3  (Nicoll, 
Quednau, et al. 1996b). There are 3 known mammalian Na+-Ca2+ exchangers, 
collectively known as SLC8 (Philipson et al. 2004). The family members, NCX1, 
NCX2 and NCX3 are products of distinct, separate genes (Nicoll, Quednau, et al. 
1996b). Despite not showing any major differences in functionality, the expression of 
these three family members is quite distinct (Linck et al. 1998). NCX1 mRNA is found 
in virtually all cell types, whereas NCX2 and 3 have only been detected in brain and 
skeletal muscle (Linck et al. 1998).  
 
In cardiomyocytes, NCX1, is expressed on surface and T-tubular sarcolemma 
(Philipson et al. 2004). In the rat brain, NCX1 is expressed in a regional pattern and is 
localised to discrete sites on the plasmalemma, some of which are in close proximity 
with intracellular Ca2+ stores (S. L. Lee et al. 1994; Philipson et al. 2004). In addition, 
NCX1, 2 and 3 proteins are expressed in a cell-specific fashion, to distinct regions of 
the rat brain (Quednau, Nicoll & Philipson 1997a; Thurneysen et al. 2002). NCX1 and 3 
are expressed in the sarcolemma of rat skeletal muscle, in a way that is muscle fibre-
specific (Deval et al. 2000; Fraysse et al. 2001). Differences in contractile responses 
between slow-twitch and fast-twitch muscle fibres was demonstrated by Léoty, in which 
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slow-twitch fibres displayed contraction in the absence of Na+, unlike the fast-twitch 
fibres (Léoty 1984; Deval et al. 2000). This suggests that contraction within fast-twitch 
fibres is dependent upon NCX1. It is unclear whether NCX1, 2 and 3 have unique 
functions in each of the cell types in which they are expressed. 
 
1.1.2 Structural Features Of NCX 
 
The first Na+-Ca2+ exchanger to be extensively studied was NCX1, which was isolated 
from cardiac sarcolemma (Nicoll et al. 1990). NCX1 was first proposed to have 12 
transmembrane domains, however subsequent analysis revealed that the first 32 amino 
acids, which form a hydrophobic segment, is a signal peptide that is cleaved during 
processing in the endoplasmic reticulum (Durkin et al. 1991; Hryshko et al. 1993). This 
first model of the exchanger was based on hydropathy analysis and was not confirmed 
experimentally. It was subsequently proposed by Nicoll and colleagues that the mature 
protein contains 9 transmembrane segments (TMS) (Figure 1.2) (Nicoll et al. 1999). 
These transmembrane segments are arranged into two sets, separated by a large 
intracellular loop of approximately 550 amino acids (Nicoll et al. 1990; Nicoll et al. 
1999) located between transmembrane segments 5 and 6. At the N terminus, there are 5 
hydrophobic TMS, whereas at the C terminus, there are 4 hydrophobic TMS.  
 
Interestingly, there are regions of NCX1 that show intramolecular homology. The 
sequence that extends between TMS 2 and 3 shares homology with the sequence that 
extends between TMS 7 and the non-transmembrane segment (see figure 1.2) 
(Shigekawa & Iwamoto 2001; Schwarz & Benzer 1997). The regions of similarity are 
the α-repeats, termed α1 and α2 respectively. These repeat regions are conserved in all 
members of the SLC8 family, suggesting functional importance (Shigekawa & Iwamoto 
2001). The large intracellular loop also contains repeated regions, which are termed the 
β repeats, β1 and β2, being regions of approximately 70 amino acids. Strikingly, these β 
repeats share homology with the cytoplasmic region of β4 integrin (Schwarz & Benzer 
1997). In addition to the β repeats, the intracellular loop contains other areas that 
contribute to the regulation of the exchanger. At the N-terminal end of the loop, there is 
an autoinhibitory region consisting of approximately 20 amino acids, termed the 
endogenous exchanger inhibitory peptide (XIP) region (Li et al. 1991). Close to the C-
terminal end of the XIP region, there is a region of approximately 135 amino acids, 
which has been shown to confer a high affinity Ca2+ binding site (Levitsky et al. 1994) 
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(this will be discussed in more detail in following sections). Also contained within the 
intracellular loop is a region that undergoes alternative splicing (S. L. Lee et al. 1994). 
This region is encoded by six small exons (labelled A to F), which are expressed in 
different combinations in a tissue specific manner (Dipolo & Beaugé 2006). Exon A or 
B, which are essential to maintaining an open reading frame, must be included in all 
splice variants. Excitable tissues, such as the heart, generally have exchangers that 
contain exon A, whereas exon B is present in virtually all other tissues. The cardiac 
splice variant, NCX1.1 contains exons ACDEF. Finally, between TMS 7 and 8 there is 
a hydrophobic domain that is proposed to form a re-entrant membrane loop, similar to 
the pore-forming region of ion channels (Nicoll et al. 1990; Dipolo & Beaugé 2006; 
Bers 2002; Nicoll et al. 1999). In the centre of the sequence, there is a GIG sequence, 
showing resemblance to the GYG motif that is found in K+ channels. 
 
 
 
Figure 1.2: Schematic Structure Of Na+-Ca2+ Exchanger. The current topological 
model for the structure of the Na+-Ca2+ shows 9 transmembrane segments, separated by 
a large intracellular loop. The α1- and α2-repeat regions are shown, forming reentrant 
loops between TMS 2 and 3 and TMS 7 and 8 respectively. Also shown is the XIP 
region. The β-1 and β-2 repeats are now known to contain the Ca2+ binding sites 
followed by the region where alternative splicing occurs. Modified from (Shigekawa & 
Iwamoto 2001). 
 
Difficulties in producing large amounts of pure functional protein and crystallising 
membrane proteins in general mean that there is no crystal structure for mammalian 
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NCX as yet. However, studies from Philipson’s group investigating the helix packaging 
of the exchanger have revealed some interesting insights into the possible 3D structure 
of this protein. In the first of 3 studies from this group, utilising cysteine mutagenesis 
and oxidative cross-linking, the proximity of the TMS to one another was investigated. 
Cysteine pairs were re-introduced into a cysteine-less exchanger, one in the N-terminal 
half and one in the C-terminal half, then expressed in HEK293 cells and spontaneous 
disulphide bond formation examined by gel mobility shifts (Qiu et al. 2001). This 
revealed that mutants S117C/V804C, A122C/Y892C, A151C/T815C and 
A151C/A821C shifted from 120kDa to 160kDa under non-reducing conditions, 
indicating the presence of a disulphide bond between the cysteines. These cysteine 
residues are located in TMS 2, 3, 7 and 8 (now thought to be TMS 9, see following 
section) (see figure 1.3 for further details), indicating that TMS7 is close to TMS3 near 
the intracellular side of the membrane and is also in close proximity to TMS2 near the 
extracellular side (Qiu et al. 2001). They also propose that TMS2 must form a 
disulphide bond with TMS8 in their mutant exchangers, suggesting that these two TMS 
are in close proximity in the native exchanger. These results indicate that the α-repeats 
are close to each other, pointing towards a role in ion translocation. Figure 1.3 shows 
the proposed packing of the TMS in the exchanger based on these experiments. 
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acid residues in length) that is capable of undergoing dramatic
conformational changes (22). The conformation of loop f may
contribute to the variation in apparent molecular mass of the
exchanger. Under reducing conditions, when there is no disul-
fide bond connecting the two TMS clusters, loop f may form a
more compact structure, and the exchanger migrates as a 120-
kDa band. When a disulfide bond between the two TMS clus-
ters brings helices into a more tightly packed bundle, loop f
may extend further from the membrane. This “parachute” ef-
fect may result in the mobility shift to 160 kDa under nonre-
ducing conditions.
By introducing paired cysteine residues back into the cys-
less background, one in each half of the protein, we show here
that a number of exchanger mutants also displayed a mobility
shift under nonreducing conditions (Fig. 3). This implies that
spontaneous disulfide bond formation occurs between the in-
troduced paired cysteines. Treatment with CuPhe significantly
enhanced the mobility shift. Thus, the mobility shift provides a
useful tool to study proximity relationships of transmembrane
helices in the exchanger.
We screened a total of 66 exchanger mutants with double
cysteines (Table I). Four pairs induced mobility shifts that were
enhanced with cross-linking reagents (Figs. 3 and 4). Based on
these data, we propose an initial packing model for TMSs 2, 3,
7, and 8 of the exchanger (Fig. 6). Disulfide bond formation
between S117C and V804C indicates that TMS7 is in close
proximity to TMS2 at the extracellular side of the membrane.
At the intracellular side of the membrane, TMS7 is in the
vicinity of TMS3 as indicated by cross-linking of A151C/A821C.
Furthermore, residues Cys-804 and Cys-821 in TMS7, which
are adjacent to TMS2 and TMS3, are located on the same
surface of TMS7 (Fig. 6) according to helical wheel modeling.
This suggests that the same surface of TMS7 interacts with
TMS2 at the extracellular and TMS3 at the intracellular side of
the membrane. Possibly TMS7 tilts in the membrane between
TMSs 2 and 3 or has a bend. A proline residue at position 813
in the center of TMS7 may facilitate a nonhelical structure
and/or a bend. On this surface of TMS7, mutations S811T (15),
FIG. 4. Cross-linking of exchanger mutants displaying mobil-
ity shifts. Crude membrane vesicles from transfected HEK cells were
treated with CuPhe (3 mM), o-PDM (0.5 mM), or p-PDM (0.5 mM) for 20
min at 20 °C. Proteins were separated by SDS-PAGE under Non-reduc-
ing or Reducing conditions and transferred to nitrocellulose membrane.
Exchanger protein was detected using anti-exchanger antibodies and
chemiluminescence as described under “Experimental Procedures”.
TABLE II
Quantification of cross-linking efficiency
Intensities of the 120- and 160-kDa exchanger protein bands on
immunoblots (Fig. 4; nonreducing conditions) were quantified by den-
sitometry using the AlphaImager system. Data (mean! S.E.; n" 3) are
the percentage of the 160 kDa band compared to total exchanger protein
bands (120 # 160 kDa).
Mutants Nontreated CuPhe o-PDM p-PDM
S117C/V804C 13.6 ! 4.3 21.3 ! 3.5 34.5 ! 8.9 14.9 ! 4.6
A122C/Y892C 5.3 ! 3.5 37.2 ! 5.8 48.3 ! 12.4 21.6 ! 4.5
A151C/A821C 14.5 ! 3.8 61.2 ! 11.4 63.3 ! 7.8 29.2 ! 6.6
Cys-less 0.9 ! 0.5 0.8 ! 0.6 0.5 ! 0.4 0.8 ! 0.3
FIG. 5. Exchanger activity of selected cysteine mutants. HEK
cells were transfected with exchanger mutant cDNAs carrying single or
double cysteines reintroduced into the cys-less exchanger. 48–72 h after
transfection, exchanger activity was assayed using a whole cell 45Ca2#
uptake protocol and normalized to activity of the wild type exchanger.
FIG. 6. Model of the TMS packing in the cardiac Na!-Ca2!
exchanger. Sideview of four key TMSs of the Na#-Ca2# exchanger
based on cross-linking data. The model constrains the two proposed
P-loops of the exchanger (Fig. 1) to be in close proximity. Also, the
!-repeats (Fig. 1) would face one another. The cytoplasmic surface
would be at the bottom.
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Figure 1.3: H lix Packing Of TMS 2, 3, 7 And 8 In The Cardiac Na+-Ca2+ 
Exchanger. Proposed model of the proximity of TMS of NCX based on cross-linking 
data by Qiu et al. Also shown are the reentrant loops of the α-repeats, which are 
modelled to be in close proximity and would face one another. The cyt plasmic surface 
is at the bottom of the model. Modified from (Qiu et al. 2001). 
 
A follow up study by the same group sought t  elucidate the position of the other TMS 
segments with reference to the already proposed helix packing of TMS 2, 3, 7 and 8 
(Figure 1.4). Using a similar method to the previous study, cysteine mutations were 
introduced i to TMS 1 or 2 and paired with cysteine 768, which is located in TMS6. 
M tants were expressed in ins ct High Five cells, then using thiol-specific cross-linkers 
containing spacer arms of known l ngths, mobility shifts on SDS-page was examined 
(Ren et al. 2006). The study showed that TMS 1 and 2 are in close proximity to TMS6. 
Interestingly, cysteine 768 was able to form cross-links with residues that are proposed 
to be near intra- and extracellular surfaces of TMS1 and 2, with cysteine 768 thought to 
lie roughly in the middle of TMS6. This suggests that TMS1 and 2 are not continuous 
α-helices, because if they were then residues that interact with Cys-768 would be 
separated by a distance of about 27 Å, meaning that any interaction would require a 
cross-linker that is longer than 10 Å (Ren et al. 2006). However, an interaction is 
observed with a cross-linker of only 6.4 Å. In addition, in the wild-type receptor, 
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cysteines 122 and 768 have also been shown to interact. Cys122 is located between the 
extracellular end of TMS2 and the reentrant loop of the α-1 repeat, which is suggested 
to be functionally important (Ottolia et al. 2005). Ren and colleagues found an 
interaction between these 2 cysteine residues, supporting a functional importance for 
TMS6 (Ren et al. 2006). An updated helix packing model was proposed based on these 
findings (Figure 1.4). One must bear in mind that the positions of the TMS are not fixed 
and must move on binding of regulatory Ca2+ in order to facilitate the exchange of Na+ 
for Ca2+, however, such structural data has not yet been published. TMS movement 
during the NCX reaction cycle may account for the reported proximity of multiple 
residues in TMS1 and 2 to Cys768 in TMS6. 
 
teine mutants was due to intramolecular, and not intermolec-
ular, interactions.
DISCUSSION
A previous helix-packing study of NCX1 demonstrated that
TMSs 2, 3, 7, 8, and their associated reentrant loops are in
proximity (6). The results of this current s udy xtend these
observations to include TMS 1 and 6. Our data show that resi-
due 768 in TMS 6 is in proximity to residues in TMS 1 and 2. A
newhelicalwheel projection ofNCX1 that includesTMSs 1 and
6 along with TMSs 2, 3, 7, and 8 is shown in Fig. 7. This figure
summarizes the results obtained in the present study and also
includes the results from Qiu et al. (6). For this model, it was
assumed that each TMS spans themembrane uninterrupted by
discontinuities and that each of the indicated residues is in a
helical part of theTMSandnot in connecting loops. Thismodel
should provide guidelines and predictions for further experi-
mentation and model refinement.
The only TMSs not yet accounted for in our helix-packing
model are TMSs 4, 5, and 9. Most of the loops connecting con-
secutive TMSs appear to be relatively short, with the notable
exception of the large loop connecting TMSs 5 and 6. It has also
been noted that consecutive TMSs tend to be near one another
in packed structures of membrane proteins (16). Therefore, it
seems likely that TMSs 4 and 5will reside in the vicinity of TMS
3. Likewise, TMS 9 is likely to be near TMS 8. Qiu et al. (6)
reported cross-linking in the nonfunctional mutant S117C/
K909C, which also supports placing TMS 9 into the area
bounded by TMSs 8, 2, and 7.
The most striking experimental result presented here indi-
cates that residues Cys-768 and Ala-767 are accessible to resi-
dues modeled to be near both the extracellular and the intra-
cellular sides of TMSs 1 and 2 (Figs. 2 and 3). Cys-768 has
previously been modeled to be in TMS 6 toward the intracellu-
lar surface of themembrane (Fig. 1) (17). However, the position
of Cys-768 can just as easily be modeled to be more toward the
center of TMS 6 without significantly reducing hydrophobicity
of the TMS. Our results strongly indicate that this is the case.
Nevertheless, accessibility of Cys-768 to both sides of themem-
brane is still surprising. If TMS 1 and TMS 2 are both continu-
ous ! helices, then the residues that interact with Cys-768
would be separated by five turns or a distance of about 27 Å.
Assuming a static interaction between the helices, a single res-
idue in themiddle of TMS 6would require a cross-linker that is
longer than 10 Å to reach both residues at either side of the
membrane. However, cross-linking was observed with M3M, a
6.4 Å cross-linker. There are a number of possibilities for how
this might occur. For example, TMS 1 and 2 may not be con-
tinuous helices. There is a growing body of x-ray structures of
membrane proteins in which TMSs are not continuous ! heli-
ces (18, 19). If there are nonhelical sections of TMSs 1 and 2,
then residuesmodeled to be on opposite sides of themembrane
could be closer than estimated from the rise of a single helix.
TMS 2 does have a proline at residue 112, about half the dis-
tance between residues 101 and 122, thatmight induce a kink in
the helix. Also, there are several tyrosines (weak helix breakers)
and a glycine (strong helix breaker) in TMS 1, although these
residues are not consecutive. Alternatively, the residues that are
modeled to be within a transmembrane-spanning region may
be in a loop connecting TMSs. Loops could be flexible and
reach in toward residue 768 if there is a vestibule-like structure
in NCX to allow accessibility. Finally, there may be flexibility in
the exchanger protein such that TMS 6 canmove depending on
FIGURE 7. Packing model for NCX with summary of the interactions
between residues in TMSs 1, 2, 3, 6, 7, and 8. a, view from above themem-
brane surface. Experimental data presented in this study (heavy lines) are
combinedwith previous studies (light lines) to show amodel for the arrange-
ment of TMSs. Residues 41 and 59 are predicted to be at the same angle but
separated by five full turns of the helix. b, sideways view of TMSs. Heavy lines
indicate cross-linking between TMS 6 and 2. Light lines indicate cross-linking
between TMS 6 and 1. For simplicity, only cross-links determined in this work
are indicated with lines.
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Figure 1.4: New Helix Packi g Model Of Cardiac Na+-Ca2+ Exchanger. Proposed 
updated helix packing model, incorporating previous data from (Qiu et al. 2001) 
coupled with new d ta on TMS 1, 2 and TMS6. Heavy lines represent cross-links 
between TMS6 and TMS2 and light lines represent cross-links between TMS6 and 
TMS1. Modified from (Ren et al. 2006). 
 
In a study by Ren and colleagues, the position of the remaining TMS were investigated 
using the same experimental procedure as previously described. Based on all cross-
linking data obtained to date, it suggests that each of the N-terminal TMS forms a cross-
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link with at least 2 of the C-terminal TMS and vice versa (Ren et al. 2010). Shown in 
figure 1.5 is the proposed helix packing of NCX in 2010. 
 
 
Figure 1.5: Computer-Generated Model Of NCX Helix Packing. Current work from 
(Ren et al. 2010) put together with previous work (Ren et al. 2006; Qiu et al. 2001) are 
combined to generate a working model of NCX. Lines are indicative of cross-link 
interactions. The grey arcs indicate residues that, upon mutation, alter the activity of 
the exchanger. Annotation of C and N within the TMS indicates at which end of the 
exchanger the TMS is located. Modified from (Ren et al. 2010). 
 
Recently, a prokaryotic homolog of mammalian NCX, NCX_Mj was found to have 
Na+/Ca2+ exchange activity and it was subsequently crystallised (figure 1.6) (Liao et al. 
2012). NCX_Mj consists of 10 transmembrane helices, which form two structural 
repeats of 5 transmembrane helices with opposing topology (Liao et al. 2012). The 
crystal structure revealed 8 of the helices, TMD 2 to 5 and TMD 7 to 10 form a tightly 
packed core perpendicularly embedded in the membrane. This part of the model fits 
with the predicted helix packing model proposed by Ren et al (Ren et al. 2010). 
Interestingly, TMD6 and TMD1 are long, with approximately 35 residues in each helix. 
!!
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They are orientated at a 45° to the surface membrane and are loosely packed against the 
core (figure 1.6) (Liao et al. 2012). The conserved α-repeat domains are bundled in the 
centre of the protein, surrounded by the helices. α-repeat helices are bent in two or three 
segments, creating space in the middle where Ca2+ and Na+ bind.  
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Figure S3. NCX_Mj structure. (A), Topology diagram of NCX_Mj. Residues 
involved in ion binding are labeled with white circles. (B), Stereo view of NCX_Mj
from the extracellular side. N- and C-terminal halves are colored orange and green, 
respectively. Dotted circle and oval indicate the external entrances of the Ca2+ and 
Na+ passageways, respectively. The dotted arrow represents the pseudo molecular 
dyad. Colored spheres represent the bound Na+ (green) and Ca2+ (red).
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Figure 1.6: Topology Of NCX_Mj. Schematic representation of NCX_Mj topology 
based on crystal structure. Residues involved in ion binding shown in white circles. 
Green circles – Na+, red circles – Ca2+. Modified from (Liao et al. 2012). 
 
The N-terminal half of the protein shares structural similarity with the C-terminal half 
but with opposite topology. The authors propose the two halves are related by a 
molecular dyad (Liao et al. 2012). Based on this structure, Philipson and colleagues 
were prompted to re-examine the propose topology for mammalian NCX1 (Ren & 
Philipson 2013). NCX_Mj shares sequence homology to NCX1 in the α-repeat regions, 
with no homology outwith this region. Using a cross-linking approach, the topology of 
the C-terminal half of mammalian NCX1 was reinvestigated, as this was the region of 
discrepancy. Cys20 is on the extracellular side and Leu102 on the intracellular side of 
TMD2 ha e been verified  previous studies (Iwamoto t al. 1999; Nicoll et al. 1999; 
Doering et al. 1998) and is consistent with NCX_Mj. Cys20 or Leu102 mutated to 
cysteine were reintroduced into a cysteine-less exchanger. Additional cysteine residues 
were introduced in the C-terminal half of the exchanger at specific locations; 825, 897 
and 938. Cysteine at 897 crosslinked with the internal Cys102 but not with Cys20, 
suggesting it is located on the intracellular side of NCX1 (Ren & Philipson 2013). The 
opposite result was obtained for cysteine at 938, which crosslinked with Cys20 but not 
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Cys102, suggesting its extracellular location. Taken together, the results indicate the 
presence of an additional TMD 8 and an extracellular C-terminus, consistent with 
NCX_Mj (figure 1.7) (Ren & Philipson 2013). Based on these results, the topology of 
NCX1 was revised to include 10 TMDs, in line with NCX_Mj crystal structure. 
 
 
Figure 1.7: Schematic Of Alternative NCX1 Topologies. A. The currently accepted 
topology of NCX1 showing 9 TMDs. B. Predicted topology of NCX1 based on NCX_Mj 
crystal structure. Circled residues show location of cysteine used to confirm NCX1 
topology. The bold section in panel A forms the new TMD8 in panel B. Modified from 
(Ren & Philipson 2013). 
 
1.1.3 Function Of NCX1 
 
The predominant role of NCX1 in cardiac tissues is the extrusion of Ca2+, however it 
can also function in a way that allows Ca2+ influx into the cell, depending on the 
electrochemical gradients of Na+ and Ca2+ (Blaustein & Lederer 1999). However, under 
physiological conditions, NCX1 predominantly functions in forward mode, i.e. the 
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extrusion of 1 Ca2+ and the influx of 3 Na+. To date, 4 modes of operation of NCX1 
have been described (Blaustein & Lederer 1999; Dipolo & Beaugé 2006),  
 
1) forward mode, responsible for Ca2+ extrusion (Na+o/Ca2+i exchange), 
2) reverse mode, responsible for Ca2+ entry (Na+i/Ca2+o exchange), 
3) homologous Ca2+o/Ca2+i exchange, 
4) homologous Na+o/Na+i exchange. 
 
1.1.4 Modes Of Function 
 
i Forward Mode 
 
The mode in which NCX functions is dependent on a variety of factors. The first of the 
four modes, is defined as external Na+-dependent Ca2+ efflux and internal Ca2+-
dependent ouabain and tetrodotoxin insensitive Na+ influx (Blaustein & Lederer 1999). 
This mode of transport is capable of being activated by internal monovalent cations (P. 
F. Baker et al. 1969; Blaustein & Christie Ector 1976; Gadsby et al. 1991; Fontana et al. 
1995) and is inhibited by a high concentration of intracellular Na+ ([Na+]i) (Dipolo & 
Beaugé 1990). In addition, it is also activated by non-transported intracellular Ca2+ 
(Hilgemann, Collins & Matsuoka 1992a), however this mode of exchange does not 
require extracellular Ca2+ to be activated (Dipolo & Beaugé 1990). Unlike other forms 
of ion exchange, the Na+/Ca2+ exchanger does not require hydrolysis of ATP to fuel 
Ca2+ efflux, as demonstrated by experiments showing that Na+/Ca2+ exchange still 
occurs in ATP-depleted cells (Dipolo & Beaugé 1990). Although Ca2+ efflux does not 
require ATP hydrolysis, ATP has a profound effect on the regulation of the exchanger, 
will be discussed in detail in following sections. 
 
ii Reverse Mode 
 
The second of the four modes, reverse mode, is defined as internal Na+-dependent Ca2+ 
influx and external Ca2+-dependent ouabain-insensitive Na+ efflux. An important 
feature of this mode of operation, which is shared by the forward mode, is the 
requirement for intracellular Ca2+. The concentration of normal resting Ca2+ within the 
cell is approximately 100nM, however the concentration for half-maximal activation of 
this mode is approximately 1µM under physiological conditions, deeming that only a 
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small number of exchangers are active (Blaustein & Lederer 1999). However, low 
micromolar concentrations of intracellular Ca2+ are capable of activating the exchanger, 
suggesting that it only contributes to significant Ca2+ entry when cytoplasmic Ca2+ is 
high, although this is not thermodynamically favourable unless there is a positive 
membrane potential. As with forward mode, reverse mode of operation is also activated 
by low concentrations of external monovalent cations, including Na+ (Fontana et al. 
1995), which are not transported. High concentrations of extracellular Na+ decrease the 
level of Ca2+ influx mediated by the exchanger. 
 
The final 2 modes of operation, homologous Ca2+ exchange and homologous Na+ 
exchange are difficult to investigate, as there is no net movement of charge across the 
membrane, unlike the previous two modes of transport. Like the reverse mode, 
homologous Ca2+ exchange is activated by external monovalent cations and inhibited by 
external Na+. A unique feature of this mode of transport however is that internal 
monovalent cation is needed for activation and high intracellular levels of Na+ inhibits 
this mode of exchange (Blaustein & Santiago 1977). The homologous Na+/Na+ 
exchange shares similarity in activation requirements with the reverse mode of 
operation, in that it also dependent on internal Ca2+ for activation. Additional activation 
parameters required include internal alkalinisation and internal ATP. This mode of 
operation can be inhibited by both internal Mg2+ and external Ca2+ (Blaustein & Lederer 
1999). 
 
As mentioned previously, Na+-Ca2+ exchange plays an important role in extruding 
excess Ca2+ following an action potential. During the cardiac action potential, Ca2+ 
enters the cell through depolarisation-activated Ca2+ channels (Bers 2002). This influx 
of Ca2+ stimulates ryanodine receptors located on the sarcoplasmic reticulum (SR), 
stimulating further Ca2+ release. The rise in free intracellular Ca2+ is able to bind to the 
contractile machinery within cardiomyocytes and initiate contraction. In order for the 
myocytes to relax, the level of intracellular Ca2+ must decrease in order to stimulate the 
dissociation of Ca2+ from the contractile machinery (Bers 2002). There are four major 
pathways that are involved in moving Ca2+ out of the cytoplasm, the sarcoplasmic 
reticulum Ca2+ ATPase, sarcolemmal Na+/Ca2+ exchanger, sarcolemmal Ca2+ ATPase 
and the mitochondrial Ca2+ uniporter. The sarcoplasmic reticulum Ca2+ ATPase pump 
removes around 70% of the intracellular Ca2+ for storage in the SR, whereas the 
Na+/Ca2+ exchanger removes approximately 28% (Bers 2002) in humans. This leaves 
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only 2% to be dealt with by the sarcolemmal Ca2+ ATPase and the mitochondrial Ca2+ 
uniporter. The Na+ that enters the cell via the Na+/Ca2+ exchanger is removed from the 
cell by the Na+ pump. 
 
1.1.5 Structure-Function Of NCX1 
 
i Function Of The α-repeats 
 
As previously discussed, there are 2 domains that show intramolecular homology, 
termed the α-repeats. One of these repeats, α1, is located at the N-terminal half of the 
exchanger, between TMS 2 and 3, the second is located in the C-terminal half in a 
region now known to form TMS8. It is proposed that α1 repeat forms a reentrant loop, 
similar to that which has been described for several ion channels (Nicoll et al. 1999; 
Iwamoto 2000). It is possible that these repeats are involved in the translocation of Na+ 
and Ca2+ across the plasma membrane. This is a rather plausible function of these 
domains, given that recent structural data suggests that these repeats are in proximity to 
one another (Qiu et al. 2001; X. Ren et al. 2006; X. Ren et al. 2010). However there is 
some debate as to the specific region of the α-repeat that is involved in the translocation 
of ions. In a study conducted by Iwamoto and colleagues, it was suggested that mutating 
specific residues in the sequence of the α-repeats alters the affinity of the exchanger for 
extracellular Ca2+ (Iwamoto et al. 2000). Of the 44 α-repeat residues that were mutated 
to cysteines, 6 showed an increase in Km (Ca) for Ca2+o when compared to the wild-type 
exchanger. They proposed that these residues may not necessarily be involved with the 
translocation of the ions themselves but may be in close proximity to the binding site, 
suggesting that mutations could indirectly alter the structure of this site and therefore 
affinity (Iwamoto et al. 2000). In addition, they also examined the role of 3 conserved 
aspartate residues in exchanger function, hypothesising that acidic residues could be 
important for binding and transport of ions. Mutations of Asp130 (in α1) and Asp829 
(in α2) to Gln or Asn resulted in a decrease of affinity for extracellular Ca2+, whereas 
mutations of Asp825 had no effect (Iwamoto et al. 2000) (sites of these mutations are 
shown in figure 1.2). It is predicted that the size of the side chains and charge of 
carboxylates in residues 130 and 829 are possibly important for maintaining normal Km 
(Ca). These mutations affected the Na+o affinity to a much lesser extent than Ca2+o. It 
appears that these conserved aspartate residues may not be directly involved with ion 
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transport, however they could line the ion translocation pathway, providing negative 
charges that promote through-space electrostatic interactions (Iwamoto et al. 2000). 
 
Much of the mutational analysis to date has focused on the α1-repeat of the exchanger. 
To this end, Ottolia and colleagues investigated its role in the binding and transport of 
ions, specifically what residues of the repeat are important for function (Ottolia et al. 
2005). Investigating the reentrant loop, mutations were introduced at residues H124N, 
N125C, F126C, T127H and D130C and the biophysical properties investigated. All 
mutations introduced generated active exchangers. H124N and D130C mutations 
resulted in an increase in Na+ affinity of these mutants, whereas affinity decreased for 
F126C, and N125C had no measureable effect (Ottolia et al. 2005). Mutants expressing 
H124N, F126C and T127H and D130C also displayed a decrease in the Hill coefficient. 
There were no significant changes in the affinity for Ca2+ in any of the mutated 
exchangers. Overall, the authors propose that the α1-repeat is not involved in the 
cytoplasmic affinity for ions but does play a role in the cooperativity of Na+ binding 
rates (Ottolia et al. 2005), as the affinity was only modestly affected by mutations 
introduced into the reentrant loop. To further validate this finding, a squid chimera 
exchanger was generated, given that the α1-repeat is conserved between the 3 
mammalian exchangers but not in the squid neuronal exchanger. Replacement of this 
repeat does not disrupt ion transport, but similar to the previous mutational data, effects 
on intracellular Na+ affinity and cooperativity of Na+ binding are observed. As 
previously described, the α1-repeat encompasses part of TMS 2, followed by the 
reentrant loop, then part of TMS 3. Ottolia and colleagues (2005) also examined the 
effect of mutations in TMS 3 of the exchanger. Mutations were introduced at 137-145 
and 147. Previously examined by Nicoll and colleagues, a mutation of G138A displayed 
moderate effects on activity, whereas mutation to serine resulted in a reduction in 
activity of the exchanger (Nicoll, Hryshko, et al. 1996a). Expression of a N143V mutant 
resulted in an inactive exchanger. However, when N143D, a functional exchanger 
results, that displays normal Na+ affinity and activity (Ottolia et al. 2005). In addition, 
mutations of residues 140, 145 and 147 displayed an alteration in the affinity for 
intracellular Na+ (Ottolia et al. 2005). Mutation of 140 and 147 resulted in a decrease of 
affinity for Na+ whereas mutations at 145 resulted in an increase affinity. These results 
suggest that TMS3 has a more critical role in both ion binding and translocation 
function of the exchanger than the reentrant loop. Through this work, Ottolia and 
colleagues challenge the widely held view that the reentrant loops form part of the ion 
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pore of the exchanger, as the only change observed when mutations are introduced in 
the α1 repeat is a change in the binding of Na+ on the opposite side of the membrane 
from the reentrant loops (Ottolia et al. 2005). Their conclusions are supported by the 
identification of ion binding sites in TMS 2 and 3 and TMS 7 and 8. 
 
There is some mutational data available for the α2-repeat, suggesting it also plays a role 
in exchanger activity. Mutations at Ser811, Asp814, Ser818 and Ser838 all resulted in 
exchangers with no exchanger activity (Nicoll, Hryshko, et al. 1996a). A reduction in 
exchanger activity was observed with mutations at Gly809, Gly837 and Asn842, 
whereas an altered current-voltage relationship was recorded for Gly837. The profound 
effect of mutations in the α-repeats suggests that they do in fact play an important role 
in regulating the binding and translocation of ions dealt with by the exchanger (Nicoll, 
Hryshko, et al. 1996a). 
 
ii Function Of The XIP Region 
 
A sequence of basic and hydrophobic amino acids, termed the XIP region, is located at 
the N-terminal end of the large intracellular loop of NCX. This sequence stretches from 
219-238 (Li et al. 1991). A peptide corresponding to this region was generated and 
shown to be a potent inhibitor of NCX exchange activity when applied to the 
intracellular surface of the exchanger, using the giant excised patch technique (Li et al. 
1991). This points towards a role for the endogenous XIP region to regulate exchanger 
activity. Mutagenesis revealed that exchanger mutants lacking residues 562-679 fails to 
be inhibited by exogenously applied XIP, suggesting that this region is involved in 
exchanger regulation by XIP (Maack et al. 2005). If the XIP binding site is on the 
intracellular loop, the structure and conformation of this region may be important for 
interaction (Ottolia et al. 2001). Utilising split exchangers, where the exchanger is split 
into its N-terminal and C-terminal halves then co-expressed in oocytes, Ottolia and 
colleagues demonstrated that the split exchanger retains sensitivity to XIP (Ottolia et al. 
2001).  
 
Further mutational analysis of the XIP region itself revealed that XIP plays a role in the 
Na+-dependent inactivation and Ca2+ regulation of the exchanger (Matsuoka et al. 
1997). Nine mutants of the XIP region were constructed (F223E, Y224T, K225Q, 
Y226T, R230Q, K229Q, ∆229-232, 229(QQTQ)232 and ∆229*237) and based on 
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electrophysiological properties, were sub-divided into two distinct groups (see figure 
1.8 for position of mutations in XIP sequence). Group 1 mutants (F223E, Y224T, 
K225Q, Y226T, R230Q), Na+-dependent inactivation was still apparent, but displayed a 
faster rate of inactivation compared to the wild-type exchanger. In contrast, group 2 
mutants (K229Q, ∆229-232, 229(QQTQ)232, ∆229*237) display a complete abolition 
of Na+-dependent inactivation (Matsuoka et al. 1997). As well as an effect on the 
kinetics of Na+-dependent inactivation, group 1 mutants display a reduced inhibition of 
Na+-dependent inactivation by Ca2+ compared to the wild-type exchanger (Matsuoka et 
al. 1997). Group 2 mutants do not show any alteration in the affinity for regulatory 
Ca2+. Therefore, these results suggest that XIP is involved in the regulation of Na+-
dependent inactivation. In addition, it appears that XIP may regulate Na+-dependent 
inactivation via an interaction with phosphatidylinositol 4,5-bisphosphate (PIP2) (Z. He 
et al. 2000). It was demonstrated that XIP binds with high affinity to PIP2, which is also 
proposed to modulate Na+-dependent inactivation, as high membrane levels of PIP2 
stimulates exchange activity by decreasing inactivation. The location of XIP is suited to 
an interaction with PIP2.  
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Figure 1.8: Mutations Of The XIP Region Of NCX Have Different Effects On 
Outward Exchange Current. The WT sequence for the XIP region is shown as one 
letter abbreviations. Mutations are shown, where dots indicate unchanged residues. 
Outward exchange current was induced by replacing 100 mM Cs with 100 mM Na ︎ at 
the cytoplasmic face of the patch (bars). Extracellular and cytoplasmic Ca2+ were 8 mM 
and 1M, respectively. Dotted lines indicate 0 current level. Modified from (Matsuoka et 
al. 1997). 
 
iii Function Of The Ca2+ Regulatory Domain 
 
As mentioned previously, there is a region of the large intracellular loop that confers a 
high affinity Ca2+ binding site. The β-repeats, a pair of domains with high sequence 
similarity, were shown to be involved in the binding of regulatory Ca2+, as mutations of 
these regions resulted in the affinity for regulatory Ca2+ being lowered (Matsuoka et al. 
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1995; Ottolia et al. 2010). Discovery of the crystal structure coupled with NMR data on 
the β-repeats revealed that both are involved in the binding of regulatory Ca2+. As such, 
the β-repeats were renamed CBD1 and CBD2 (Ca2+ binding domain 1 and 2 
respectively). CBD1 and CBD2 both possess an immunoglobulin fold, similar to that 
found in the cadherins and fibronectins (Hilge et al. 2006). Each of the domains is a 7-
strand antiparallel β-sandwich, containing Ca2+ binding sites at the head and 
unstructured loop F-G at the tail (see figure 1.9 for a schematic representation). The 
connection between the two domains is short, therefore it has been assumed that they 
are arranged in a head-to-tail configuration (Ottolia et al. 2010). Both sites are capable 
of binding Ca2+, however the number of ions they bind and the affinity with which the 
ions bind is different for each of the 2 domains.  
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Figure 1.9: Schematic Representation Of Ca2+ Regulatory Domains. A depicts the 
structure of CBD1, blue arrows represent the β-strands, residues involved in 
coordination of Ca2+ are shown as red circles. The red box around strand A’ shows the 
break in hydrogen bonding between strand A and B caused by the β-bulge. B depicts the 
structure of CBD2, blue arrows represent the β-strands, the disordered F-G loop is 
shown in red, Lys585 is shown as a yellow circle, orange circles show residues involved 
in Ca2+ coordination and Lys585 stabilisation. Again, the red box around strand A’ 
indicates the break in hydrogen bonding between strand A and B. Modified from (Nicoll 
et al. 2006; Besserer et al. 2007). 
!
!
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CBD1 binds 4 Ca2+ ions, which are coordinated by an extensive network of amino acid 
residues (Nicoll et al. 2006). The sites in which Ca2+ binds are termed Ca1, Ca2, Ca3 
and Ca4. This extensive network connects the 4 Ca2+ ions that are clustered in the distal 
loops of the β-sandwich. The 4 binding sites are suggested to be arranged in a 
parallelogram-like configuration, which are coordinated by aspartic and glutamic acid 
residues, that form polydentate interactions between 2 or 3 of the Ca2+ ions (Nicoll et al. 
2006). The residues involved in the coordination of the Ca2+ are predominantly located 
in the C terminus (Asp498, Asp499, Asp500) and in loop E-F (Asp446, Asp447, Ile449, 
Glu451, Glu454). There are also additional interactions that take place between Glu385 
in the A-B loop, Asp421 in the C-D loop and 3 water molecules (Nicoll et al. 2006). Of 
these residues, Glu451, Asp421 and Asp500 are suggested to be key residues that help 
coordinate the 4 Ca2+ ions into a tightly bound cluster. It appears that this complex 
coordination scheme involves carboxylate groups from aspartic acid and glutamic acid 
residues to form interactions with the Ca2+ ions. The Ca2+-free form of CBD1, shows a 
loss of structural integrity in the upper half of the molecule (Hilge et al. 2006). Residues 
that form Ca2+ binding sites become unstructured following the release of Ca2+. This is 
thought to be due to the lack of basic residues in the binding sites, which therefore are 
not able to counter the repulsive forces between the glutamate and aspartate residues. 
 
In contrast to CBD1, CBD2 only binds 2 Ca2+ ions, at sites Ca1 and Ca2. The first Ca2+ 
binding site (Ca1) is octacoordinated with carboxylate groups from 3 acidic residues, a 
carbonyl backbone and 2 water molecules (Besserer et al. 2007). Glu516 from the A-B 
loop and Glu648 from the C-terminal end of the binding site, form bidendate 
interactions with the Ca2+, and together with Asp578 and Glu580, coordinate the 
primary Ca2+ in its binding site. The second Ca2+ binding site (Ca2) is heptacoordinated 
by 5 water molecules, Asp552 and Asp578 (Besserer et al. 2007). Two of the water 
molecules are coordinated to a lysine residue at position 585, which forms a salt bridge 
with Glu582. Asp578 is involved in the coordination of both primary and secondary 
Ca2+ ions, through a bridging bidentate ligand, which connects the primary and 
secondary binding sites. In the Ca2+-free form of CBD2, there are no major 
conformational changes, except a slight shift in the loops that coordinate the Ca2+ ions 
(Besserer et al. 2007). The E-F loop shifts towards the C-D loop and the C-terminus is 
shifted away from the E-F loop. This shifts Lys585 to the same position that was 
occupied by the Ca2+ ion in the secondary binding site, enabling this residue to form salt 
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bridges with Asp552 and Glu648, with the oxygen from the carbonyl group of Glu580 
hydrogen-bonded to Lys585. This series of interactions between these residues prevents 
the CBD2 from unfolding in the same manner as CBD1, allowing the primary site in 
CBD2 to aid rapid binding of Ca2+ (Besserer et al. 2007). The role of these two binding 
sites in the regulation of the exchanger will be discussed in more detail in following 
sections. 
 
1.1.6 Regulation Of NCX 
 
The Na+/Ca2+ exchanger is subject to various modes of regulations, which are 
predominantly regulated through specific regions in the large intracellular loop. Below, 
the different modes of regulation are discussed. 
 
i Na+-dependent Inactivation 
 
As described previously, the Na+/Ca2+ exchanger exchanges 3 Na+ for 1 Ca2+, activated 
by a rise in intracellular Ca2+ during the action potential. Not only is it capable of 
transporting these ions but is also regulated by them. Hilgemann described a decrease in 
exchange current, which occurs during activation by cytoplasmic Na+ (Hilgemann 
1990). This is termed Na+-dependent inactivation. It is proposed that this inactivation is 
induced by the binding of Na+ ions to cytosolically disposed translocation sites 
(Hilgemann, Matsuoka, Nagel & Collins 1992c). This was supported by 4 findings in 
Hilgemann’s study, application of Na+ to the cytoplasmic side induces inactivation of 
the outward current, a reduction in extracellular Ca2+ decreases the extent of the 
inactivation, depolarisation does not affect inactivation and finally application of Na+ to 
the extracellular side in outside-out patches induced an inward current that did not show 
signs of decaying (Hilgemann, Matsuoka, Nagel & Collins 1992c). Na+-dependent 
inactivation is time-dependent, showing a decline of 80% in the outward current in giant 
excised patches with a time constant of approximately 1s (Hilgemann 1990). Treatment 
of the exchanger with chymotrypsin, which proteolyses the large intracellular loop of 
the exchanger, decreases the level of Na+-dependent inactivation observed, suggesting a 
role for the intracellular loop in this process (Hilgemann 1990; Hilgemann, Matsuoka, 
Nagel & Collins 1992c).  
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In an extensive study by Hilgemann and colleagues, it was demonstrated that Na+-
dependent inactivation is sensitive to a number of regulatory factors. Addition of Ca2+ 
to the cytoplasmic side of the membrane results in activation of an outward current and 
inhibition of Na+-dependent inactivation (Hilgemann 1990; Hilgemann, Matsuoka, 
Nagel & Collins 1992c). Temperature and pH are also factors that affect Na+-dependent 
inactivation. A higher pH of 7.8 resulted in a much reduced decay of the outward 
current, suggesting that no to little inactivation is occurring (Hilgemann, Matsuoka, 
Nagel & Collins 1992c), whereas at pH 6.8, current decayed by approximately 85%. An 
increase in temperature alters the peak current and increases the rate of inactivation, 
resulting in a faster decay of the current (Hilgemann, Matsuoka, Nagel & Collins 
1992c). Na+-dependent inactivation of exchange activity can be reversed by addition of 
Mg-ATP to giant excised patches (Hilgemann & Ball 1996), which is also capable of 
increasing the current observed in these patches. This effect is also mimicked by 
addition of PIP2 and inhibited when membranes were treated with a 
phosphatidylinositol-specific phospholipase C, indicating a role for PIP2 in the 
regulation of Na+-dependent inactivation (Hilgemann & Ball 1996; Reeves & 
Condrescu 2008). In addition to regulation of Na+-dependent inactivation by pH, 
temperature, cytoplasmic Ca2+ and ATP, the endogenous XIP region is also capable of 
regulating this process. As discussed previously (see Structure-Function of XIP 
section), Matsuoka and colleagues demonstrated that mutations in the endogenous XIP 
region of the exchanger alters the kinetics or completely abolishes Na+-dependent 
inactivation, supporting a role for the intracellular loop in its regulation (Matsuoka et al. 
1997). 
 
In terms of physiological relevance, the role of Na+-dependent inactivation is subject to 
debate. A study by Chernysh and colleagues utilising Chinese Hamster Ovary (CHO) 
cells expressing the canine NCX demonstrate that at physiological concentrations of 
intracellular Na+ (10mM), there is very little Na+-dependent inactivation observed 
(Chernysh et al. 2008). They postulate that while Na+-dependent inactivation is 
probably not relevant under normal physiological conditions, under ischemic 
conditions, when [Na+]i is high, there is low ATP/PIP2, and low pHi, this would promote 
Na+-dependent inactivation, resulting in a reduction in the level of influx and thus 
reducing the possibility of Ca2+ overload (Chernysh et al. 2008). While this study 
confirms results from giant patch studies, there are also significant differences. For 
example, the authors find that in CHO cells the wild-type NCX1 exchanger is 
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remarkedly resistant to Na+-dependent inactivation, even at high levels of intracellular 
Na+, which contrasts to data from other groups (Hilgemann, Matsuoka, Nagel & Collins 
1992c; Chernysh et al. 2008; Hryshko 2008). These differences observed in exchanger 
regulation and activity could be caused by the different approaches used by these 
groups, some employing giant patch clamping and the others cell-based fluorescence 
techniques. The exact contribution of Na+-dependent inactivation to the regulation of 
the exchanger in normal physiological conditions is still unknown, however it has been 
shown that in ischemia-reperfusion injury, reverse mode of Na+/Ca2+ exchange 
contributes to the Ca2+ overload (C. Lee & Hryshko 2004; Imahashi et al. 2005; Wang 
et al. 2007; Hryshko 2008). It appears that the pharmacological agents, SEA0400 and 
KB-R7943 result in an apparent transport mode selectivity (C. Lee et al. 2004), as 
pharmacological interventions appear to stablise the Na+-dependent inactivation of the 
exchanger, reducing the cardiac injury observed under these settings. More work is 
needed to elucidate the exact role of Na+-dependent inactivation in a physiological 
setting. 
 
ii Ca2+ Regulation 
 
NCX is capable of not only transporting Ca2+, it is also regulated by it. It is important to 
understand that transported Ca2+ is distinct from regulatory Ca2+, i.e. Ca2+ that regulates 
NCX is not transported and vice versa. In a complementary study to their work on Na+-
dependent inactivation, Hilgemann and colleagues sought to characterise the role of 
Ca2+ in the regulation of the exchanger. Na+-dependent inactivation is strongly regulated 
by cytoplasmic Ca2+, increasing concentrations of Ca2+ increases the rate of recovery 
from the Na+-dependent inactive state (Hilgemann, Collins & Matsuoka 1992a). Ca2+i is 
also capable of activating the exchanger, as there is no activation of outward current by 
Na+ in the absence of Ca2+i (Hilgemann 1990). It was proposed that Na+ and Ca2+ 
regulated the exchanger at distinct sites as they argued that high Na+i would displace 
Ca2+i from its regulatory site, resulting in a bell-shaped concentration-current relation, 
which was not observed (Hilgemann, Collins & Matsuoka 1992a). In addition, it was 
demonstrated that while both Ca2+ and ATP applied at the intracellular surface are both 
capable of activating an exchange current, they do this by separate mechanisms 
(Hilgemann 1990). Similar to Na+-dependent inactivation, regulation by Ca2+ is 
abolished by chymotrypsin treatment, indicating the regulatory domain for Ca2+ lies 
within the intracellular loop (Hilgemann 1990). 
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Figure 1.10: Structure Of CBD1 And CBD2. The residues involved in coordination of 
Ca2+ into each of the binding sites in the CBDs are shown. Notes that CBD1 has 4 
binding sites and CBD2 has 2. The residues underlined are those that were mutated in 
(Ottolia et al. 2009) and water molecules are shown as red spheres. Modified from 
(Ottolia et al. 2009). 
 
It is indeed in the intracellular loop of the exchanger where the 2 CBDs lie (see figure 
1.10 for structure of both CBDs). The exact role of each of the domains in Ca2+ 
regulation is only beginning to be elucidated via mutational studies (Besserer et al. 
2007; Ottolia et al. 2009; Ottolia et al. 2010; John et al. 2011). Mutational analysis of 
the CBD2 domain revealed that it is important for the regulation of NCX by regulatory 
Ca2+, as regulation is lost when key residues in each of the two binding sites, Ca1 and 
Ca2 are mutated (Besserer et al. 2007). E516L, D552V, D578V and E683V contribute a 
carboxylate group to the binding of regulatory Ca2+, hence why they were selected for 
mutational analysis. In addition, K585E, involved in providing a positive charge to 
prevent unfolding of the protein in the absence of Ca2+, was also chosen. Effect of 
mutations was assessed by electrophysiological techniques, using wild-type or mutant 
exchangers injected into Xenopus oocytes and biophysical properties studied by using 
the giant patch technique (Besserer et al. 2007). Exchange current was generated by 
application of 100mM Na+ to the intracellular surface in the presence of 8mM Ca2+ in 
the pipette (which represents the extracellular surface), as well as submicromolar 
regulatory Ca2+ at the intracellular surface. The wild-type exchanger behaves as 
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expected, in the absence of regulatory Ca2+, very little exchange current is observed in 
response to application of Na+, however in the presence of regulatory Ca2+, Na+ results 
in a current that partially inactivates to a steady state over a few seconds (Besserer et al. 
2007). At high regulatory Ca2+ concentrations, peak current is enhanced and Na+-
dependent inactivation is reduced. In contrast to the wild-type, mutations of the residues 
involved in coordinating Ca2+ to the primary site of CBD2 abolishes the sensitivity to 
regulatory Ca2+ (Besserer et al. 2007). E516L, D578V and E683V are located in the 
primary site, and in response to regulatory Ca2+, peak current or Na+-dependent 
inactivation are unaffected, showing the same result in the absence of regulatory Ca2+. 
Based on this result, the primary site of CBD2 is essential for maintaining regulation of 
NCX by Ca2+. 
 
D552V, located in the secondary site of CBD2, is the one residue that is involved in 
coordination of Ca2+ binding to the secondary site only. The effect of a rise in 
regulatory Ca2+ results in an increase in the peak current and a decrease in Na+-
dependent inactivation in wild-type exchanger responses (Besserer et al. 2007). When 
comparing the results from wild-type and D552V mutant exchangers, there are no 
significant changes in the response to regulatory Ca2+. This indicates that the secondary 
site in CBD2 is not necessary for regulation of NCX by Ca2+. Mutations were also 
introduced in Lys585, which is involved in maintaining tertiary structure in the absence 
of regulatory Ca2+ binding. K585E displayed full regulation by Ca2+, but with lower 
affinity compared to the wild-type exchanger (Besserer et al. 2007). Na+-dependent 
inactivation was more decreased in K585E mutant. Therefore, Lys585 is not essential for 
NCX to retain regulatory function (Besserer et al. 2007). 
 
The roles of the individual Ca2+ coordination sites of CBD1 were also examined by 
mutational analysis. Mutations introduced at sites coordinating Ca2+ to Ca1 and Ca2, 
D421A and E451A, resulted in outward currents that peaked rapidly and then decayed 
over several seconds due to Na+-dependent inactivation (Ottolia et al. 2009), which was 
similar to results obtained for the wild-type exchanger. Raising intracellular Ca2+ 
concentrations resulted in an increased in peak currents from both wild type and mutant 
exchangers. Similar to wild type, mutant exchangers show the same reduction in Na+-
dependent inactivation in response to increasing intracellular Ca2+ concentrations. These 
results indicate that Ca1 and Ca2 of CBD1 do not play a major role in the regulation of 
NCX by regulatory Ca2+ (Ottolia et al. 2009). 
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Mutational analysis of the residues coordinating sites Ca3 and Ca4 yielded more 
interesting insights into the contribution of each binding site to Ca2+ regulation. 
Previous work showed that mutants D447V, D498I and D500V altered the affinity of 
the exchanger for cytoplasmic Ca2+, which are involved in coordinating Ca2+ at both 
Ca3 and Ca4 (Matsuoka et al. 1995). Therefore, biophysical properties of E385A and 
the double mutant D446A/D447A were characterized and the effects of D500V were 
further investigated (Ottolia et al. 2009). E385A is involved in the coordination of Ca3, 
whereas the double mutant D446A/D447A and D500V will interfere with Ca3 and Ca4. 
All 3 mutants required higher concentrations of Ca2+i compared to wild-type exchanger 
to initiate exchanger currents. In addition, the affinity of the mutants for Ca2+i was 
decreased by approximately 5-fold (Ottolia et al. 2009). This points towards Ca3 and 
Ca4 having a significant role in the regulation of NCX by Ca2+. In addition to creating 
mutants with residues mutated that affect individual sites, a mutant, with 7 of the 10 
amino acid residues that are involved with coordination of Ca2+ into the binding sites of 
CBD1 mutated, was generated (designated M7, mutations introduced E385A, D421A, 
D446A, D447A, D498A, D499A and D500A). The M7 mutant retained Ca2+ regulation, 
however the affinity was undetermined due to lack of saturation, indicating a role for 
CBD2 in the regulation of the exchanger (Ottolia et al. 2009). As well as still retaining 
Ca2+ regulation, all mutants displayed a reduction in Na+-dependent inactivation. 
Furthermore, the Ca2+-dependence of the steady-state current was investigated for 
E385A and D500V. In wild-type exchangers, steady-state current has a higher 
dependence on Ca2+ than peak current, whereas in E385A, the sensitivity of peak 
current to Ca2+ has decreased. In D500V, the steady-state current was demonstrated to 
be saturable and displays a similar affinity for Ca2+ as the peak current. The peak 
current is reduced and the sensitivity of steady-state current to Ca2+i is increased 
(Ottolia et al. 2009). These results indicate that Ca3 and Ca4 have important roles in 
exchanger regulation mediated by Ca2+i. 
 
Further to the work carried out in this study, Ottolia and colleagues introduced 
mutations within CBD2, to better understand its role in the regulation of the exchanger 
by Ca2+. As discussed previously, it demonstrated that mutations E516L, D578V and 
E638V abolished Ca2+ regulation of the exchanger. These residues are located in Ca1 of 
CBD2. Given the obvious importance of Ca1 in maintaining Ca2+ regulation of NCX, it 
was hypothesised that introduction of positive charges at these residues may simulate a 
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positive charge and “trick” the exchanger that Ca2+ is bound at Ca1 (Ottolia et al. 2009). 
With this in mind, E516R and E683R were investigated in the presence and absence of 
Ca2+. D578R has previously been shown to be regulated by Ca2+ (Dunn et al. 2002). In 
the absence of Ca2+, both mutants display outward current, which is further raised by 
increasing Ca2+ concentrations, indicating that both mutants are still partially regulated 
by Ca2+ (Ottolia et al. 2009). Introduction of neutral amino acid residues at the same 
sites do not show the same biophysical properties. In addition, mutation K585E, which 
results in the introduction of a negative charge, slightly decreases the Ca2+ sensitivity of 
the peak outward current, and Na+-dependent inactivation is abolished at much lower 
Ca2+ concentrations than compared to the wild-type exchanger. Therefore, introduction 
of a negative charge at Lys585 increases the affinity for Ca2+ to relieve Na+-dependent 
inactivation. As previous discussed, this residue is involved in maintaining tertiary 
structure of CBD2 in the absence of regulatory Ca2+ binding. Furthermore, using this 
mutation on the M7 mutant background, it was predicted that this would increase the 
affinity of CBD2 for regulatory Ca2+ and may rescue the low affinity for Ca2+ of the M7 
mutant (Ottolia et al. 2009). This in fact turned out to be the case, as an increase in 
affinity of the peak current for Ca2+ was observed. Taken together, these results suggest 
that CBD1 regulates Ca2+ regulation of the exchanger and CBD2 is required for Ca2+ 
regulation to occur. 
 
To determine if any conformational changes occur in the CBDs in response to Ca2+ 
regulation of the exchanger, FRET analysis was used to determine structural changes. 
Both the full-length exchanger and isolated CBD peptides were used in the analysis. 
Full length Na+/Ca2+ exchanger, labeled with a single fluorophore, was expressed in 
Xenopus laevis oocytes then subjected to FRET measurements (John et al. 2011). FRET 
was observed for these exchangers, demonstrating that they are close enough to 
generate a signal, supporting previous data that NCX exists as oligomers (X. Ren et al. 
2008b; John et al. 2011). Analysis of changes in FRET as a function of fluorophore 
concentration, NCX was determined to exist as a dimer in the plasma membrane. The 
authors suggest that dimerisation may be important for trafficking of NCX to the 
plasma membrane, as it was previously shown that co-expression of a tagged WT-NCX 
and a mutant NCX resulted in the tagged NCX remaining in the endoplasmic reticulum 
(Ottolia et al. 2007). Addition of Ca2+ to the cytoplasmic surface of giant patch clamp 
experiments, revealed an increase in FRET, suggesting that the distance between the 
intracellular loops of the exchangers decreases in response to Ca2+ (John et al. 2011). To 
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determine which CBD is involved in initiating the conformational change, mutagenesis 
techniques were employed. Residues that are involved in Ca2+ binding to either CBD1 
or CBD2 were mutated. D421A, E451A and D500V were introduced into the 
exchanger, which interfere with the binding of Ca2+ to all four binding sites in CBD1. 
These mutations completely abolish Ca2+ induced movement of NCX. In stark contrast, 
mutation E516L in CBD2 does not have a significant effect on FRET observed in 
response to Ca2+ (John et al. 2011). However, although it appears that CBD1 is 
responsible for the conformational changes in response to Ca2+, it is still not sufficient 
to regulate NCX if CBD2 is nonfunctional.  
 
To further elucidate the role of Ca2+ binding to the 2 domains, 3 peptides were 
generated, CBD1 (residues 371-501), CBD2 (residues 501-689) and CBD12 (residues 
371-689), which were linked to CFP and YFP at their N and C terminal ends 
respectively. Addition of Ca2+ to the peptides, resulted in a decrease in FRETE (FRET 
efficiency) values, with the largest decrease in CBD1 (John et al. 2011). Consistent with 
results obtained for full-length NCX, mutations of residues 421, 451 and 500 resulted in 
loss of Ca2+-dependent movements of CBD12, further supporting a role for CBD1 in 
initiating these movements. Despite these results suggesting that CBD1 initiates 
conformational changes in response to Ca2+, this does not prove that CBD2 does not 
also play a role. The authors admit that the placement of the fluorophores may not be in 
the best position to detect movements in CBD2 and are currently investigating this. 
 
iii ATP Regulation 
 
The role of ATP in the regulation of the Na+/Ca2+ exchanger has also been investigated. 
In the study examining the regulation of the exchanger by cytoplasmic Ca2+, the effect 
of ATP was also examined (Hilgemann, Collins & Matsuoka 1992a). ATP 
demonstrated a similar inhibitory effect on Na+-dependent inactivation as cytoplasmic 
Ca2+. Application of 10mM ATP to excised patches resulted in an increased outward 
current, with a decreased inactivation phase, suggesting that ATP causes an acceleration 
of the recovery from Na+-dependent inactivation (Hilgemann, Collins & Matsuoka 
1992a). The rate of recovery upon removal of Na+ in the presence of ATP increases, and 
the decay of current generated during Na+ application is slower, indicating that ATP 
slows the transition of the exchanger into an inactivated state. Current decay induced by 
removal of Ca2+ was also decreased in response to ATP, as the outward current decayed 
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by approximately 80% in response to Na+, however after application of ATP, current 
only decayed by 10% (Hilgemann, Collins & Matsuoka 1992a). Interestingly ATP also 
protects against inhibition of the exchanger induced by lowering the cytoplasmic pH 
(Dipolo & Beaugé 2002). The authors hypothesise that these effects of ATP may be 
important in cardiac ischemia where a combination of acidosis and a rise in cytoplasmic 
Na+ occurs. However, there is further evidence that the effect of ATP can be inhibited 
by applying a phospholipase C that specifically hydrolyses phosphatidylinositol (PI-
PLC) to membrane patches (Hilgemann & Ball 1996). Indeed, this effect of PI-PLC on 
ATP can be attenuated by application of PIP2 to the patch, suggesting that ATP acts 
upstream of PIP2, which is responsible for the stimulation of the current. 
 
iv PIP2 Regulation 
 
Since the realisation that ATP exerts its effects upon the exchanger via PIP2, 
Hilgemann’s group focused their efforts on elucidating the effects of PIP2 on exchanger 
function as well as surface expression, proposing that PIP2 has a role in endocytosis of 
the exchanger (Hilgemann & Ball 1996; Yaradanakul et al. 2007; Shen et al. 2007). As 
discussed the previous section, PIP2 can alleviate the inhibitory effect of PI-PLC on 
ATP stimulation of exchanger current (Hilgemann & Ball 1996). PIP2 application 
results in an increase of peak outward current as well as increasing the steady-state 
current in mouse myocyte and Baby Hamster Kidney (BHK) cell patches, with no effect 
on the inward current in the absence of cytoplasmic Na+ (Yaradanakul et al. 2007). 
Inactivation processes are also ablated by application of PIP2, such that removal of 
cytoplasmic Ca2+ does not result in current inactivation, therefore suggesting an effect 
on the CBDs. These effects are easily reversed following washout of PIP2.  
 
In CHO cells expressing the M1 muscarinic acetylcholine receptor, M1, and NCX, 
treatment with carbachol, a muscarinic agonist results in rapid inhibition of outward 
exchange current, coupled with a small rise in capacitance that slowly decays over 3 
minutes, suggesting exocytosis of the exchanger (Yaradanakul et al. 2007). Capacitance 
of a cell is usually indicative of a change in the size of the cell, suggesting a rise in 
endocytosis or exocytosis of exchangers, as fusion of vesicles containing exchangers 
would increase the surface area of the cell membrane. The authors suggest that this 
effect is due to a direct effect of M1-receptor induced PIP2 depletion on exchanger 
function.  
! 31 
 
The effect of carbachol on inward NCX current in this model is different to the effect 
previously described for outward exchange current. Application of carbachol potentiates 
inward NCX current with an initial decrease in capacitance followed by an increase 
(Yaradanakul et al. 2007). However, at high cytoplasmic Ca2+, carbachol is unable to 
potentiate the current. It appears that the effect of carbachol and its ability to activate 
internalisation of the exchanger is dependent on cytoplasmic Ca2+ concentrations. There 
are contradictions raised by this study. There is evidence pointing towards a role for 
PIP2 in internalisation of the exchanger, however when depleted, internalisation rises. 
The authors explain this could be due to PIP and PIP2 rebounding during continued 
activation of M1 receptors (Zaika et al. 2006). To investigate the significance of PIP2 
synthesis, wortmannin was applied in the presence of carbachol, resulting in an 
abolition of the internalisation of the exchanger (Shen et al. 2007), suggesting that 
synthesis of phosphoinositide is important in exchanger internalisation as this process is 
inhibited by wortmannin. Therefore it does appear that PIP2 is important for exchanger 
internalisation (Yaradanakul et al. 2007; Shen et al. 2007). 
 
Given the effects of PIP2 on the exchanger, it was logical to try and elucidate where on 
the protein its binding site is located. In a study by He and colleagues, it was 
demonstrated that the XIP region is the most likely candidate for the binding site of 
PIP2 (Z. He et al. 2000). Utilising PIP2 loaded vesicles immobilized on PVDF 
membranes, they showed that radiolabelled-XIP bound strongly to very low 
concentrations of PIP2. Unlabelled XIP is able to displace this binding, unlike other 
peptides of other regions of the exchanger, suggesting that binding between XIP and 
PIP2 is specific. To further define the specificity of this interaction, wild-type and a 
mutant exchanger with 9 amino acids of the XIP region deleted were expressed in 
Xenopus oocytes (Z. He et al. 2000). In the deletion mutant, the response to PIP2 is 
completely lost. In the wild-type exchanger, Na+-dependent inactivation is reduced, 
increasing steady-state current as a result. Na+-dependent inactivation is lost in the 
deletion mutant, with no different in current between control and PIP2 stimulated 
patches.  
 
Two mutants that were previously used that show disrupted Na+-dependent inactivation, 
in which the XIP also plays a role (Matsuoka et al. 1997), were utilised to further 
support the role of the XIP region in the regulation of the exchanger by PIP2. The 
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K229Q mutant lacks Na+-dependent inactivation, whereas the F223E mutant shows 
enhanced Na+-dependent inactivation. Application of PIP2 to the K229Q mutant 
exchanger results in a small stimulation of exchange current, approximately 5% (Z. He 
et al. 2000). The authors propose that the inactivation process results in the exchanger 
having reduced affinity for PIP2, and postulate that inactivation may indicate 
dissociation of PIP2 from its binding site on the exchanger. In line with this, PIP2 has no 
effect on the outward current produced by the F223E exchanger mutant (He et al. 2000). 
These results suggest that the XIP region binds to PIP2, which is thus able to regulate 
the inactivation processes of the exchanger. 
 
v Phosphorylation Of NCX1 
 
Evidence regarding the phosphorylation status of NCX1 is controversial. Despite a 
number of papers published on the issue, there is still no consensus on whether NCX1 is 
subject to direct phosphorylation (Morad et al. 2011; Ruknudin et al. 2007). Direct 
measurement of NCX1 phosphorylation has proven to be difficult (Wei 2003; 
Condrescu et al. 1995). Two groups have reported phosphorylation of NCX1 in vitro by 
PKA (Wei 2003; Schulze et al. 2003), with one group demonstrating in vitro 
phosphorylation of NCX1 by PKC (Iwamoto et al. 1996). The paucity of groups 
reporting in vitro and in vivo phosphorylation of NCX1 casts doubt on whether NCX1 
is regulated directly by β-adrenergic signalling. The majority of evidence for NCX1 
phosphorylation comes from PKA-mediated “back-phosphorylation”. Back-
phosphorylation gives an indirect measure of phosphorylation levels of proteins by 
determining if it can be further phosphorylated. Wei et al demonstrated that NCX1 
immunoprecipitated from control and failing hearts showed decreased back-
phosphorylation in failing hearts, leading to the conclusion that NCX1 is 
hyperphosphorylated (Wei 2003). However, high levels of phosphatase activity have 
been reported during maladaptive cardiac hypertrophy and failure (Cheng et al. 2010). 
Based on this, it would be predicted that control NCX1 would also be 
hyperphosphroylated, which is not the case (Wei 2003). Another study provided 
evidence detailing an increase in NCX1 activity and an increase in phosphorylation, 
however it is still reliant on back phosphorylation and not a true in vivo assay 
(Ruknudin et al. 2000). Although lines of evidence exist to support NCX1 
phosphorylation, there is no direct measure.  
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In contrast to evidence supporting NCX1 phosphorylation, rigorous testing on the role 
of phosphorylation of NCX1 has been carried out. Hilgemann addressed whether ATP 
or ATP-dependent phosphorylation was capable of regulating NCX1. However, no 
functional changes in NCX1 current resulting from phosphorylation following 
application of PKA or PKC catalytic subunits to giant excised patches of cardiac 
myocytes or Xenopus oocytes expressing canine NCX1 were observed (Hilgemann & 
Ball 1996; Linck et al. 1998; Matsuoka & Hilgemann 1994). In addition, investigation 
of β-adrenergic stimulation on NCX1 current was performed in guinea pig, mouse and 
rat ventricular myocytes. Effect of isoproterenol on NCX1 current was attributed to 
contaminating ICFTR-Cl, which is also sensitive to Ni2+. In addition, no significant 
difference was observed in the Ni2+-sensitive current following treatment with forskolin. 
It appears that frog heart NCX1 is modulated by PKA, which can be recapitulated in 
canine NCX1 by creating a chimera of canine NCX1 that contains exon X from frog 
NCX1 (He et al. 2003). This suggests that mammalian NCX1 is not directly regulated 
by PKA.  A rather elegant approach to determine whether or not NCX1 is regulated by 
PKA was recently carried out (Wanichawan et al. 2011). Using bioinformatics analysis 
and peptide arrays, NCX1 was screened for putative PKA sites. Several NCX1 peptides 
were phosphorylated, however only one site was identified following mutational 
analysis (threonine 699). Upon expressing wild-type NCX1 or T699A NCX1 in 
HEK293 cells, no phosphorylation was observed, suggesting NCX1 is not a direct 
physiological substrate of PKA (Wanichawan et al. 2011). Although some groups have 
demonstrated changes in NCX1 activity following β-adrenergic stimulation, this may be 
due in part to differences in electrophysiological measurements. To answer whether 
NCX1 is directly regulated by PKA or indeed PKC, more sophisticated single molecule 
imaging techniques will be required to visualise direct interaction of these two 
molecular players. 
 
1.1.7 Contribution Of NCX To Cardiovascular Disease 
 
Given that the Na+/Ca2+ exchanger plays a pivotal role in Ca2+ homeostasis in the heart, 
and the balance of Ca2+ is important to maintenance of excitation-contraction coupling, 
it seems logical to discuss its role in cardiovascular disease. Cardiovascular disease is 
characterised by a mismanagement of Ca2+ that leads to disrupted contraction and 
ultimately heart failure. The disrupted excitation-contraction coupling can be attributed 
to altered sarcoplasmic reticulum Ca2+ accumulation and is proposed to contribute 
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significantly to heart failure pathophysiology (Schillinger et al. 2003). This altered SR 
Ca2+ content in heart failure is proposed to be caused by 3 major factors, 1) an increase 
in the leak of Ca2+ from ryanodine receptors, 2) reduced SERCA activity and 3) 
increased Ca2+ extrusion mediated by NCX (Hasenfuss & Schillinger 2004). As 
discussed previously, in human cardiomyocytes, the balance of Ca2+ removal from the 
cytoplasm by SERCA and NCX is approximately 70% to 28%. However, it has been 
demonstrated in several studies that this ratio shifts to 50:50 in heart failure (Pogwizd et 
al. 1999; Pieske et al. 1999). The proposed reason for this shift is that, in heart failure, 
NCX is upregulated both at the mRNA and protein levels (Pogwizd et al. 1999). This 
results in increased exchange activity, shifting the ratio in favour of NCX. However, the 
rate of exchange does not change, it is simply that there are more exchangers present at 
the sarcolemmal membrane. Pogwizd and colleagues propose that upregulation of NCX 
could contribute to the mechanical dysfunction and arrhythmogenesis observed in heart 
failure. Thus suggesting that upregulation of NCX could enhance Ca2+ extrusion from 
myocytes in early heart failure, but may limit SR Ca2+ loading and cellular Ca2+ 
transients as the heart failure progesses (Pogwizd et al. 1999).  
 
Due to these findings, recent work has focused on the effect of NCX inhibition in 
various models of heart failure. Hobai and colleagues demonstrated that partial 
inhibition of NCX is able to restore Ca2+ handling in a canine model of heart failure 
induced by rapid pacing (Hobai et al. 2004). Application of the peptide, XIP, to 
myocytes from failing hearts, resulted in an increase in the cytoplasmic Ca2+ transients, 
due to the aforementioned shift to Ca2+ extrusion mediated by NCX being partially 
reduced. In addition, since NCX activity was reduced by XIP, myocytes were still able 
to autoregulate intracellular Ca2+ by taking up and releasing more Ca2+ from the SR, 
despite impaired basal SERCA function (Hobai et al. 2004). They postulate that lower 
SR rate of Ca2+ uptake in heart failure, (accompanied by only a 28% downregulation of 
SERCA (O'Rourke et al. 1999)), could be a result of lower amplitude Ca2+ transients 
and lack of Ca2+ stimulation of SERCA, suggesting there may be a cycle between 
decreased SR Ca2+ release and uptake which is interrupted by XIP (Hobai et al. 2004). 
Treatment of failing myocytes with XIP results in improved SR Ca2+ load and 
improvement of the stimulus-dependent positive Ca2+ staircase, as NCX is no longer 
able to extrude the excess Ca2+ from the cytoplasm as effectively.  
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In support of these findings, using an opposite approach, Schillinger and colleagues 
demonstrated a similar effect using adenovirus to increase NCX expression in isolated 
rabbit myocytes (Schillinger et al. 2000). Overexpression of NCX resulted in a decrease 
of the Ca2+ content of the SR, decrease myocyte shortening and blunted forced 
frequency relationship. Utilising the NCX inhibitor, SEA-0400, Ozdemir et al 
investigated the effect of this inhibitor on left ventricular myocytes from healthy pigs or 
mice and mice with heart failure (Ozdemir et al. 2008). They showed that inhibition of 
NCX could display adverse effects in heart failure, as resting Ca2+i is raised and 
relaxation is slowed. However, SR load is increased, meaning that SR uptake is 
preserved, preventing excessive concentrations of cytoplasmic Ca2+ (Ozdemir et al. 
2008). 
 
Knockout and single point mutations in vivo have also been performed on the Na+/Ca2+ 
exchanger to elucidate its role in normal healthy conditions and in heart failure. Global 
knockout of the exchanger leads to embryonic lethality by around E9 – E10.5 
(Wakimoto et al. 2000; Cho et al. 2001; Koushik et al. 2001). However there is some 
controversy surrounding the exact role of NCX in the embryonic lethality observed. 
Henderson et al showed that cardiac-specific knock-out of NCX in mice, which ablates 
80-90% of NCX expressed in the heart, develops to adulthood (Henderson et al. 2004). 
In addition, reintroduction of NCX1 into transgenic mice partially rescues the 
phenotype observed in total knockouts (Cho et al. 2003). The single amino acid 
substitution mutant, which substitutes an asparagine at position 874 to a lysine residue, 
generated by Wansleeben et al also results in embryonic lethality (Wansleeben et al. 
2010). This whole body knock-in mutant was identified via a genetic screen of N-ethyl-
N-nitrosourea (ENU) induced mutations as it affected development of embryos. This 
residue is located in the reentrant loop of the α2-repeat. These embryos die at 
approximately embryonic day E10.5 due to cardiac abnormalities, although expression 
of the exchanger is unchanged at this time compared to wild-type controls. However, 
cardiomyocytes isolated from mutant embryos at E9 display altered characteristics. 
These cells are found fibrillating and contracting randomly, compared to wild-type 
cells, which contracted normally and synchronously in small clusters (Wansleeben et al. 
2010). In addition, Ca2+ transients were smaller in amplitude and fewer in frequency, 
and the action potential was rarely detected and was not repetitive as in wild-types. This 
study also showed that mutants had defective placentation, lack of yolk-sac 
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vascularisations, abnormalities of heart development, culminating in impaired blood 
circulation (Wansleeben et al. 2010). 
 
The model produced by Henderson and colleagues contradicts many of these findings as 
the mice survive to adulthood. Utilising Cre/loxP technology, they were able to generate 
a cardiac-specific ablation of NCX1. Exon 11 was selected as the group had previous 
evidence to suggest that this region was critical for exchange activity (Nicoll, Hryshko, 
et al. 1996a). Exon 11 encodes for amino acid residues 722-813, which corresponds to 2 
TMS, see figure 1.11 for details. The model displays an 80-90% reduction in protein 
levels of NCX1, as measured by immunoblot. There is also a 110kDa band observed 
that corresponds to the exchangers that possess the deletion, but this band is reduced, 
which the authors propose indicates that it is degraded rapidly (Henderson et al. 2004). 
On the whole, the mice appear normal, however they do display reduced cardiac 
contractility. At 7-8 weeks of age there is no change in the thickness or chamber size, 
suggesting an absence of hypertrophy. Although mice have functional myocardium, 
they are unable to cope with stress as homozygous females cannot survive the stress of 
breeding (Henderson et al. 2004). Cardiac function of the knockouts also declined with 
age, and ultimately leads to death, presumably due to heart failure as post mortems 
revealed enlargement of the heart. In addition excitation-contraction coupling of the 
knockout myocytes appears normal. The major difference between knockout and 
control cells is the activity of the L-type Ca2+ channels. The activity is decreased by 
approximately 50%, and perhaps demonstrates a coping mechanism by the myocytes to 
limit the level of Ca2+ influx during the action potential (Henderson et al. 2004). The 
action potential of knockout cells is also altered, lacking the plateau following the 
upstroke that is displayed by control cells, caused by less L-type Ca2+ current, which is 
responsible for the plateau. Taken together, the data outlined above demonstrate that 
complete loss of activity of NCX should be met with caution as it may lead to serious 
adverse cardiac effects. 
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Figure 1.11: Excision Of Exon 11 Deletes Amino Acids 722-813. Topological model 
of NCX1 showing the domains eliminated by excision of exon 11 using Cre-loxP 
technology. Modified from (Henderson et al. 2004). 
 
1.2 Palmitoylation 
 
1.2.1 Overview Of Palmitoylation Mechanism 
 
Palmitoylation is a post-translational modification of a protein with a fatty acid. There 
are two forms of palmitoylation described to date, S-palmitoylation and N-
palmitoylation. S-palmitoylation refers to the addition of palmitate (C16) to cysteine 
residues via a thioester linkage (Linder & Deschenes 2003) (see figure 1.12). However, 
it is not only palmitate that can be linked to proteins, other fatty acids such as saturated, 
monosaturated and polyunsaturated species can be linked to the protein via S-acylation 
(Smotrys & Linder 2004). These fatty acids that are linked in this way can have varying 
chain lengths, typically 14 carbon atoms or longer. N-palmitoylation on the other hand 
is slightly different from S-palmitoylation. N-palmitoylation was first described for 
Sonic Hedgehog (Pepinsky et al. 1998), where palmitate is added to the N-terminal 
cysteine residue via an amide link (see figure 1.12). When palmitate is added to this 
cysteine, a thioester intermediate is formed which is followed by the formation of a 
stable amide link (Linder & Deschenes 2007). The addition of palmitate to the cysteine 
residue is catalysed by palmitoyl-acyl transferases, although there is evidence to suggest 
that palmitoylation can occur spontaneously. Palmitoyl-CoA has been shown to be 
capable of S-acylating cysteine residues using peptides derived from palmitoylated 
proteins (Quesnel & Silvius 1994). Rhodopsin and G-protein α-subunits have also been 
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shown to undergo spontaneous S-acylation (O'Brien et al. 1987; Duncan & Gilman 
1996; Mollner et al. 1998). Despite being possible in vitro, not all proteins are able to 
undergo spontaneous S-palmitoylation. Attempts to autoacylate proteins that are 
palmitoylated in vivo have proved unsuccessful (Duncan & Gilman 1996). Although 
autoacylation occurs in vitro for some proteins, so far whether this occurs in vivo has 
yet to be proven.  
 
Figure 1.12: Addition Of Fatty Acids To Cysteine Residues Via S-Palmitoylation And 
N-Palmitoylation. S-palmitoylation is characterised by the addition of palmitate to a 
cysteine residue via a thioester linkage whereas N-palmitoylation occurs when a N-
terminal cysteine is amide linked to palmitate. Modified from (Resh 2006). 
 
 
 
 
!
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1.2.2 Control Of Palmitoylation 
 
Protein palmitoylation has been shown to be either dynamic, (i.e. cycling through 
phases of palmitoylation and depalmitoylation throughout the lifetime of the protein) or 
stable. As mentioned previously, palmitate or other long chain fatty acid groups can be 
S-acylated to the protein via protein acyl transferases and palmitate is removed by 
thioesterases or hydrolases. 
 
i Protein acyl transferases 
 
Until recently, the enzymes responsible for catalysing the transfer of palmitate and other 
long chain fatty acids on to proteins were largely unknown. Largely, work carried out in 
Saccharomyces cerevisiae led the way for the discovery of yeast protein acyl 
transferases (PATs) and thus enabled identification of their mammalian counterparts. 
Using a genetic screen based on palmitoylation-dependent Ras proteins, the enzyme that 
palmitoylates Ras was identified (Bartels et al. 1999). However, trying to isolate the 
identified enzyme proved unsuccessful, which sparked the belief that palmitoylation 
occurs spontaneously (Mitchell 2006). This hypothesis was further enhanced by the 
instability of enzyme activity after solubilisation (Linder 2001). Another key 
identification led to the discovery of the genes involved in Ras palmitoylation, the 
identification of a palmitoylation-dependent Ras2 molecule (Mitchell et al. 1994). 
Possible enzymes responsible for palmitoylation were identified using mutagenesis of 
the yeast genome to identify lethal mutations in the presence of palmitoylation-
dependent Ras2 protein. Using a palmitoylation-dependent Ras2 yeast strain, mutations 
that resulted in a decrease or inhibition of Ras2 palmitoylation were isolated (Bartels et 
al. 1999). These mutations were termed ERF (Effectors of Ras Function) (Mitchell 
2006). Study of the Erf ezymes in yeast helped elucidate their structure and defining 
features, which have thus led to the identification of their mammalian counterparts. 
Deletion of Erf2, results in a reduction in palmitoylation of Ras2 and decreased 
membrane association (Bartels et al. 1999). A defining characteristic of Erf2 is the Asp-
His-His-Cys (DHHC) domain located between TMD 2 and 3 (Mitchell et al. 2006). 
Scanning the yeast genome identified 7 other DHHC containing proteins, Akr1, Akr2, 
Pfa3, Swf1, Pfa4 and Pfa5. Akr1 (Roth et al. 2002), Erf2 (Lobo et al. 2002) and Pfa3 
(Smotrys et al. 2005) have been demonstrated to catalyse palmitoylation. Identification 
of this conserved DHHC motif between yeast PATs led to the identification of DHHC-
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containing proteins within mammals, insects and plants (Mitchell et al. 2006). There are 
24 identified DHHC containing proteins within humans. 
 
 
 
Figure 1.13: DHHC-containing protein topology. Proposed topology model of DHHC-
containing protein acyl-transferases based on hydropathy analysis of yeast Akr1p. 
Modified from (Politis et al. 2005). 
DHHC proteins are predicted to be multi-pass membrane proteins, with between 4 and 6 
transmembrane domains (Politis et al. 2005). The DHHC domain, which is predicted to 
mediate acylation, lies on the cytosolic side, which was confirmed experimentally for 
Akr1 (figure 1.11) (Politis et al. 2005). The majority of DHHC proteins have been 
found to localise to the secretory pathway, predominantly Endoplasmic Reticulum (ER) 
and Golgi Apparatus (Golgi) (Ohno et al. 2006; Korycka et al. 2012). Interestingly, 
some DHHC proteins are associated with the plasma membrane (Dipolo & Beaugé 
2006; Ohno et al. 2006; Noritake et al. 2009; Greaves & Chamberlain 2010; Korycka et 
al. 2012). A large amount of effort has gone into investigating the mechanism of action 
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of DHHCs. It has long been known that DHHC proteins can be palmitoylated when 
incubated with palmitoyl-CoA (Mitchell et al. 2006). Additionally, mutation of the 
conserved cysteine residue within the DHHC motif abolishes palmitoyl transfer and 
autoacylation (Lobo et al. 2002; Roth et al. 2002). It is hypothesised that DHHC 
autoacylation is a transient intermediate with DHHC enzymes using a two-step ping-
pong mechanism to catalyse transfer of palmitate. Using an HPLC, peptide-based PAT 
assay enabled kinetic constants for substrates to be determined (Jennings & Linder 
2012). Single turnover assays confirmed that autoacylation represents a transient 
intermediate of the two-step ping-pong mechanism. In addition, this study also showed 
differences in preferences for available acyl-CoA between DHHC2 and DHHC3 to 
autoacylate with and transfer acyl chains longer than 16-carbon palmitate (Jennings & 
Linder 2012).  
Recently, oligomerisation of DHHCs was described (Lai & Linder 2013). Formation of 
dimers and higher-order oligomers is a property of numerous membrane proteins 
including ion channels, transporters and receptors. Bioluminescence resonance energy 
transfer (BRET) uses Renilla luciferase (the luminescent energy donor) and its substrate 
coelenterazine, which transfers energy to a GFP variant (the energy acceptor) (Achour 
et al. 2011). Using BRET, homomultimerisation of DHHC2 and DHHC3 was 
demonstrated in intact cells as well as membrane preparations (Lai & Linder 2013). 
However, BRET suggested that these oligomers were not stable and were dynamic at 
the cell membrane. Interesting, mutation of the cysteine within the DHHC motif results 
in increased oligomerisation. Surprisingly, inhibition of enzyme activity resulted in 
increased oligomerisation, while in contrast, increasing palmitoyl-CoA availability 
decreased oligomerisation (Lai & Linder 2013). This suggests that when in an 
oligomeric state, DHHCs are inactive. However, convalently linked DHHC3 dimers are 
enzymatically active, although less so than the monomeric form. 
One of the major questions surrounding the discovery of DHHCs is why are there 23 
isoforms. 12 of the DHHCs are found to be expressed in the Golgi alone (Ohno et al. 
2006). Co-expression studies in mammalian cells have revealed that DHHCs display 
substrate specificity (Fukata et al. 2004). In support of this, a study conducted in yeast 
confirmed that inactivation of specific DHHCs led to loss of palmitoylation of specific 
substrates (Roth et al. 2006). Several SNARE proteins showed reduced palmitoylation 
upon mutation of the ER-localised DHHC protein, Swf1. This study also showed that 
some DHHCs show preference to particular types of substrates: Swf1 targeted 
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transmembrane proteins with juxtamembrane cysteine residues, whereas most Akr1p 
substrates were soluble proteins (Roth et al. 2006). These data suggest that DHHCs do 
indeed display substrate specificity. It was shown that structural features regulate 
DHHCs substrate specificity. Huntingtin has been demonstrated to be palmitoylated by 
DHHC17 but not DHHC3 (Huang et al. 2009). DHHC17 possess several ankyrin 
repeats at its N-terminus and transfer of this region to the N-terminus of DHHC3 results 
in binding and palmitoylation of huntingtin to the same level as wild-type DHHC17 
(Huang et al. 2009). Although transfer of the ankryin repeat allows DHHC3 to 
palmitoylate an non-target protein, there are targets known to be targets of both 
DHHC17 and DHHC3 (Greaves et al. 2008; Greaves et al. 2009).  
Not only are structural features of DHHCs important for substrate specificity, but the 
substrates themselves also possess features that influence which DHHCs palmitoylates 
them. It has been demonstrated for SNAP25 that it is palmitoylated by DHHC3, 
DHHC7 and DHHC17 (Fukata et al. 2006). The sequence downstream of the 
palmitoylation site within SNAP25 is important for directing palmitoylation by 
DHHC17 (Greaves et al. 2009). Although this region is important for directing 
DHHC17, it is not required for palmitoylation by DHHC3 and DHHC7 of SNAP25. 
Supporting this data, Src homology 4 (SH4) domain purified from Vac8 was 
palmitoylated by not only Pfa3 but also by other DHHC proteins (Nadolski & Linder 
2009), thus suggesting that regions outwith acylation sites contribute to DHHC 
substrate specificity. It is emerging that DHHC-substrate interactions involve 
palmitoylation of target cysteine residues in the substrate and the DHHC domain, as 
well as interactions between other sites/domains present within both proteins (Greaves 
& Chamberlain 2010). 
 
ii Thioesterases 
 
In addition to enzymes that catalyse the addition of palmitate to target proteins, 
enzymes that remove it are involved in the control of palmitoylation. To date, relatively 
few proteins that are involved in depalmitoylation have been identified. Only a few acyl 
protein thioesterases (commonly referred to as thioesterases) have been identified to 
catalyse depalmitoylation (Hornemann 2014). Acylprotein thioesterase-1 (APT1) was 
originally isolated from rat liver as a lysophospholipase (Sugimoto et al. 1996), but it 
was later shown to have a preference for palmitoylated proteins (Duncan & Gilman 
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1998; Zeidman et al. 2009). APT1 is a cytosolic protein with widespread tissue 
distribution (Toyoda et al. 1999). It removes palmitate from proteins on the cytosolic 
surface of membranes (Linder & Deschenes 2007). APT1 has demonstrated 
lysophospholipase activity towards palmitoylated glycerol-3-phosphocholine (Sugimoto 
et al. 1996) and can remove palmitate from Giα, H-Ras and endothelial nitric-oxide 
synthase (Duncan & Gilman 1998; Yeh et al. 1999; Linder & Deschenes 2007; Duncan 
2002). In yeast cell deficient in an APT1 homologue, deacylation of Giα is decreased 
(Duncan 2002). Infusion of APT1 protein caused 50% reduction in steady state 
palmitoylation and reduced Gαq palmitoylation and membrane association in 
permeabilised platelets (Sim et al. 2007). Co-expression of APT1 with eNOS results in 
increased levels of eNOS depalmitoylation compared to eNOS alone (Yeh et al. 1999). 
Dislocation of SNAP-23 from plasma membrane has been reported upon increasing 
APT1 levels in cells (Sim et al. 2007).  
 
To date, no consensus motif has been described to target thioesterases (Zeidman et al. 
2009). Based on data discussed previously, APT1 is promiscuous in the substrates it 
depalmitoylates. APT1 can depalmitoylate structurally different substrates, soluble 
intracellular proteins as well as integral membrane proteins (Zeidman et al. 2009). 
Despite its promiscuity, APT1 does display specificity towards substrates it 
depalmitoylates. Caveolin, an integral membrane protein which is palmitoylated on 
cysteine residues within its intracellular C-terminal domain (Dietzen et al. 1995), is not 
depalmitoylated by APT1 under conditions where eNOS depalmitoylation is reported 
(Yeh et al. 1999). Furthermore, substrates are not depalmitoylated with similar 
efficiencies. Rat APT1 has been reported to be 10-fold more efficient at 
depalmitoylating Gαi1 compared to Ras (Zeidman et al. 2009), which is more 
pronounced in yeast APT1 (Duncan 2002). Activation status of substrates may 
influence catalytic efficiency of APT1; free Gαi1 is more readily depalmitoylated than 
heterotrimeric Gαi1 (Duncan 2002). 
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Figure 1.14: Schematic Representation Of Thioesterases. Schematic demonstrating 
interplay between DHHCs and acyl protein thioesterases. Modified from (Hornemann 
2014). 
 
An alternative explanation for variation in substrate specificity of APT1 could be due to 
selectivity of fatty acids linked to substrates (Zeidman et al. 2009). Semliki Forest virus 
(SFV) protein E2 and influenza virus protein HEF are acylated with palmitic and stearic 
acid respectively, and are strong APT1 substrates. In contrast, SFV E1 protein, which is 
mainly modified with palmitate (Veit et al. 1996), is a poor APT1 substrate (Veit & M. 
F. G. Schmidt 2001). These results suggest that APT1 does not demonstrate preference 
for fatty acid chain length in order to depalmitoylate substrates. Recently, an APT1 
inhibitor, palmostatin B was developed, shown to affect Ras localisation and signalling 
(Dekker et al. 2010). Following palmostatin B treatment, H- or N-Ras relocalise from 
the plasma membrane to endomembrane compartments and growth-factor induced 
activation of Ras on the Golgi is blunted. Palmostatin B could be useful for studying the 
role of APT1 in cells.  
 
The crystal structure of APT1 has been solved (Devedjiev et al. 2000). This revealed 
that APT1 is a member of the large family of α/β hydrolases and has a classical triad 
composed of Ser114, His203 and Asp169 in APT1 (Devedjiev et al. 2000). A Blast 
search of APT1 sequence reveals homologues in a wide variety of species, including 
humans and other mammals as well as lower organisms (Zeidman et al. 2009). Thus, the 
conservation of APT1 throughout evolution indicates an essential role for this 
thioesterase. 
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APT2 is a homolog of APT1 and shows 64% amino acid sequence homology (Toyoda 
et al. 1999). Similar to APT1, APT2 mRNA has been reported in several different 
tissues, suggesting widespread, ubiquitous expression (Toyoda et al. 1999). APT2 has 
been reported to depalmitoylate GAP-43 (Tomatis et al. 2010). Singly acylated GAP-43 
were deacylated faster than doubly acylated counterparts, which was not catalysed by 
APT1. APT2 has also been shown to depalmitoylate H-Ras (Rusch et al. 2011).  
Despite evidence showing that APT1 and APT2 are capable of depalmitoylating 
proteins, there is little data on the mechanism by which this is achieved. A recent study 
showed that APT1 and APT2 are themselves palmitoyated and inhibiting palmitoylation 
affected their membrane localisation as well as that of substrates (Kong et al. 2013). 
APT1 catalyses self-depalmitoylation, and that of APT2, thus promoting dynamic 
palmitoylation of both thioesterases. Inhibition of APT1 with palmostatin B results in 
increased membrane association of APT2. In constrast, inhibition or knockdown of 
ATP2 had no effect on APT1. It is likely that more thioesterases remain to be 
discovered and studied in depth. 
 
Palmitoyl-protein thioesterase 1 (PPT1) has been reported to depalmitoylate proteins via 
thioesterase activity. PPT1 is located in lysosomes and depalmitoylates substrates 
during the process of protein degradation, therefore is unlikely to be involved in 
dynamic palmitoylation (Hellsten et al. 1996; Verkruyse & Hofmann 1996). PPT1 has 
been shown to interact with F(1)-complex of mitochondrial ATP synthase and levels of 
F(1) α and β subunits were increased in PPT1-deficient mice (Lyly et al. 2008). PPT1 
was isolated from bovine brain extracts based on its ability to depalmitoylate [3H]-
palmitate-labeled H-Ras (Camp & Hofmann 1993). In addition to H-Ras 
depalmitoylation, PPT1 was shown to depalmitoylate Gα subunits and acyl Co-As in 
vitro, showing preference for carbon chain lengths between 14 and 18 (Soyombo & 
Hofmann 1997). Interestingly, mutations within the PPT1 gene were found to be 
associated with infantile neuronal ceroid lipofuscinosis (INCL) (Vesa et al. 1995). 
Accumulation of granular deposits inside cells is associated with INCL, and 
[35S]cysteine-labeled lipid thioesters accumulated in immortalized lymphoblasts from 
INCL patients, which was reversed by adding recombinant PPT1 (Lu et al. 1996). 
Recombinant PPT1 was taken up by cells and trafficked to lysosomes (Hellsten et al. 
1996), supporting the normal function of PPT1, which is to depalmitoylate proteins as 
they are degraded.  
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PPT2 is a homlog of PPT1 that shares 18% identity at the amino acid level (Soyombo & 
Hofmann 1997). PPT2 has comparable thioesterase activity to PPT1, and is also a 
lysosomal enzyme. Unlike PPT1, PPT2 does not remove palmitate from palmitoylated 
proteins that serve as substrates for PPT1. PPT2 shows specificity for palmitoyl-CoA, 
indicating a novel role in hydrolysis of lipid thioesters in lysosomes (Soyombo & 
Hofmann 1997).  
 
iii Hydrolases 
 
APT1 is a member of the α/β-hydrolase domain (ABHD) family. The ABHD family 
contains at least 19 proteins and is part of a superfamily of proteins that contain an α/β-
hydrolase fold (Ollis et al. 1992). The α/β-hydrolase fold is composed of 8 β-strands, 
with the second strand being anti-parallel (Lord et al. 2013). These β-strands form a 
core β-sheet, surrounded by helices and loops connecting the β-strands. The hydrolase 
activity is due to a catalytic triad of nucleophile-acid-histidine residues, located on loop 
regions. Nucleophilic residues, such as serine, cysteine or aspartic acid are located in a 
tight loop, known as the nucleophilic elbow following β5 strand. The nucleophilic 
elbow can be identified by a Sm-X-Nu-X-Sm consensus motif, where Sm is a small 
reside, X is any residue and Nu is the nucleophilic residue (Nardini & Dijkstra 1999). 
This motif is GXSXG in most ABHD members. The acidic residue is predominantly 
either a glutamate or aspartate, located after strand β7. The histidine residue within the 
catalytic triad is conserved between ABHD proteins (Nardini & Dijkstra 1999) and is 
located in a variable loop following the final β strand. The majority of ABHD proteins 
contain a conserved His-XXXX-Asp motif, which has previously been linked to 
acyltransferase activity (Ghosh et al. 2008; Montero-Moran et al. 2010). As a result, 
several ABHD have been predicted to have both hydrolase and acyltransferase activity. 
In a study to characterise dynamic protein palmitoylation, targets of hexadecyl 
fluorophosphonate (HDFP), a candidate probe for depalmitoylating enzymes, were 
identified. Several ABHD proteins were shown to interact with HDFP (Martin et al. 
2011). The authors argue that interaction with HDFP identifies hydrolases that show 
preference for lipid substrates. However, ABHD show diverse function, therefore it is 
unlikely that all share similar functional activity. Further study will be required to 
determine substrates for these enzymes and whether they are truly involved in 
depalmitoylating palmitoylated proteins. 
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Figure 1.15: Human ABHD Family. A. Phylogenic relationship of ABHD proteins, 
based on Clustal W alignment. Numbers are indicative amino acid number in full-
length protein. Red lines – predicted active site nucleophile, blue lines – predicted acyl 
transferase motif (HXXXXD). B. Conserved nucleophilic and acyltransferase motifs. -- 
indicates where the acyltransferase motif is absent. Modified from (Lord et al. 2013).  
1.2.3 Palmitoylation And Role In Control Of Protein Biology 
 
Large-scale profiling studies revealed that the number of proteins that undergo 
palmitoylation varies from ~50 in yeast (Roth et al. 2006) to several hundred in 
mammals (Martin & Cravatt 2009; W. Yang et al. 2010). Palmitoylation has been 
reported for both soluble and transmembrane proteins, and the list of target proteins is 
expanding. A number of key cellular functions have shown to be affected by 
palmitoylation, such as membrane targeting, membrane cycling, regulation of activity 
and endocytosis.  
 
i  Membrane Targeting 
 
Palmitoylation has been implicated in the trafficking of proteins between intracellular 
organelles and in the segregation or clustering of proteins within membrane 
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compartments (Linder & Deschenes 2007). Due to the localisation of DHHCs to 
membranes, palmitoylation must occur at membranes. Therefore, proteins that are 
palmitoylation targets must interact with the membrane at least transiently (Smotrys & 
Linder 2004). Following palmitoylation, stable membrane association is promoted. 
Palmitoylation is often found with N-myristoylation or prenylation to regulate 
membrane interactions of soluble proteins (Salaun et al. 2010). N-myristolylation or 
prenylation of target proteins acts to increase hydrophobicity and promote membrane 
association, however single lipid modifications are only sufficient for transient 
membrane interactions (Shahinian & Silvius 1995). Two closely positioned lipid 
modifications, however, promotes stable membrane association (Shahinian & Silvius 
1995). Therefore, at the cellular level, myristolyation and prenylation may act to 
facilitate transient membrane association to enable interaction with membrane-bound 
DHHCs and allow palmitoylation to occur. As a result, palmitoylation is essential for 
stable membrane attachment of several proteins, such as farnesylated Ras and 
myristoylated Gα subunits (Hancock et al. 1990; Linder et al. 1993; Parenti et al. 1993). 
However, several soluble proteins are exclusively modified by palmitoylation. 
Therefore it has been suggested that these proteins rely on intrinsic weak membrane 
affinity for transient membrane association to enable interaction with DHHCs and thus 
palmitoylation.  
For a number of proteins, palmitoylation appears to serve as a signal for rentention in 
the Golgi or ER or as a cue to traffic substrates to membranes (Greaves & Chamberlain 
2007). In the case of AMPA receptors, in which all subunits are palmitoylated, 
palmitoylation at 1 site was enhanced by overexpressed of DHHC3, resulting in Golgi 
accumulation of the receptor and decreased cell surface expression (Hayashi et al. 
2005). This suggests that preferential palmitoylation at this site promotes retention of 
the receptor in the Golgi. Interestingly, this effect of palmitoylation on targeting of 
proteins is not restricted to AMPA receptors. Palmitoylation of PSD-95 at 2 N-terminal 
cysteines is required for trafficking to the synaptic membrane (Craven et al. 1999; El-
Husseini et al. 2000) and disruption of dual palmitoylation of PSD-95 blocks ion 
channel clustering mediated by PSD-95. Similarly, palmitoylation of γ2 subunit of 
GABAA receptors by DHHC3 has been demonstrated to regulate membrane trafficking 
(Keller et al. 2004). As with PSD-95 and γ2 subunit of GABAA receptors, human δ 
opioid receptor is palmitoylated at 2 sites and is dynamically regulated at one of these 
sites (Petaja-Repo et al. 2006). Inhibition of palmitoylation with 2-BP results in 
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decreased cell surface expression, suggesting that palmitoylation is required for efficient 
intracellular transport. These results suggest that palmitoylation is required for 
biosynthetic delivery of substrates to the plasma membrane. For mucin-like MUC1 
protein, palmitoylation at 2 cysteine residues is not required for targeting to the cell 
surface, but is linked to trafficking from recycling endosomes to the plasma membrane 
(Kinlough et al. 2006). Utilising an ω-alkynyl fatty acid analogue, Wnt and Sonic 
Hedgehog (Shh) were shown to be palmitoylated and that membrane association of 
these proteins was promoted by palmitoylation (Gao et al. 2011). In a similar manner, 
palmitoylation of GAP43 is required for its membrane targeting (Gauthier-Kemper et al. 
2014). Palmitoylation, in this instance, tags GAP43 for global sorting via exocytic 
vesicles. It was also demonstrated that phosphorylation of palmitoylated GAP43 
regulates its mobility and plasma membrane targeting. 
 
ii Membrane Cycling 
 
The best studied example of palmitoylation regulating membrane cycling are the Ras 
oncogenic proteins. Ras membrane targeting is dependent on the C-terminus of the 
protein, which includes the CaaX box and a hypervariable domain that contains a 
palmitoylation site or a polybasic residue (Wright & Philips 2006). N-Ras and H-Ras 
are palmitoylated following targeting to the ER (Linder & Deschenes 2007). The 
secretory pathway and a functional Golgi are required for plasma membrane localisation 
of N-Ras and H-Ras. Appropriate trafficking of N-Ras and H-Ras requires 
palmitoylation. N-Ras is palmitoylated on a single cysteine residue, which is sufficient 
for trafficking to the plasma membrane from the ER. H-Ras, however, can be 
palmitoylated on one or both of two cysteine residues, Cys181 and Cys184 (Roy et al. 
2005). Palmitoylation of Cys184 results in Golgi localisation of H-Ras. In contrast, 
palmitoylation of Cys181 causes plasma membrane localisation to cholesterol-rich 
micro-domains (Linder & Deschenes 2007). These results suggest that site-specific 
palmitoylation of H-Ras can influence trafficking and microdomain localisation. In 
addition to microdomain localisation, differential palmitoylation of N-Ras and H-Ras 
governs distinct Golgi sub-compartment localisation (Lynch et al. 2014). Doubly-
palmitoylated H-Ras is distributed throughout the Golgi, whereas singly palmitoylated 
N-Ras is confined to the trans Golgi. Singly palmitoylated H-Ras shows a similar Golgi 
localisation to that of singly palmitoylated N-Ras. Conversely, doubly palmitoylated N-
Ras showed Golgi localisation similar to wild-type H-Ras (Lynch et al. 2014). 
! 50 
 
Palmitoylation of Ras proteins is highly reversible, with half life ranges from 20 
minutes to 2 hours for H-Ras (Magee et al. 1987; Lu & Hofmann 1995; Baker et al. 
2003). The role of dynamic palmitoylation was elegantly demonstrated using 
quantitative fluorescence microscopy and photobleaching techniques (Rocks et al. 2005; 
Goodwin et al. 2005). Palmitoylated Ras isoforms are found at the plasma membrane, 
whereas depalmitoylated forms are found predominantly at the ER and the Golgi 
(Apolloni et al. 2000; Choy et al. 1999). Using fluorescence recovery after 
photobleaching (FRAP), Golgi-localised Ras was repopulated by rapid exchange rather 
than by a vesicle mediate mechanism (Rocks et al. 2005). The rapid replacement of Ras 
by a non-vesicle mediated mechanism was reminiscent of nonpalmitoylated Ras, 
suggesting interconversion of Ras between palmitoylated and depalmitoylated states. In 
addition, fluorescently-labelled N-Ras coupled to farnesylated peptides with reversible 
palmitoyl thioester-linkage resulted in wild-type N-Ras associating with the Golgi and 
plasma membrane (Rocks et al. 2005). In contrast, N-Ras coupled to farnesylated 
peptides with non-cleavable hexadecyl group resulted in non-specific membrane 
association. These results suggest that palmitoylation is required for correct subcellular 
targeting of Ras, and that depalmitoylation is also required for Ras trafficking. 
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Figure 1.16: Palmitoylation And Depalmitoylation Are Required For Ras 
Trafficking. 1: Farnesylation targets H/N-Ras to the ER. Post-prenylation processing 
of CaaX box results in C-terminal farnesyl carboxymethylester (OMe). 2: H/N-Ras is 
palmitoylated. Dual modified H/N-Ras can traffic to the Golgi (3) and the plasma 
membrane (4) via the classical secretory pathway. 5: H/N-Ras can be depalmitoylated 
by thioesterases at the plasma membrane, causing rapid non-vesicular exchange with 
endomembranes (6). 7: H/N-Ras may be trapped on the Golgi by another PAT. The 
palmitoylation cycling accounts for dynamic subcellular trafficking of Ras by vesicular 
(solid arrows) and non-vesicular (dashed arrows) pathways. Modified from (Linder & 
Deschenes 2007).  
 
iii Regulation Of Ion Transport 
 
Recent advances in proteomic approaches to characterise protein palmitoylation has 
revealed an important role for palmitoylation in the regulation of various ion channels 
and transporters (Shipston 2011). Plasma membrane localisation of ion channels is 
dependent on interplay between channel synthesis, trafficking to membrane and 
internalisation, recycling and degradation. Palmitoylation influences this cycle by acting 
at distinct stages of the trafficking pathway (Shipston 2011). For some channels, such as 
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voltage-gated Na (Nav1.2) (J. W. Schmidt & Catterall 1987) and potassium (Kv1.5) 
(Zhang et al. 2007), palmitoylation has been reported to occur early in the biosynthetic 
pathway and regulates channel maturation. In case of nicotinic acetylcholine receptors, 
palmitoylation is involved in formation of ligand binding sites (Alexander et al. 2009; 
Drisdel et al. 2004). Blocking palmitoylation with 2-bromopalmitate results in loss of 
ligand binding sites. Failure to form ligand binding sites in the absence of 
palmitoylation of α4β2 and α7 subtypes suggests that palmitoylation occurs during 
subunit assembly and regulates formation of binding sites (Alexander et al. 2009). The 
role of palmitoylation on membrane targeting of ion channels varies from channel to 
channel. NMDA receptors, which have 2 distinct clusters of palmitoylation sites within 
their C-terminal region, are regulated in different ways depending on the site of 
palmitoylation (Hayashi et al. 2009). Palmitoylation within the first cluster of cysteine 
residues increases phosphorylation by Src protein tyrosine kinases, thus promoting 
stable membrane expression of NMDA receptors. In contrast, palmitoylation of the 
second cluster results in accumulation of receptors within the Golgi and thus reduces 
membrane expression. These results suggest that palmitoylation is capable of 
differential regulation of NMDA-receptor trafficking, which may be important for 
synaptic plasticity (Hayashi et al. 2009). Similarly, palmitoylation of AMPA receptors 
on TMD2 results in accumulation in the Golgi and decreased membrane expression 
(Hayashi et al. 2005), whereas palmitoylation on a C-terminal site decreases interaction 
with 4.1N protein and regulates AMPA- and NMDA-induced AMPA receptor 
internalisation. However, this is not the case for all ion channels. Palmitoylation of BK 
channels regulates cell-surface targeting but is not essential (Jeffries et al. 2010). 
 
In addition to regulation of membrane trafficking of ion channels, palmitoylation also 
governs spatial organisation once at the plasma membrane. The mammalian water 
channel aquaporin-4 (AQP4) assemble into square arrays and mediate bidirectional 
water transport across membranes (Suzuki et al. 2008). However, only the shorter 
isoform forms these square arrays. The longer form AQP4M1 possesses 2 
palmitoylation sites at its N-terminus. Mutation of these residues resulted in square 
array formation by AQP4M1, suggesting palmitoylation prevents it from forming 
square arrays (Suzuki et al. 2008). P2X7, an ATP-gated channel, requires 
palmitoylation to be targeted to lipid rafts (Gonnord et al. 2009). Abolition of P2X7 
palmitoylation results in a decrease in cell surface expression and ER retention and 
promotes proteolytic degradation. In the case of P2X7, the palmitoylated form is found 
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in detergent-resistant membranes. This suggests that palmitoylation is involved in 
targeting P2X7 to lipid rafts (Gonnord et al. 2009). In neurons, palmitoylation has been 
shown to play a role in the synaptic clustering of ion channels, as well as their agonist-
induced internalisation (Shipston 2011). Palmitoylation of γ2 subunit of neuronal 
GABAA receptors is involved in membrane targeting as well as synaptic clustering. 
Mutational or pharmacological inhibition of palmitoylation resulted in decreased 
synaptic clustering of GABAA receptors and steady-state membrane localisation 
(Rathenberg et al. 2004). As mentioned previously, palmitoylation regulates agonist-
induced internalisation of AMPA receptors (Hayashi et al. 2005). The pool of 
palmitoylated GluR2 subunits increased in response to acute AMPA or NMDA 
treatment, but not GluR1 (G. Yang et al. 2009). Therefore, these results suggest that 
palmitoylation of AMPA receptors is a subunit-specific process that plays a role in its 
regulation and trafficking.  
 
Despite a number of studies examining the effect of palmitoylation on membrane 
targeting and spatial organisation of a number of ion channels, few studies have 
elucidated the effect of palmitoylation on activity (Shipston 2011). Palmitoylation of 
voltage sensitive Kv1.1 channel revealed a role for palmitoylation in the regulation of 
channel activity (Gubitosi-Klug et al. 2005). Kv1.1 is palmitoylated within an 
intracellular linker domain between TMDs 2 and 3 at Cys243. Mutation of this cysteine 
results in a 20-mV leftward shift in the current-voltage relationship of the channel, 
compared to wild-type. The authors argue that this is due to palmitoylation modulating 
voltage sensing via protein-membrane interactions (Gubitosi-Klug et al. 2005). 
Palmitoylation was demonstrated to regulate epithelial Na+ channels (Mueller et al. 
2010). Abolition of palmitoylation of β subunits at Cys43 and Cys557 by mutagenesis 
showed significantly decreased amiloride-sensitive whole cell currents. In addition, 
Na+-inhibition was enhanced and open probability was reduced compared to wild-type 
ENaC (Mueller et al. 2010). Finally, palmitoylation of β2a subunit of Cav2.2 channels is 
involved in the voltage-dependent inactivation of this channel. Blockade of 
palmitoylation via mutagenesis of palmitoylated cysteine residues reduces the voltage-
dependent inactivation mediated by β2a subunit (Stephens et al. 2000). Thus, it appears 
that palmitoylation can regulate activity of target ion channels, presumably by either 
modulating their interaction with the membrane or by changing their structure thus 
impacting their activity. 
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Interestingly, for several ion channels and transporters, palmitoylation has been shown 
to influence regulation by other post-translational modifications. It was demonstrated in 
GluR6 kainate receptors that palmitoylation influenced regulation by phosphorylation 
(Pickering et al. 2005). Unpalmitoylated mutant GluR6 served as a better substrate for 
PKC-mediated phosphorylation. Similarly, palmitoylation inhibited PKC-mediated 
phosphorylation of GluR1 subunits of AMPA receptors (Lin et al. 2009). The disruption 
of phosphorylation in both cases is likely due to steric hindrance as the palmitoylated 
cysteine is adjacent to the consensus phosphorylation site. Conversely palmitoylation 
can promote phosphorylation. Fyn-dependent tyrosine phosphorylation of NR2A 
subunit of NMDA receptors is lost upon mutation of palmitoylated residues (Hayashi et 
al. 2009). As a result, NMDA receptors are prone to internalisation, which is prevented 
upon enhancement of phosphorylation by palmitoylation. In addition, the cardiac 
Na+/K+ ATPase is also regulated indirectly by palmitoylation of its accessory protein, 
phospholemman (PLM) (Tulloch et al. 2011). Palmitoylation of PLM results in 
inhibition of Na+/K+ ATPase. In addition, phosphorylation of PLM at Ser68 promotes 
its palmitoylation, which is lost upon mutation of Ser68. Phosphorylation of PLM has 
historically been reported to enhance Na+/K+ ATPase activity (Fuller et al. 2004; Fuller 
et al. 2009; Fuller et al. 2012). Therefore it is surprising that phosphorylation of PLM 
results in increased palmitoylation. It is hypothesised that phosphorylation enhances the 
mobility of the intracellular domain of PLM, thus making it more accessible to PATs 
(Tulloch et al. 2011). Cross-talk between phosphorylation and palmitoylation also 
occurs for the BK channel. Palmitoylation of a dicysteine motif in an alternative spliced 
C-terminal STREX domain, promotes association of this domain with the plasma 
membrane (Tian et al. 2008). PKA phosphorylation of a serine upstream from this 
region results in dissociation of STREX from the plasma membrane, thus leading to 
channel inhibition. Not only does palmitoylation influence ion channel targeting, but 
also activity and its regulation by other post-translational modifications. 
 
iv Massive Endocytosis (MEND) 
 
Recently, a novel role for palmitoylation was described. A newly discovered form of 
endocytosis, termed massive endocytosis (MEND) was shown to be regulated by 
palmitoylation (Hilgemann et al. 2013; Lin et al. 2013). MEND was demonstrated to be 
initiated by excessive influx of Ca2+ and to occur during cell wound healing response 
(Corrotte et al. 2013). The major characteristic of MEND is internalisation of large 
! 55 
portions of ordered plasma membrane, up to 50% (Lariccia et al. 2011). In response to 
stimulation of NCX1 outward exchange current (influx of Ca2+ ions), resulting in 
mitochondrial membrane depolarisation, formation of permeability transition pores 
(PTPs) was initiated. As a result of mitochondrial PTPs opening, Coenzyme A is 
released into the cytoplasm (Hilgemann et al. 2013). Increases in cytoplasmic CoA 
results in synthesis of Acyl-CoA, providing substrates for DHHC enzymes. This 
increases palmitoylation of transmembrane proteins and promoting their clustering into 
ordered domains. Thus an increase in ordered domains to a critical size triggers MEND. 
In addition, metabolites that promote PTP opening rapidly initiate MEND. Depletion of 
cellular fatty acids by addition of fatty-acid free BSA suppressed MEND in BHK 
fibroblast cells. Surprisingly, inhibition of palmitoylation with 2-BP results in inhibition 
of MEND by ~70%, supporting a role for palmitoylation in the reaction pathway that 
triggers MEND (Hilgemann et al. 2013). In addition, siRNA knockdown of DHHC5 
from BHK fibroblasts results in blockade of MEND. This suggests that generation of 
cytoplasmic acyl CoA promotes palmitoylation of substrates by DHHC5. However, 
addition of CoA alone was not sufficient to induce MEND, only when added in the 
presence of PKC activators or H2O2, both activated by Ca2+ influx, in MEND observed. 
PKC activation or H2O2 release is predicted to increase palmitoylation site availability 
and thereby perpetuating MEND (Hilgemann et al. 2013). 
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Figure 1.17: Hypothetical MEND Pathway. In response to membrane depolarisation, 
mitochondrial PTPs open and release CoA into the cytoplasm. CoA is metabolised to 
acyl CoA, which serves a substrate for DHHC5. This results in palmitoylation of 
transmembrane proteins, which causes them to cluster. Upon reaching a critical point, 
this clustering of proteins causes internalisation of the surface membrane via MEND. 
Modified from (Hilgemann et al. 2013). 
 
In addition to MEND in BHK fibroblasts, a physiological context was also examined 
(Lin et al. 2013). Acute ischemic events are becoming an increasingly prevalent cause 
of death. Surprisingly, most of the damage caused by ischemia occurs during 
reoxygenation of the tissue, as mitochondria generate reactive oxygen species (ROS) at 
an increased rate (Jennings 2013). A key characteristic of reperfusion injury is the 
swelling of mitochondria and opening of PTPs, ultimately leading to cell death. Given 
the evidence described above, the authors sought to determine whether MEND played a 
key role in reperfusion injury following ischemia. Using mouse right ventricular (RV) 
cardiac strips, MEND was initiated during reoxygenation of anoxic muscle (M. J. Lin et 
al. 2013). Additionally, MEND was accompanied by an increase in palmitoylation. 
MEND could be blocked in these experiments by treatment of cardiac tissue with agents 
that protect the heart from reperfusion injury, such as cyclosporine and adenosine. 
Furthermore, mouse RV strips from gene-trapped DHHC5 (DHHC5-GT) mice, in 
which DHHC5 expression is almost absent, subjected to ischemia-reperfusion show 
decreased MEND. This is associated with a decrease in palmitoylation of known 
DHHC5 targets, namely PLM and flotillin-2. Finally, DHHC5-GT mice show increased 
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contractile responses post ischemia, compared to WT controls. This suggests that down-
regulation of palmitoylation may mimic preconditioning (Lin et al. 2013). Thus it 
appears that internalisation of sarcolemmal membrane during ischemia-reperfusion may 
contribute to acute death of cardiac function during such episodes. 
 
1.3 Project Aims 
 
Palmitoylation is becoming an increasingly important post-translational modification, 
regulating a wide variety of proteins and their activity. Currently, the cardiac palmitoyl 
proteome is uncharacterised and the effect of palmitoylation largely unexplored. Given 
the important role of ion homestasis within cardiac muscle to maintain efficient cardiac 
function, regulation of the molecular players involved merits further study. NCX1 is 
involved in the removal of Ca2+ following contraction. Although regulation of NCX1 by 
the ion transporters as well as PIP2 regulation has been well studied, regulation by post-
translational modifications has not. To date, palmitoylation of NCX1 has not been 
documented, nor the effect on its activity. 
 
This study examines palmitoylation of NCX1 and the functional consequences thereof. 
Palmitoylation of NCX1 in cardiac tissue will be verified, followed by mass 
spectrometry analysis to determine other palmitoylated proteins within cardiac muscle. 
Additionally, using mass spectrometry and site-directed mutagenesis, palmitoylation 
site(s) within NCX1 will be elucidated. In addition to determining the cardiac palmitoyl 
proteome, control of palmitoylation via expression of DHHCs within cardiac muscle 
will be investigated. As with all novel findings, a functional role must be established. 
Whether palmitoylation functionally affects NCX1 activity will be determined. Finally, 
given the role of NCX1 in cardiovascular disease, whether palmitoylation of NCX1 is 
differentially regulated in in vivo models of heart failure will be elucidated. 
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2.1 Chemicals And Reagents 
 
All general chemicals were of highest grade available and obtained from Sigma Aldrich 
(Gillingham, Dorset, UK) and Fisher Scientific (Loughborough, Leicestershire, UK) 
unless otherwise stated. 
 
2.2 Ethics Statement 
 
All work involving animals was undertaken using a method designated Schedule 1 of 
the Animals (Scientific Procedures) Act 1986. Experiments approved by local ethical 
review board. 
 
2.3 Adult Rat Ventricular Myocyte Isolation  
 
2.3.1 Myocyte Isolation 
 
Ventricular myocytes were isolated by retrograde perfusion in the Langendorff mode. 
Prior to cardiac excision, the Langendorff apparatus was switched on and water jacketed 
solution reservoirs were warmed to 37°C. Solutions in Table 2.1 were prepared and 
solutions 1, 2 and 3 (without collagenase) were added to individual solution reservoirs 
and allowed to equilibrate to 37°C. Additionally, 50 ml aliquots of solution 1 were 
stored at -20°C to allow the solution to cool, which is used following excision to 
preserve cardiac function.  
 
Male adult Wistar rats, weighing 250g to 300g, were terminated in accordance with 
Schedule 1 procedures as set by the UK Home Office. Rats were terminated by cervical 
dislocation following intraperitoneal injection with 200mg/ml Na+ pentobarbital  
(Euthatal, Merial, UK). Hearts were excised as quickly as possible to minimise 
ischemia. Following excision, hearts were immediately immersed in ice cold buffer 1 
(See table 1) to lower oxygen demand. Hearts were cannulated via the aorta, with 3.5ml 
per minute of buffer 1 being pumped by a peristaltic pump. Once cannulated, the flow 
of buffer was increased to 10 ml per minute. Once the coronary circulation had cleared 
from remnants of blood, perfusion was continued with buffer 2, which contains EGTA. 
The function of the EGTA is to chelate the Ca2+ in the heart and prevent contraction. 
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After 4 minutes, hearts were then perfused with buffer 3 (containing collagenase) for a 
further 8 minutes. 
 
Buffer Constituents pH 
10X Myocyte Isolation 
Buffer 
1300 mM NaCl 
54 mM KCl 
14 mM MgCl2 
4 mM NaH2PO4 
42 mM HEPES 
7.3 
Base Buffer 1:10 dilution of 10X MIB 
10 mM Glucose 
20 mM Taurine 
10 mM Creatine 
7.3 
1 1X Base Buffer 
0.75 mM CaCl2 
0.001kU/ml Heparin 
7.3 
2 1X Base Buffer 
0.1 mM EGTA 
7.3 
3 1X Base Buffer 
0.1 mM CaCl2 
0.625 mg/ml Collagenase 
(Worthington, USA) 
7.3 
4 1X Base Buffer 
1% BSA 
0.5 mM CaCl2 
7.3 
5 1X Base Buffer 
1 mM CaCl2 
7.3 
 
Table 2.1: Cardiac Myocyte Cell Isolation Buffers. Buffers used in the isolation of 
cardiac myocytes by retrograde collagenase digestion using the Langendorff method. 
 
During perfusion, buffer 3 was recirculated to save collagenase. After 2 minutes, buffer 
3 was collected into a weigh boat. Once 8 minutes had passed, ventricles were cut down 
and immersed in buffer 3. The heart was cut into small pieces and placed in a 50 ml 
Falcon tube which was incubated at 37°C, while being bubbled with oxygen for 5-10 
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minutes. This solution was triturated to assess digestion. Once sufficiently digested, the 
solution was filtered through 200µM count nylon mesh (Cadisch, UK) into a 50 ml 
centrifuge tube and left to settle in a water bath at 35°C for 8 minutes. The supernatant 
was removed and settled cardiac myocytes were slowly resuspended in buffer 4. Cells 
were allowed to settle in the water bath for 10 minutes, after which supernatant was 
removed and cells were gently resuspended in buffer 5. Finally, cells were allowed to 
settle for an additional 10 minutes before the supernatant was removed and fresh buffer 
5 was added. 
 
2.3.2 Assessment Of Healthy Viable Cells 
 
Cells were assessed for quality and yield. Quality was assessed by eye under a 
microscope. If >70% of cells were rod-like in shape, it was considered a successful 
isolation (see Figure 2.1). Yield was assessed using a Bradford Assay measured on a 
spectrophotometer. Typical yields were approximately 30 mg of protein. 
 
 
 
Figure 2.1: Isolated Adult Rat Ventricular Myocytes (ARVM). Isolated rat ventricular 
myocytes as assessed by light microscopy. Healthy, Ca2+ tolerant myocytes have a 
straight, rod like morphology. Unhealthy cells are rounded in morphology. Image 
provided by Dr Jacqueline Howie. 
 
 
 
 
 
! 62 
2.4 Cell Culture 
 
2.4.1 Culture Conditions 
 
Cell culture reagents were supplied by Gibco™ (Life Technologies, Paisley, UK) and 
all tissue culture plastics were supplied by Nunc. Cell lines were maintained in the 
appropriate growth media and supplemented as recommended by ATCC and Life 
Technologies. In addition, 1% Penicillin/Streptomycin (P/S) was added to culture media 
for maintenance of stock plates. Cells were grown in vented cap flasks in the presence 
of 5% CO2 and maintained at 37°C in a water jacketde incubator. All tissue culture 
practices were carried out in a sterile class II biological safety cabinet. All reagents used 
were sterile and pre-warmed to 37°C. The cell lines used during the course of this 
research are indicated in Table 2.2. 
 
2.4.2 Subculture Of Cells 
 
All cell lines used were adherent and grown in 75cm2 flasks. Once a monolayer reached 
~90% confluency, cells were sub-cultured. Media was removed by aspiration and the 
cells washed with 5ml sterile Phosphate Buffered Saline (PBS) to remove all traces of 
growth media. Trypsin-EDTA (2ml) was added and the flask incubated at 37°C for 2-3 
minutes until cells detached, visible by microscopy. Growth media (8ml) was added 
back to the flask and cell triturated to prevent clumping. A proportion of cell suspension 
was then removed to another flask and the final volume of growth media adjusted to 
10ml. 
 
2.4.3 Freezing And Revival Of Cell Stocks 
 
Stocks of cells were frozen routinely at low passage (<25) for long-term storage in a 
liquid nitrogen store. Cells were grown to ~90% confluency and detached using trypsin 
as previously described (section 2.4.2). Growth media (5ml) was added to cells then 
transferred to a sterile 15ml centrifuge tube. Cells were pelleted by centrifugation at 
1500rpm for 5minutes at room temperature. The supernatant was removed by aspiration 
and cell pellet resuspended in 6ml of freezing media (90% Fetal Calf Serum (FCS) and 
10% of the cryoprotectant dimethyl sulphoxide (DMSO)). Appromixately 1.5ml of cell 
suspension was added per cryovial (Thermo Scientific, Cat.no.: 363401) and placed in a 
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cryo freezing vessel and stored at -80°C overnight. This allows cells to be cooled slowly 
to preserve cell viability. Cryovials were transferred to liquid nitrogen for long-term 
storage where available otherwise they were stored at -80°C. Upon cell revival, 
cryovials were thawed rapidly in order to minimise cell damage. Cells were thawed by 
addition of 5ml of pre-warmed media until cells were completely thawed. Cell 
suspension was transferred to a 25cm2 vented cap tissue culture flask. Growth media 
was changed the following day to remove traces of DMSO. 
!
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2.5 Cell Based Assays 
 
2.5.1 Transient Transfection Of Cell Lines 
 
Cells were seeded to 70-80% confluency in 6-well or 12-well dishes. In the case of cells 
for confocal microscopy, cells were seeded on to poly-L-lysine coated coverslips in a 
12-well plate. When cells were to be used for biotinylation of cell surface proteins using  
sulfo-SS-NHS-biotin (see section 2.5.4), wells coated with poly-L-lysine. Briefly, 0.1% 
(w/v) poly-L-lysine (Invitrogen, UK) was diluted 1:10 with PBS and added to wells 
then incubated at room temperature for 15 minutes. Wells were washed 3 x with PBS 
and allowed to dry at room temperature for 10 minutes. Once seeded, cells were left to 
adhere overnight. 
 
For transient transfection of cells, 1µg of DNA was mixed with 100µl (12-well) or 
250µl (6-well) Opti-MEM (Life Technologies, Cat. No.: 31985070). Separately, 4µl 
(12-well) or 8µl (6-well) per well of Lipofectamine 2000 was added to a sterile tube for 
each transfection and mixed with 100µl (12-well) or 250µl (6-well) of Opti-MEM and 
incubated at room temperature for 5 minutes. The Opti-MEM/Lipofectamine 2000 mix 
was then added to each DNA/Opti-MEM mix, vortexed briefly and incubated at room 
temperature for 20 minutes. Following incubation, the transfection mix was added to 
each well and incubated overnight at 37°C. Cells were harvested 16-18 hours post 
transfection. For transfection experiments with DHHCs, provided by Professor Mike 
Shipston, see (M. Fukata et al. 2004). Hemagglutinin (HA)-tagged mammalian DHHC 
clones in pEFBOS-HA were used. DHHS clones were generated by site-directed 
mutagenesis as described in section 2.10. NCX-YFP clones were generated using the 
methods described in section 2.9. 
 
2.5.2 Generation Of Stable Cell Lines 
 
To generate stable cell lines, the Flp-In™ T-Rex™ System from Life Technologies, 
which generates a tetracycline inducible cell line, was used. When the 
pcDNA™5/FRT/TO inducible expression vector containing the gene of interest is 
cotransfected with pOG44 Flp recombinase expression plasmid into a Flp-In™ T-Rex™ 
mammalian host cell line, the pcFNA™5/FRT/TO plasmid containing the gene of 
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interest is inserted in a Flp recombinase-dependent manner into the genome of the target 
cell. The FRT/TO expression plasmid contains a hygromycin resistance gene, that after 
homologous recombination confers hygromycin resistance to the resultant cell line (see 
figure 2.2). 
 
 
Figure 2.2: Schematic Of Methodology For Generation Of Inducible Stable Cell 
Lines. Detailed flowthrough of gene insertion using the Flp-In™ Inducible cell line 
system. Modified from Invitrogen. 
 
To generate inducible stable cell lines, Flp-In 293 cells were transfected with 
pcDNA5/FRT/TO expression vector containing the gene of interest in combination with 
the Flp recombinase plasmid, pOG44. To maximise success, 3 ratios of pOG44 to 
pcDNA5/FRT/TO were selected, 5:1, 9:1 and 12:1. Flp-In 293 cells were seeded at 70-
80% confluency in a 6-well plate as previously described. The following day, wells 
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were transfected with the ratios of pOG44:pcDNA5/FRT/TO with Lipofectamine 2000 
as previously described (Section 2.5.1). After transfection, cells were trypsinised briefly 
and transferred to a 25cm2 flask. Growth media containing 15µg/ml Blasticidin was 
added to cells and left for 2-3 days for cells to acclimatise to the selection. Hygromycin 
at a concentration of 100µg/ml was then added to the cell culture. During this step, the 
majority of the cells die. Media was changed the following day to remove dead cells 
and cell debris and fresh growth media containing both antibiotics was added. Cell 
cultures were monitored until small colonies of resistant cells appeared. These resistant 
cells were cultured then tested for gene integration through induction with tetracycline 
and also for zeocin sensitivity to ensure efficient recombination (figure 2.3). The Flp-In 
293 cells contain an integrated FRT site and express the lacZ-Zeocin fusion gene. Co-
transfection of pcDNA5/FRT/TO and pOG44 results in Flp recombinase mediating a 
homologous recombination event between the FRT sites in the genome and the 
pcDNA5/FRT/TO plasmid (figure 2.2). This results in insertion of the gene of interest 
into the FRT site within the cell genome. As a result the SV40 promoter and the ATG 
start codon are brought within close proximity and frame, disrupting the lacZ-Zeocin 
fusion gene. Thus, this confers hygromycin resistance and zeocin sensitivity.  
 
 
 
Figure 2.3: Bright Field Images Comparing Effects of Hygromycin And Zeocin On 
Flp-In 293 Inducible Cell Lines. Images show cells grow in the presence of 
hygromycin (Hygro) and in the presence of zeocin. Successful gene recombination is 
determined by hygromycin resistance and zeocin sensitivity. 
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2.5.3 Treatment Of Cells With Global Palmitoylation Inhibitor, 2-
Bromohexadecanoic Acid 
 
In order to inhibit palmitoylation, a non-specific DHHC inhibitor was utilised. 2-
bromohexadecanoic acid (2-BP) was prepared fresh before each treatment by dissolving 
in DMSO to a final concentration of 100mM. This was then aliquoted into sterile 1.5ml 
eppendorf tubes to give a final concentration of 100µM when added to wells. To ensure 
even distribution of 2-BP, 1ml of media was removed from the treatment well and 
added to the tube containing 2-BP. This mix was then triturated to mix the media with 
2-BP then added back to the treatment well. Treatments of 2-BP were incubated with 
cells overnight and cells harvested for respective experiments. 
 
2.5.4 Labelling Of Cell Surface Proteins With Biotin 
 
Following transfection or induction of cells, where appropriate, cells were labelled with 
the cell-impermeable amine reactive biotinylation reagent sulfo-NHS-SS-biotin 
(Pierce), which binds to cell surface resident proteins. Cells were washed 3 x with PBS, 
being careful to avoid cell loss. Biotinylation solution was prepared by dissolving 
1mg/ml sulfo-SS-NHS-biotin in PBS, which was then added to cells and incubated at 
37°C for 10minutes. Cells were washed 3 x with PBS to remove traces of excess 
reagent. Cells were lysed in 1% Triton/PBS supplemented with protease inhibitor 
cockatil (Calbiochem, Cat.no.: 539134) then biotinylated proteins purified as described 
in section 2.6.3.  
 
2.5.5 Confocal Microscopy Analysis Of Transiently Transfected Cell Lines 
 
Cells for confocal microscopy were seeded on to glass coverslips. Following 
transfection, cells were washed 3 x with PBS. Cells were fixed with 4% 
paraformaldehyde (PFA) for 10 minutes at room temperature. After fixation, cells were 
washed 3 x with PBS. To stain for the Golgi apparatus, Grasp65, involved in stacking of 
Golgi cisternae (Barr et al. 1997), fused to mCherry (generously provided by Dr Jon 
Lane, University of Bristol) was transfected into cells at the same time as YFP-fusion 
constructs. To stain the endoplasmic reticulum (ER), a ER directed plasmid encoding 
the ER targeting sequence of calreticulin fused to the 5’ end of DsRed2 and the ER 
retention sequence KDEL fused to the 3’ end of DsRed2 (provided by Dr Chris 
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Connolly, University of Dundee), was transfected into cells at the same time as the 
YFP-fusion constructs. Cells were washed 3 x with PBS. Coverslips were mounted onto 
glass slides using 100µl Hydromount (National Diagnostics, Hull, UK) containing 1µl 
of 1µg/ml DAPI (Sigma, UK) and 1µl of 50mg/ml Dabco (Sigma, UK). Slides were 
covered and left to dry overnight. Coverslips were sealed with clear nail polish to ensure 
oil from the confocal oil objectives would not contaminate the cells. Fluorescence 
micrographs were produced using a Leica SP5 Confocal Microscope. Wavelengths used 
to detect YFP were 519nm to 542nm DSRED2-ER 575nm to 644nm and 
mCherryGrasp65 580nm to 700nm. 
 
2.6 Protein Analysis 
 
2.6.1 Bradford Assay 
 
Total protein concentrations of cell lysates were determined using the Bio-Rad protein 
assay (Bio-Rad Laboratories, Hempstead, UK). The assay is based on measurement of a 
differential colour change of a dye in response to various protein concentrations. Bio-
Rad reagent is supplied as a 5-fold concentrate and was diluted with ultrapure water 
prior to use. Disposable 1ml micro-cuvettes were filled with 995µl of diluted Bio-Rad 
reagent, to which 5µl of protein lysate was added and mixed with end over end 
agitation. Samples were incubated at room temperature for 2-3 minutes prior to 
analysis. The spectrophotometer (Jenway) absorbance was set to zero using a cuvette 
filled with 1ml of Bio-Rad reagent without protein. The spectrophotometer was pre-
loaded with a concentration curve for determining protein concentrations. Absorbance 
of protein samples were analysed following incubation. 
 
2.6.2 Purification Of Palmitoylated Proteins By Resin Assisted Capture 
 
To purify palmitoylated proteins from cell lysates or tissues, resin assisted capture of 
acylated proteins (Acyl Rac) was used, based upon the method developed by Forrester 
and colleagues (Forrester et al. 2011). 2mg of protein from tissue or 1-well of cells from 
a cell culture dish was lysed in 300µl of blocking buffer (see Table 2.3) containing 1% 
methyl methanethiosulfonate (MMTS) or N-ethylmaleimide (NEM) where indicated. 
Lysates were incubated on a shaking heat block at 40°C at 1400rpm for 4 hours. 
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Following incubation, 3 volumes of acetone were added to precipitate proteins from 
sample, which were then incubated overnight at -20°C. 
 
Chemical Concentration 
 Blocking Buffer Binding Buffer 
HEPES 100mM 100mM 
SDS 2.5% 1% 
EDTA 1.0mM 1.0mM 
MMTS 1% - 
 
Table 2.3: Buffer Compositions For Acyl Rac. Details of buffers used to acyl rac and 
concentrations of their respective constituents. Note, MMTS is added fresh each time to 
blocking buffer prior to use. 
 
After precipitation of protein, samples were centrifuged at 17,000g for 5 minutes at 
room temperature. Once pelleted, proteins were washed vigorously 5 times with 70% 
acetone to remove residual MMTS. Pellets were air-dried following wash steps. Protein 
pellets were dissolved in 140µl of binding buffer by shaking at 1400rpm at 40°C until 
no pellet was observed. Samples were briefly centrifuged to collect the sample. A 20µl 
analytical sample, unfractionated (UF) was retained for analysis by SDS-PAGE. During 
resolubilisation, thiopropyl sepharose 6B (GE Healthcare, Cat.no.: 17-0420-01) was 
rehydrated for 15 minutes in ultrapure H2O at room temperature with end over end 
agitation. Following rehydration, sepharose was equilibrated into 1:1 volume of binding 
buffer. Additionally, a 2M stock of hydroxylamine (ha) was prepared fresh and adjusted 
to pH 7.5. In some cases, 2M NaCl was added to acyl rac reaction in place of ha to 
serve as a negative control. 
 
Once samples were dissolved and UF removed, 50µl of sepharose slurry was added to 
each sample, to give approximately 5mg of sepharose per sample. Hydroxylamine was 
added to each sample to a final concentration of 200 mM. Samples were then incubated 
for 2.5 hours at room temperature with end over end agitation. Following incubation, 
samples were centrifuged at 17,000g for 1 minute. Where indicated, unbound (UB) 
fractions were retained for analysis. Sepharose was washed 5 times with 1ml of binding 
buffer, incubating with end over end agitation for 2-3minutes and centrifuging in 
between each wash. Following the final wash, wash buffer was removed and sepharose 
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was resuspended in 50µl of 2X SDS PAGE loading buffer containing 100mM DTT. 
Samples were heated at 37°C for 10 minutes to elute proteins. 
 
2.6.3 Purification Of Biotin Labelled Cell Surface Proteins Via Streptavidin 
Affinity Capture 
 
Proteins were solubilised by incubation at 4°C with gentle shaking for 30 minutes. 
Lysates were then scraped from wells into pre-chilled 1.5ml microcentrifuge tubes and 
then centrifuged at 17,000g for 5minutes at 4°C to remove insoluble material. The 
supernatant was transferred to a clean tube. A protein assay was performed to determine 
protein concentration and the protein content of all samples was normalised. A 50µl 
sample was taken as an analytical fraction prior to purification. Approximately 30µl of 
streptavidin sepharose which had been previously equilibrated with 1% Triton X-
100/PBS was added to each cell lysate which were then incubated with end over end 
rotation at 4°C overnight. Following overnight incubation, samples were centrifuged at 
4°C at 17,000g for 1 minute. A 50µl sample of the unbound fraction was taken prior to 
removal of the supernatant. The sepharose was washed 3 times with 1% Triton X-
100/PBS. Proteins captured on the sepharose where then eluted by resuspending the 
sepharose in 100µl of 2X SDS Loading Buffer supplemented with 100mM DTT and 
incubated at 37°C for 10minutes.  
 
2.6.4 Co-Immunoprecipitation 
 
Protein-protein interactions were assessed using co-immunoprecipation. Anti-HA 
Affinity Matrix (Roche, Cat.no.: 11815016001) was equilibrated in 2mg/ml 
octaethylene glycol monododecyl ether (C12E10)/PBS with protease inhibitor cocktail 
(Calbiochem, Cat. no.: 539134) and 0.1M PMSF (co-IP lysis buffer) for 1 hour at room 
temperature. Cells transfected with DHHCs and WT NCX-YFP or empty vector were 
lysed in 300µl of co-IP lysis buffer. Lysates were scraped into 1.5ml microcentrifuge 
tubes and agitated at 4°C for 30 minutes to solubilise membrane proteins. Lysates were 
centrifuged at 17,000g for 5 minutes at 4°C to remove insoluble material. Supernatant 
was transferred to a clean, prechilled 1.5ml microcentrifuge tube. A 30µl sample was 
retained as IP input sample. The resulting pellet was dissolved in 600µl SDS PAGE 
buffer to assess efficiency of solubilisation. 200µl cell supernatant was used in the IP. 
HA-beads were given a final wash and resuspended in 100µl per IP reaction. 100µl of 
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slurry was added to each IP reaction, which were incubated overnight with end-over-
end rotation at 4°C. The following day, 50µl of unbound supernatant was taken from 
each IP and mixed 1:1 with SDS PAGE buffer. Beads were washed 5 times with 1ml of 
0.5mg/ml C12E10/PBS with protease inhibitor cocktail and PMSF (co-IP wash buffer) 
at 4°C. Proteins were eluted from HA-beads by resuspending in 20µl of 2x SDS PAGE 
sample buffer supplemented with 5% β-mercaptoethanol and 100mM DTT. Samples 
were heated at 65°C for 10 minutes, then centrifuged at 17,000g for 1 minute and 
analysed by western blotting. 
 
2.6.5 Cell Fractionation 
 
Briefly, cell media was removed and cells were lysed in 150µl of PBS containing 0.05% 
digitonin, protease inhibitor cocktail (Calbiochem, Cat. no.: 539134), 0.1µM PMSF. 
Cell lysates were then scraped and transferred to clean 1.5ml microcentrifuge tubes, a 
small analytical sample was taken and incubated at 4°C for 10 minutes with end over 
end rotation. Following incubation, cell lysates were centrifuged at 17,000g for 5 
minutes. The supernatant was collected and mixed 1:1 with 2X SDS Loading buffer 
(cytosolic fraction). The pellet was then lysed in 150µl of PBS/1% Triton X-100 with 
protease inhibitors and PMSF as before. This lysate was then incubated at 4°C for 10 
minutes with end-over-end rotation. Lysates were then centrifuged at 17,000g for 5 
minutes. The supernatant was collected and mixed 1:1 with 2X SDS Loading buffer 
(membrane fraction). The remaining pellet was lysed directly in 300µl of 2X SDS 
Loading Buffer (insoluble material). Samples were then analysed by Western Blotting.  
 
2.6.6 Sucrose Gradient Fractionation Of Caveolin-enriched Membranes 
 
Caveolin-enriched buoyant membranes were prepared from isolated ARVMs as 
described in (Wypijewski et al. 2013). ARVMs were homogenised and sonicated in 
500mM sodium biocarbonate, pH 11, supplemented with 1mM DTT, 1mM EDTA and 
protease and phosphatase inhibitors. Lysates were adjusted to 45% sucrose by addition 
of an equal volume of 90% (w/v) sucrose in 25mM MES, 150mM NaCl, pH 6.5. 4ml 
was transferred to an ultracentrifuge tube and overlaid with 4ml of 35% sucrose and 
4ml of 5% sucrose. Sucrose gradients were centrifuged overnight at 270,000g. 1ml 
fractions were collected and each volumes of each were analysed by SDS-PAGE and 
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western blotting. Fractions 4 and 5 and 8 – 12 were pooled and palmitoylated proteins 
were captured using acyl rac.   
 
2.7 Gel Electrophoresis 
 
2.7.1 Gel Preparation 
 
Solutions containing either 6% acrylamide or 20% acrylamide were prepared (See Table 
2.4 for details). 
 
Chemical Percentage Percentage 
 6% 20% 
H2O 16ml 1.6ml 
1.5M Tris.HCl pH=8.8 7.6ml 6.3ml 
10% SDS 300µl 250µl 
30% Acrylamide 6ml 16.7ml 
10% APS 125µl 80µl 
TEMED 12.5µl 12.5µl 
 
Table 2.4: Gradient Gel Recipe. Respective volumes of buffer stocks required to 
prepare 6-20% gradient gels. 
 
Chemical  
 8% 10% 12% 15% 
H2O To 10ml To 10ml To 10ml To 10ml 
1.5M Tris.HCl pH=8.8 375mM 375mM 375mM 375mM 
10% SDS 0.1% 0.1% 0.1% 0.1% 
30% Acrylamide 8% 10% 12% 15% 
10% APS 0.1% 0.1% 0.1% 0.1% 
TEMED 0.6mM 0.4mM 0.4mM 0.4mM 
 
Table 2.5: Alternative Gel Recipe. Respective constituents of alternative percentage 
gels. 
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Chemical Stacking Gel 
H2O to 5ml 
1M Tris.HCl pH=6.8 126mM 
10% SDS 0.05% 
30% Acrylamide 2.49% 
10% APS 0.05% 
TEMED 0.5mM 
 
Table 2.6: Stacking Gel Recipe. Volumes and constituents of stacking gels for 
polyacrylamide gels. Total volume is 5ml, which was scaled up for gradient gels. 
 
Buffer Chemical Concentration pH 
2x SDS PAGE Loading 
buffer 
Tris 
SDS 
Glycerol 
Bromophenol Blue 
β-mercaptoethanol 
100mM 
4% (w/v) 
20% (w/v) 
0.02% (w/v) 
5% (v/v) 
 
 
6.8 
10X Tris/Glycine Tris 
Glycine 
0.25M 
1.92M 
 
- 
1X Running Buffer Tris 
Glycine 
SDS 
25mM 
192mM 
0.1% (w/v) 
 
- 
1X Transfer Buffer Tris 
Glycine 
SDS 
Methanol 
25mM 
192mM 
0.01% (w/v) 
20% (v/v) 
 
- 
 
Table 2.7: Buffers For Protein Gel Electrophoresis And Western Blotting. Buffers and 
constituents for protein gel electrophoresis and western blotting. 
 
2.7.2 Sample Preparation 
 
Prior to loading samples into the well for gel electrophoresis, samples were heated to 
37°C for 10 minutes. Following incubation, samples were centrifuged at 17,000g for 1 
minute. In the case of samples containing agarose beads, this collected at the bottom of 
! 75 
the tube, therefore not interfering with sample loading. Samples were allowed to cool to 
room temperature prior to loading. 
 
2.7.3 Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
 
For casting gels, BioRad 0.75mm spacer plates (BioRad, Cat.no.: 1653310) and BioRad 
short plates (BioRad, Cat.no.: 1653308) were used.  Gradient gels or 8% Acrylamide 
gels were used for experiments where indicated. Alternative percentage gels to gradient 
gels were cast according to the composition, shown in table 2.5. Following addition of 
the resolving gel to the plates, resolving gels overlaid with 80µl of water-saturated 
butan-1-ol. Butan-1-ol was then washed off after resolving gels had polymerised and 
stacking gel (Table 2.6) was added to each gel, with combs to form wells being added 
immediately after. 5µl of PageRuler Plus prestained protein ladder (Pierce, Cat.no.: 
26619) was loaded. Running buffer was used according to the recipe outline in Table 
2.7. All wells were loaded with 5ul of respective samples. Gels were run for 20 minutes 
at constant voltage of 120V. The voltage was then increased to 200V until the dye front 
was at the bottom of the gel. 
 
2.7.4 Western Blotting 
 
Following SDS-PAGE to separate proteins, proteins were transferred to a PVDF 
membrane. The following set-up was used, 1 sheet of extra thick blotting paper, PVDF 
membrane, SDS-Page gel, 2 x sheets of thin blotting paper, 1 sheet of extra thick 
blotting paper. Prior to transfer, PVDF membrane was equilibrated in methanol for 5 
minutes at room temperature. The methanol was then removed and replaced with 
Transfer Buffer (see Table 2.7) for 5 minutes. The blotting paper was also equilibrated 
in Transfer Buffer prior to transfer. The SDS-Page gel was removed from the plate and 
placed on the PVDF, ensuring all bubbles were removed to enable even transfer. The 
sheets of thin blotting paper were then placed on top of the gel, and a roller used to 
remove an additional air bubbles. The final sheet of extra thick blotting paper was 
placed on top and the roller was used again to remove air bubbles. This sandwich was 
assembled in a BioRad Trans-Blot Turbo Transfer System (BioRad, Cat.no.: 170-4155) 
and transferred at 25V 1.0A for 30 minutes. Following transfer, membranes were 
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incubated in 5% milk/PBST for 1 hour. Membranes were incubated overnight at 4°C 
with primary antibodies (dilutions indicated in table 2.6). 
 
The following day, membranes were agitated for up to 1 hour at room temperature with 
multiple changes of PBS-T. Secondary antibodies raised to the appropriate species for 
the primary antibody were then applied to the membrane and incubated at room 
temperature with shaking for 1 hour. Secondary antibodies were prepared in 5% 
milk/PBST. Following incubation with secondary antibodies, membranes were agitated 
for 1 hour and 30 minutes at room temperature with multiple PBS-T changes. To 
visualise the proteins on the membrane, Immobilon HRP Substrate (Millipore, Cat. No.: 
11556345) was used. Solution A and Solution B were mixed 1:1 and applied to the 
membrane, which was placed on a stretch of saranwrap. The HRP substrate was 
incubated with the membranes for 5 minutes at room temperature, with membranes 
being flipped over after 2.5 minutes to ensure even coverage of the HRP substrate. 
Excess HRP substrate was removed from the blot, which was then placed between 2 
sheets of plastic wrap before being exposed using chemiluminescence on a BioRad 
imaging system. 
 
Antibody Species Manufacturer Dilution Used 
NCX1 (R3F1) Mouse Swant 1:1000 
Caveolin-3 Mouse BD Biosciences 1:5000 
Flotillin-2 Mouse BD Biosciences 1:5000 
SERCA2a Mouse Thermo Scientific 1:5000 
GAPDH Mouse Sigma 1:1000 
H-Ras Rabbit Santa Cruz 1:300 
GFP Rabbit Abcam 1:2000-1:5000 
Anti-mouse  Pierce Range: 1:2000-
1:10,000 
Anti-rabbit  GE Healthcare Range: 1:2000-
1:5000 
 
Table 2.8: Antibodies Used In Western Blotting Analysis. Details of antibodies used in 
western blotting and their respective dilutions. 
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2.7.5 Detection Of Total Protein Using SimplyBlue™ SafeStain Gel Stain 
 
To detect all proteins from a given experiment, polyacrylamide gels were stained with 
SimplyBlue™. Following electrophoresis, gels were placed in 100ml of MilliQ water 
and heated on high for 1 minute in a microwave until the solution almost reached 
boiling point. Gels were agitated on an orbital shaker for 1 minute following heating. 
Gels were washed in this manner twice more. Following the last wash step, 20ml of 
SimplyBlue™ SafeStain was added and gels heated on high for 45 seconds to 1 minute 
until the solution approached boiling point. Gels were agitated on an orbital shaker for 5 
minutes. Gels were washed with 100ml MilliQ water for 10 minutes on an orbital 
shaker. For storage, gels were stored in 20% NaCl solution. Gels were imaged using 
chemiluminescence on a BioRad imaging system. 
 
2.8 mRNA Preparation And Quantitative PCR 
 
2.8.1 Rat Heart Isolation 
 
To identify DHHC gene expression in adult rat heart, mRNA was prepared. Hearts were 
excised as previously described (Section 2.3.1). In this instance, hearts were perfused 
briefly with buffer 1 to remove blood from the coronary circulation. Hearts were snap 
frozen in liquid nitrogen and stored at -80°C until required. 
 
2.8.2 RNA Preparation 
 
In order to extract RNA from rat heart, the whole heart was pulverised using mortar and 
pestle prechilled to minimise RNA degradation. A small volume of liquid nitrogen was 
added to the mortar, to which frozen whole heart was added. This was then crushed and 
pulverised to a fine powder, taking care to ensure that tissue remained frozen by adding 
more liquid nitrogen as needed. This procedure was repeated for a total of 4 hearts. 
 
Following tissue preparation, RNA was prepared using the SV Total RNA Isolation 
System (Promega, Cat.no.: Z3101). Approximately 60mg of powder heart tissue was 
used to generate RNA. RNA was extracted as per the manufacturers instructions. 
Briefly, RNA Lysis Buffer (RLA) was added to the powdered tissue. The lysate was 
diluted by addition of RNA Dilution Buffer (RDA). Lysates were centrifuged for 10 
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minutes. Cleared lysates were transferred to clean microcentrifuge tubes and 95% 
ethanol was added to the lysate and transferred to Spin Basket Assembly and 
centrifuged to immobilise lysate on the filter. Lysates were washed with RNA Wash 
Solution (RWA) followed by DNase treatment for 15 minutes at room temperature. 
DNase treatment was stopped by addition of DNase Stop Solution (DSA) and 
centrifuged for 1 minute. RNA immobilised on filter was washed with RWA twice 
before elution with Nuclease-free water. RNA was snap-frozen in liquid nitrogen and 
stored at -80°C until required. 
 
2.8.3 cDNA Preparation 
 
Approximately 200ng of RNA was used to generate cDNA from adult rat hearts. The 
cDNA reaction was performed in the presence and absence of GoScript Reverse 
Transcriptase, to serve as positive and negative controls respectively. cDNA was 
prepared using GoScript Reverse Transcription System (Promega, Cat.no.: A5000) as 
per the manufacturers instructions. Briefly, RNA was mixed with random primers 
(0.5µg/reaction) and heated at 70°C for 5 minutes followed by 5 minute incubation in 
ice water. GoScript™ 5X reaction buffer, MgCl2, PCR Nucleotide Mix, Recombinant 
RNasin® Ribonuclease Inhibitor, Nuclease-free water and GoScript™ Reverse 
Transcriptase were added to reactions. Reactions were annealed at 25°C for 5 minutes 
followed by 1 hour extension at 42°C. Reverse transcriptase was inactivated at 70°C for 
15 minutes. cDNA was stored at -80°C until required. 
 
2.8.4 Quantitative PCR 
 
The resultant mRNA generated in section 2.8.3 was sent to Professor Mike Shipston’s 
lab at University of Edinburgh for analysis. Briefly, mRNA expression for each DHHC 
was quantified relative to the geometric mean of β-actin and GAPDH using Fast Start 
Universal SYBR Green Mastermix (Roche, UK) in a 25µl reaction using an ABIPrism 
7000 real-time PCR machine. Reactions were performed in 25µl volumes using 0.2µM 
primers. Between 55-115ng of cDNA generated from 4 independent heart samples was 
used per reaction. Cycling conditions were 50°C for 2 minutes, 95°C for 10 minutes, 
followed by 40 cycles of 95°C for 15s and 60°C for 1 minute. All primers used were 
previously validated with efficiencies calculated to be within 0.1 of the control using the 
equation e = 10(-1/slope) – 1. Internal reference controls were endogenous β-actin and 
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GAPDH, amplified using primer sets Rn_Actb_1_SG QT00193473 and 
Rn_Gapd_1_SG QT00199633. DHHC primers were designed in house with the 
exception of DHHCs 6 (Rn_Zdhhc6_1_SG QT02382807), 19 (Rn_Zdhhc19_1_SG 
QT01575462) and 25 (RnZdhhc25_1_SG QT00436163), which were purchased from 
Qiagen.  
 
2.9 Cloning Using TOPO® TA Cloning System 
 
2.9.1 Amplification Of DNA For Cloning 
 
In order to make stable expressing NCX1 cell lines, cDNA encoding NCX1 inserted 
into the appropriate expression vector for the Flp-In™ T-REx™ inducible expression 
system. Firstly NCX1 was amplified from adenovirus containing the sequence for 
canine NCX1.1 (kindly provided by Professor Godfrey Smith, University of Glasgow). 
A master mix containing H2O, 10X Pfu Reaction Buffer, PCR Nucleotide mix, primers 
and Pfu DNA Polymerase was added to each sample. Pfu DNA Polymerase is a high 
fidelity enzyme resulting in fewer misreads in the final PCR product, designed for use 
in generating large PCR products. Primers used in this reaction are detailed in table 
2.10. The amount of each reagent required was as follows, 
 
For 1 sample, 
31.1µl H2O (to 40µl) 
  4µl 10X Reaction Buffer 
  2µl PCR Nucleotide Mix (10mM each) 
  0.8µl NCX1 Canine Forward Primer (50µM stock)  
  0.8µl NCX1 Canine Reverse Primer (50µM stock) 
  0.8µl Pfu DNA Polymerase 
 ---------------------------------------------------------------------------------------------- 
  39.5µl master mix per sample 
  + 0.5µl NCX1 containing adenovirus 
 
Samples were amplified on an Eppendorf Thermal Cycler on the following program, 
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1. 95°C for 2 minutes 
2. 95°C for 1 minute 
3. 50°C for 30 seconds 
4. 72°C for 6 minutes 
5. Go to 2 for 30 times 
6. 72°C for 10 minutes 
7. 4°C forever. 
 
Following PCR, 0.5µl of GoTaq DNA Polymerase (Promega, Cat.no.: M3002) was 
added to each reaction and incubated at 72°C for 10 minutes. This was to add 5’ 
overhangs on to PCR products as the Pfu DNA Polymerase does not do this and it is a 
requirement of the TOPO TA Cloning Kit (Invitrogen, Cat.no.: K4500-001). 
 
2.9.2 Visualisation Of PCR Products By Agarose Gel Electrophoresis 
 
Products from the PCR were analysed using gel electrophoresis. Agarose gels were 
prepared by dissolving 1% (w/v) of agarose in 1X TBE. Agarose was dissolved by 
heating in a microwave on high power until the agarose had dissolved. Liquid agarose 
was allowed to cool briefly, then approximately 1µl of ethidium bromide was added. 
The liquid agarose was then poured into a gel cast, ensuring all air bubbles were 
removed before a comb was inserted to form the wells. A 5µl sample of the PCR 
product was taken and mixed with Blue/Orange Loading Dye 6X (Promega, Cat.no.: 
G1881) then loaded onto the gel. A 1kb DNA ladder (Promega, Cat.no.: G2101) was 
loaded into an adjacent lane to verify PCR product size. The gel was run at a constant of 
80V for 1 hour. Gels were analysed using the BioRad imager under UV light to 
visualise DNA bands on a gel. 
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Figure 2.4: Representative Image Of PCR Product Visualisation. Agarose gel shows 
NCX1 PCR product following amplification. Successful PCR is indicated by a single 
product at approximately 3000bp. 
 
2.9.3 TOPO Reaction For Ligation Of DNA Into TOPO Vector 
 
Once the PCR products had been analysed, the TOPO cloning reaction was set-up in the 
following manner, 
 
4µl PCR Product 
1µl Salt Solution 
1µl TOPO vector 
--------------------- 
6µl final volume 
 
This reaction was incubated at room temperature for 20 minutes. 
 
2.9.4 Preparation Of Agar Plates 
 
Agar plates were prepared by melting agar on high power in a microwave. Once melted, 
the agar was cooled to 55°C and ampicillin or kanamycin was added to a final 
concentration of 100µg/ml and 30µg/ml respectively. The antibiotic-containing agar 
was then poured into 10cm plates and allowed to set under a flame. If required, once dry 
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40µl of 40mg/ml X-gal in DMF was added and spread over the agar plate. Plates were 
prewarmed at 37°C or stored at 4°C. 
 
2.9.5 Transformation Of Top10 Competent Cells 
 
The TOPO ligation reaction was transformed into TOP10 cells that were supplied with 
the TOPO TA Cloning System. Cells were defrosted on ice. Once defrosted, 2µl of the 
TOPO cloning reaction was added to the cells and mixed gently. The transformation 
was incubated on ice for 30 minutes. Cells were then heat shocked at 42°C for 30 
seconds. Following heat shock, 250µl of SOC media was added to the transformation 
and incubated at 37°C with 220rpm shaking for 1 hour. Following the incubation of the 
transformation reaction, this was plated onto the agar plates at 10% and 90% densities 
as recommended by the manufacturers. The plates were incubated inverted overnight at 
37°C. 
 
2.9.6 Extraction Of DNA From Positive Clones 
 
TOPO® TA cloning utilizes blue/white screening, allowing rapid and efficient 
identification of recombinant E.coli. This technique relies on the activity of β-
galactosidase, an enzyme present in bacteria, which cleaves lactose into glucose and 
galactose. The presence of lactose within the surrounding environment triggers the lacZ 
operon in E.coli, resulting in production of β-galactosidase. The TOPO® TA vector 
carries a short segment of the lacZ gene. The E.coli strain used contains a lacZΔM15 
deletion mutation. As such, when the TOPO® TA vector is taken up by cells, functional 
β-galactosidase enzyme is produced via α-complementation. α-complementation serves 
as a marker for successful recombination of genes within the bacterial genome. A 
multiple cloning site (MCS) is present within the lacZ, into which foreign DNA can be 
inserted. Therefore, when E.coli takes up TOPO TA vector containing the gene of 
interest, α-complementation does not occur and functional β-galactosidase is not 
produced. Cells are plated on plates containing X-gal, which in the presence of 
functional β-galactosidase is hydrolysed to 5-bromo-4-chloro-indoxyl, which dimerises 
to produce insoluble blue pigment 5,5’-dibromo-4,4’-dichloro-indigo. As a result the 
colonies formed by non-recombinant cells appear blue in colour, while recombinant 
ones appear white. In cases where blue/white screening was not applicable, colonies 
were picked at random. Colonies were picked off the plate using a 200µl pipette tip and 
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placed in 50µg/ml ampicillin-containing LB Broth. These mini-preps were then 
incubated overnight at 37°C with 220rpm shaking to allow the E.coli to grow and 
replicate. The following day, DNA was extracted using a Qiagen QuickLyse Miniprep 
Kit as per the manufacturers instructions (Qiagen, Cat.no.: 27406). DNA concentration 
was determined using a NanoDrop 2000 Spectrophotometer. 
 
2.9.7 Restriction Enzyme Digest Of DNA 
 
Based on DNA concentrations, the highest yield from density plated (90% and 10%) 
was selected for restriction enzyme digest. At the same time as digesting the NCX1 
products, the target expression vector FRT/TO was also digested. Restriction enzyme 
digests were set up in the following way, 
 
6µg  TOPO containing NCX1 or FRT/TO vector 
  3µl  10X Buffer E 
  0.3µl  100X BSA 
  1µl HindIII 
  1µl BamHI 
 
This reaction was then incubated at 37°C for 1 hour. Following incubation, samples 
were separated on an agarose gel, as described previously. In the presence of correct 
products from the restriction enzyme digest, bands were excised from the gel. The DNA 
was extracted using Macherey-Nagel NucleoSpin® Gel and PCR Clean-up kit 
(Macherey-Nagel, Cat.no.: 740609) as per the manufacturers instructions.  
 
2.9.8 Ligation Of DNA Into FRT/TO Expression Vector 
 
Following DNA extraction, LigaFast (Promega, Cat.no.: M8221) was used to insert 
NCX1 into the FRT/TO vector. The reaction was set-up in the following way, 
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 Vector Insert 2X LigaFast Buffer T4 DNA Ligase H2O 
Vector only 100ng - 5 1 to 10µl 
V + Insert 100ng 63ng 5 1 to 10µl 
 
Table 2.9: Ligation Reaction Set-Up. Details of the ratios of insert DNA to vector DNA 
in the ligation reaction. 
 
The ratio of insert to vector was calculated using the manufacturers recommendations. 
Ligation reactions were incubated for 15 minutes at room temperature. Following 
incubation, the ligation reactions were transformed into DH5α competent cells.  
 
i Transformation Of DH5α Competent Cells 
 
DH5α competent cells were thawed gently on ice prior to transformation. 50µl of 
competent cells were added to 1µl DNA, 5X KCM (500mM KCl, 30mM CaCl2, 50mM 
MgCl2) and water to a final volume of 100µl. Transformation reactions were incubated 
on ice for 20 minutes, followed by 10 minutes at room temperature. Reactions were 
then spread on pre-warmed antibiotic-containing agar plates which were incubated 
overnight at 37°C. In the case of kanamycin resistant plasmids, before plating 1ml of 
LB was added and incubated at 37°C for 1 hour in an orbital shaker at 220rpm. Prior to 
plating transformed competent cells were recovered by centrifugation at 2000rpm for 5 
minutes and supernatant removed. Approximately 100µl of LB was not removed and 
the cell pellet was resuspended and this suspension plated on pre-warmed agar plates 
and incubated at 37°C overnight. 
 
Colonies were selected the following day for mini-preps. To ensure DNA extracted 
contained gene of interest, restriction enzyme digests were carried out. NCX1 was 
inserted into FRT/TO between two restriction sites, HindIII and BamHI. Restriction 
enzyme digest with HindIII alone or HindIII and BamHI verified resultant DNA. In the 
presence of HindIII alone, no insert will be removed from the plasmid, with the single 
digestion resulting in linearisation of the plasmid. In the presence of both HindIII and 
BamHI, NCX1 would be ‘cut’ out of the plasmid. This results in two distinct bands 
observed via agarose gel electrophoresis, one corresponding to the plasmid and the 
other, NCX1. Shown in figure 2.5, only when both restriction enzymes are used, 
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plasmids that have successfully ligated produce two distinct bands. Positively identified 
products were sequenced by The Genetics Core Services Unit, Ninewells. 
 
 
Figure 2.5: Positive Clones Identified By Restriction Enzyme Digestion. 
Representative gel showing a positively identified clone following digestion with 
restriction enzymes. Constructs were digested with one (single) or both (double) 
restriction enzymes. Positive clones defined as 2 distinct bands observed following 
double restriction enzyme digest. 
 
Following sequencing, correct constructs were selected and grown as maxi-preps by 
harvesting 1ml of mini-prep reaction and adding it to 200ml of LB Broth containing the 
appropriate antibiotic. Maxi-preps were incubated overnight at 37°C with 220rpm 
shaking. After incubation, a glycerol stock was made by mixing 250µl of the maxi-prep 
with 250µl of 50% glycerol and rapidly frozen. This glycerol stock was then stored at -
80°C. DNA was extracted from the maxi-prep using a Qiagen HiSpeed Plasmid Maxi 
Kit (Qiagen, Cat.no.: 12663) as per the manufacturers instructions. 
 
2.10 Mutagenesis 
 
2.10.1 Single-Site Mutagenesis 
 
To determine the palmitoylation site of NCX1, cysteine to alanine mutations were 
introduced into the FRT/TP/NCX1. A QuikChange Lightening Site-Directed 
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Mutagenesis kit was utilised, with primers designed to yield specific mutations 
throughout the NCX1 protein (see table 2.10). The mutagenesis reaction was prepared 
as follows, 
 
2.5µl 10X Reaction buffer 
  0.5µl Forward primer (125ng)  
  0.5µl Reverse primer (125ng)  
  0.5µl dNTP mix 
  0.75µl QuikSolution reagent 
------------------------------------------------------------------------------------ 
  100ng µl DNA 
 
+ H2O to final volume of 25µl 
 
then add 0.5 µl of QuikChange Lightning Enzyme 
 
Reactions were then amplified using an Eppendorf Thermal Cycler using the following 
conditions, 
1. 95˚C for 2 minutes 
2. 95˚C for 20 seconds 
3. 60˚C for 10 seconds 
4. 68˚C for 30 seconds/kb of plasmid length 
5. Go to 2 18 times 
6. 68˚C for 5 minutes 
7. 4˚C forever. 
 
Once PCR reaction finished, 1µl of Dpn I restriction enzyme was added to each reaction 
and mixed thoroughly. This reaction was incubated at 37˚C for 5 minutes in order to 
digest any remaining non-mutated parental DNA. The resultant product was then 
transformed into XL-1 Blue supercompetent Cells provided with the kit. 
 
i Transformation Of XL-1 Blue Supercompetent Cells 
 
XL-1 Blue supercompetent cells were thawed gently on ice prior to transformation. For 
each reaction, 25µl was aliquoted into a pre-chilled 14-ml BD Falcon polypropylene 
round-bottom tube. 1µl of Dpn I-treated DNA from each reaction was added to separate 
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aliquots of the cells. The transformation reaction was mixed gently by swirling the tube 
and incubated on ice for 30 minutes. Reactions were heat pulsed at 42°C for 45 seconds 
then placed on ice for 2 minutes. 0.25ml of SOC media, preheated to 42°C was added to 
each transformation reaction and incubated at 37°C for 1 hour with shaking at 225rpm. 
Following incubation, transformation reactions were plated on to antibiotic-containing 
agar plates (See section 2.4.4). Agar plates were incubated overnight at 37°C. Resultant 
colonies were selected and grown as mini-preps as previously described and DNA 
extracted. Extracted DNA was then sent for sequencing. 
 
2.10.2 Multiple-Site Mutagenesis 
 
Following generation of single-site cysteine to alanine mutants of NCX1, mutants with 
multiple cysteine residues mutated to alanine were required. To achieve this, the 
QuikChange Multi-Site Directed Mutagenesis Kit was utilised, with primers designed to 
yield desired mutations (described in table 2.10). In the same way as the single-site 
mutants, multi-site mutant reactions were as follows, 
 
2.5µl 10X Reaction buffer 
  0.2µl Forward primer (50ng of each primers used) 
  1µl dNTP mix 
  0.75µl QuikSolution reagent 
------------------------------------------------------------------------------------ 
  100ng DNA 
 
+ H2O to final volume of 25µl 
 
then add 1µl of QuikChange Lightning Enzyme 
 
Multi-site reactions were then amplified using an Eppendorf Thermo Cycler using the 
following conditions, 
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1. 95˚C for 1 minute 
2. 95˚C for 1 minute 
3. 55˚C for 1 minute 
4. 65˚C for 2 minutes/kb of plasmid length 
5. Go to 2 30 times 
6. 4˚C forever. 
 
Following the PCR reaction, multi-site reactions were incubated with 1µl of Dpn I 
restriction enzyme to digest non-mutated parental DNA. This reaction was then mixed 
briefly and incubated at 37°C for 1 hour. The resultant product was then transformed 
into XL-10 Gold ultracompetent Cells provided with the kit. 
 
i Transformation Of XL-10 Gold Ultracompetent Cells 
 
XL-10 Gold ultracompentent cells were gently thawed on ice prior to transformations. 
For each multi-site mutagenesis reaction, 22.5µl of ultracompetent cells were aliquoted 
into pre-chilled 14ml BD Falcon polypropylene round-bottom tubes. 1µl of β-ME mix 
provided with the kit was added to cells, then swirled gently. Cells were incubated on 
ice for 10 minutes, swirling every 2 minutes. 1.5µl of Dpn I-treated DNA from each 
multi-site reaction was added to each separate aliquot of cells. Transformation reactions 
were mixed gently then incubated on ice for 30 minutes. Reactions were heat pulsed at 
42°C for 30 seconds followed by incubation on ice for 2 minutes. Following this 
incubation, XL-10 Gold ultracompetent cell transformation reactions were treated in the 
same way as XL-1 Blue supercompetent cells as previously described. 
 
2.10.3 Generation Of NCX-YFP Fusion Construct  
 
To determine how palmitoylation affects trafficking and anchoring of proteins, cDNA 
encoding YFP fused to the N terminus NCX1 large intracellular loop was generated. 
This allowed visualisation of protein localisation by confocal microscopy. First, the 
intracellular loop of wild-type, cysless or C739 containing NCX1 plasmids were 
amplified. These site mutants were previously generated during multi-site site directed 
mutagenesis reactions (section 2.10.2). Intracellular loops were amplified in the 
following way, with primer designed against the intracellular loop of NCX1 (see table 
2.10 for details), 
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  4µl 10X Reaction Buffer 
  0.8µl NCX Intra Forward Primer 
  0.8µl NCX Intra Reverse Primer  
  2µl PCR Nucleotide Mix (10mM each) 
  0.8µl Pfu DNA Polymerase  
---------------------------------------------------- 
0.5µl FRT/TO NCX1.1 Plasmid 
 
+ H2O to final volume of 40µl 
 
Reactions were amplified on an Eppendorf Thermo Cycler under the following 
conditions, 
1. 95˚C for 2 minutes 
2. 95˚C for 1 minute 
3. 60˚C for 30 seconds 
4. 72˚C for 4 minutes 
5. Go to 2 30 times 
6. 72˚C for 10 minutes 
7. 4˚C forever. 
 
Following PCR reactions, clones were subjected to TOPO TA Cloning as previously 
described then subcloned into pEYFP-C1 expression plasmid as previously described 
(section 2.9) and transformed into DH5α competent cells. 
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2.11 Mass Spectrometry 
 
2.11.1 Filter Aided Sample Preparation 
 
For protein samples to be analysed by mass spectrometry to identify palmitoylated 
proteins and respective palmitoylation sites, SDS was removed from samples. Since 
elution of palmitoylated proteins from thiopropyl sepharose cannot be achieved without 
the presence of SDS, a method to remove the SDS prior to mass spectrometry was 
sought. The Fingerprints Unit in the College of Life Sciences recommended Filter 
Aided Sample Preparation (FASP) (Liebler & Ham 2009). Samples for mass 
spectrometry were purified by acyl rac, which was scaled up to incorporate 90mg of 
protein from isolated ventricular myocytes (see section 2.3 for details). SDS-Loading 
buffer without bromophenol blue was prepared and used for elution (Table 2.8). 
Proteins were eluted in 100µl. A small analytical sample was retained, with the 
remaining sample mixed 1:5 with UA (see table 2.8). This was then loaded into a 
Microcon YM-10 (Millipore, Cat. No. number 42407) filtration unit and centrifuged at 
14,000g for 40 minutes at 4°C. The flow-through was discarded after each wash except 
where indicated. The filtration unit was washed with UA and centrifuged at 14,000g for 
40 minutes at 4°C. Previously palmitoylated cysteine residues were alkylated with 
iodoacetamide (IAA) to differentially alkylate these residues from non-palmitoylated 
residues. The sample was mixed with 100ul of IAA in a thermomixer at 37°C at 600rpm 
for 1 minute before being incubated for 5 minutes without mixing. Filtration units were 
centrifuged at 14,000g for 30 minutes. 
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Buffer Chemical Concentration pH 
Tris/HCl  Tris 0.1M 8.5 
Tris/HCl Tris 0.1M 8.0 
UA Urea 
Tris/HCl 
8M 
0.1M 
8.5 
UB Urea 
Tris/HCl 
8M 
0.1M 
8.0 
IAA Solution Iodoacetamide 
UA 
0.05M 
8M 
8.5 
NaCl NaCl 0.5M - 
ABC NH4HCO3 0.05M - 
SDS-Lysis Buffer SDS 
Tris/HCl 
DTT 
4% (w/v) 
0.1M 
0.1M 
7.6 
 
Table 2.11: Buffers Used In FASP. Details of buffers used during the FASP protocol 
to prepare proteins for mass spectrometry.  
 
Following centrifugation, 100µl of UB was added to the sample then centrifuged at 
14,000g for 40 minutes. This step was repeated twice more. The proteins immobilized 
on the microcon YM-10 were digested using trypsin Gold (Promega). 100µl of UB was 
added to the sample, before 120µl ABC containing 1µl of 1µg/µl trypsin. Filtration units 
were then mixed in a thermomixer for 1 minute at 600rpm before being incubated 
overnight in a humidity chamber at 37°C. Filtration unit were then centrifuged at 
14,000g for 40 minutes and flowthrough retained. Filtration units were washed with 
50µl 0.5M NaCl and centrifuged at 14,000g for 20 minutes. Flowthrough from both 
centrifugation steps were combined and the sample sent to the FingerPrints Proteomic 
Facility for mass spectrometry analysis. Small aliquots of wash steps and final elution 
steps were retained and analysed by SDS-PAGE Gel electrophoresis and stained with 
SimplyBlue™ SafeStain to visualise proteins (Figure 2.6). 
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Figure 2.6: SimplyBlue™ Stained SDS-PAGE Polyacrylamide Gel Of FASP 
Analysis. Coomassie blue stained acrylamide gel of acyl rac following FASP prior to 
mass spectrometry. MW – molecular weight, UF – unfractionated, HA/SM – 
hydroxylamine/starting material, NaCl/SM – sodium chloride/starting material. 
 
2.12 Electrophysiology 
 
Electrophysiology is the study of the electrical properties of biological cells and tissues. 
This technique can be used to record the electrical activity of ion channels, transporters 
and exchangers across the cell membrane. Depending on the configuration used, 
recordings can be from multiple (whole-cell configuration), single (cell-attached, 
outside-out excised patch, inside-out excised patch) ion transport mechanisms. In this 
work, whole-cell patch clamp was used, which is described below. Patch clamping set-
ups range from simple rigs to elaborate arrangements, however there is a basic set of 
conditions that must be accounted for in all cases for successful patch clamping. Basic 
set-ups require a platform with minimal mechanical interference; microscope for 
visualisation of the preparation; manipulators to position micropipettes; electronics to 
perform stimulation, recording and analysis in an electrically clean environment.  
 
Electrodes for electrophysiological recordings were produced from glass capillaries 
containing a filament with an outer diameter of 1.5mm and pulled using a 
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Flaming/Brown micropipette puller (Model P97, Sutter Instrument Co. USA). Once 
pulled, glass microelectrodes were fire polished to smooth and clean the tips using a 
Narishige microforge (MF-83, Japan). Electrodes were used on the day of preparation 
and kept in a container with a lid to prevent debris building up at the tip, which would 
prevent the establishment of a giga ohm seal. All experiments were carried out at 35°C, 
measured by heated perfusion tube (HPT-2A, Scientifica, UK). Cells were collected 
from the incubator and placed on the microscope stage. Excess growth media was 
removed by aspiration, then a custom made insert was put in the dish to reduce the bath 
volume to approximately 200µl. Perfusion of the bath was achieved using a 3-way 
stopcock perfusion system, allowing switching between different reservoirs. The 
perfusion was switched on and the HPT-2A enabled to heat the incoming solution to 
give a final bath temperature of 35°C. Cells were equilibrated for 5-10 minutes prior to 
experimental procedures. 
           
Chemical Extracellular Intracellular 
NaOH 120mM 20mM 
KOH - 5mM 
MgCl2 1mM - 
CsOH - 100mM 
Ca-sulfamic 1.5mM 12mM 
EGTA - 20mM 
HEPES 10mM 10mM 
D-glucose 10mM 8mM 
Mg-ATP - 5mM 
TEA-OH - 20mM 
NMDG 40mM 25mM 
 
Table 2.12: Composition Of Electrophysiology Buffers. Details of buffers used in IV 
ramp recordings. pH of the extracellular solution was 7.0 and the intracellular solution 
was 6.8. 
 
2.12.1 Cell-attached configuration 
 
Microelectrodes were filled with intracellular solution (see Table 2.12) and secured on a 
PatchStar micromanipulator (Scientifica, UK). Microelectrodes with resistance between 
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1.8-2.2MΩ were selected for experiments. A small amount of positive pressure was 
applied by mouth to the microelectrode, which was lowered into the bath, using 
PatchStar micromanipulator (Scientifica, UK). Square wave voltage perturbation (5mV) 
was used to assess pipette capacitance. Upon selecting a target cell, microelectrodes 
were positioned above the cell and lowered towards the cell membrane using the fine 
manipulator controls. Negative pressure was applied through gentle suction by mouth 
once the electrode was touching the cell membrane, as indicated by a small rise in 
resistance, typically about 1MΩ. This negative pressure aided the formation of a giga-
ohm seal. After establishing the giga-ohm seal, microelectrode capacitance was 
compensated using the fast and slow controls until the input and output signals were 
equal. 
 
2.12.2 Whole-cell configuration 
 
Following microelectrode capacitance compensation, the holding potential of the cell 
was changed to the calculated NCX1 reversal potential -30mV, which is calculated as 
follows, 
 
  
where, 
 
 
 
 
Thus, if membrane potential is equal to ENa/Ca then NCX1 is in equilibrium. Increasing, 
constant levels of negative pressure were applied by mouth until the membrane was 
ruptured and whole-cell configuration established. Cell capacitance and series resistance 
were adjusted until input and output signals were equal. The intracellular environment 
of the cell was allowed to dialyse with the microelectrode solution before commencing 
recordings. 
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2.12.3 IV Ramps 
 
IV ramps were used to measure NCX1 currents (Ander et al. 2007). This allows the 
measurement of both inward and outward exchange currents in one protocol. Cell 
holding potential was ramped from +80mV to -100mV (Figure 2.7), as this allowed 
maximal outward and inward exchange currents to be recorded. Voltages used are 
approximate as liquid junction potentials were not compensated. Sequences of 5 sweeps 
were obtained for each cell during the ramp protocol. Following recording of NCX1 
currents, the perfusion reservoir was switched to extracellular solution where Na+ and 
Ca2+ were replaced with equal concentrations of Li+ and Mg2+ respectively. Li+ and 
Mg2+-containing solution was allowed to enter the bath and cells were incubated for 5 
minutes to ensure the bath solution had completely switched. IV ramps were repeated 
with the same cell in the presence of Li+ and Mg2+. Upon cessation of the Li+ and Mg2+ 
treatment, the dish was discarded and replaced with a new dish of cells. For analysis, all 
NCX1 IV ramps were normalised by subtracting the current remaining after Li+ and 
Mg2+ treatment. Cells with access resistance of 3-5MΩ were selected for analysis. 
Analysis of NCX1 IV ramps was performed using pClamp10 and GraphPad Prism 6. 
Calculation of retification index was performed by normalising current obtained at 
+80mV for each cell line to respective current at -80mV.  
 
 
 
Figure 2.7: IV Ramp Protocol For Electrophysiology. Electrophysiological protocol 
used in the recording of NCX1 IV ramp protocol. Vm – membrane potential, mV – 
millivolt, s – second. 
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2.13 Left Ventricular Heart Failure 
 
To assess the role of palmitoylation in cardiac failure, an aortic banding model of left 
ventricular (LV) failure in the rat was employed. To induce heart failure, a titanium clip 
(internal diameter 0.6 mm) was placed around the ascending aorta in animals at 5 weeks 
of age (60-80g). Control animals received sham surgery. The development of LV 
hypertrophy and subsequent failure was determined by echocardiography in rats under 
2% isofluorane anaesthesia. LV structure and function were assessed using a GE Vivid 
7 pro with 12 MHz transducer. Heart failure was defined as ejection fraction <45%. 
Changes in cardiac function were confirmed by direct measurement of LV pressure-
volume relationships using Millar pressure-conductance catheters prior to tissue 
collection. Compensated hypertrophy was evidence at 16-20 weeks, which progressed 
to failure by approx. 25 weeks. This procedure was performed in the lab of Dr Sarah 
Calaghan at University of Leeds and the tissue kindly gifted for experiments. 
Approximately 3mg of tissue, as determined by Bradford protein assay, from each sham 
and banded animal was subjected to acyl rac followed by western blot analysis as 
described previously. 
 
2.14 Cardiac Hypertrophy In Vivo Model 
 
In addition to investigating the role of palmitoylation in heart failure, an in vivo model 
of cardiac hypertrophy was also analysed. The recently published method by 
Boguslavskyi et al was utilised to induce left ventricular hypertrophy in mice 
(Boguslavskyi et al. 2014). Briefly, hypertrophy was induced by pressure overload 
following suprarenal aortic constriction (banding) in 6-week-old C57BL/6J mice. 
Tissue was harvested 3 days, 14 days, 4 weeks and 8 weeks after surgery, to yield a full 
time course of disease progression. Heart excision was performed after terminal 
anaesthesia by i.p. injection of pentobarbital (Pentoject 200 mg/ml solution) at dose 300 
mg/kg and heparin (150 U). Whole hearts were homogenised in PBS, and a small 
aliquot was shipped to our laboratory for experiments. Between 1-2mg of tissue 
(matched for each experimental group), as determined by Bradford Assay, 
palmitoylated proteins were purified by acyl rac from each experimental group and 
analysed by SDS-PAGE gel electrophoresis followed by western blotting. 
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Chapter 3: Determining NCX1.1 Palmitoylation 
In Cardiac Muscle 
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3.1 NCX1.1 Displays Intramolecular Aggregation Following Prolonged Heating 
 
Purification of acylated proteins by resin assisted capture (Acyl Rac) was used to assess 
palmitoylation of NCX1.1 in cardiac muscle. During this protocol, samples are heated 
for 4 hours at 40°C. Routinely, NCX1 would appear as two distinct molecular weight 
bands, 160kDa and 120kDa via western blot analysis after acyl rac (Figure 3.1). To 
investigate whether this was a product of the prolonged heating or due to the disulphide 
bond in NCX1.1 (Santacruz-Toloza et al. 2000), isolated ARVM were lysed in the 
presence and absence of DTT. During this protocol, ARVM were solubilised in 
blocking buffer and incubated with 50mM DTT for 30 minutes at 40°C, with analytical 
samples taken prior to and following incubation. Lysates were incubated for 4 hours at 
40°C with NEM, after which proteins are precipitated overnight and resolubilised. 
Analytical samples were taken following incubation with NEM and following 
resolubilisation after precipitation. Samples were analysed by SDS-PAGE gel 
electrophoresis followed by western blotting. Membranes were incubated with NCX1 or 
caveolin-3 primary antibodies and visualised on a BioRad imaging system. 
 
 
 
Figure 3.1: NCX1 Displays Intramolecular Aggregation Following Prolonged 
Heating. Following prolonged exposure to high temperatures, NCX1 appears as a 
double band on western blots. SM – starting material, DTT – Dithiothreitol, UF – 
unfractionated. 
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Prior to heating, NCX1 migrates as a single 120kDa molecular weight band (figure 3.1) 
under non-reducing conditions. However, following exposure to 40°C for 30 minutes 
(Post-DTT lane in figure 3.1) in the presence and absence of DTT, NCX1 is observed a 
two molecular weight bands, 160kDa and 120kDa. The two distinct molecular weight 
bands are still seen following heating for 4 hours (Post-NEM lane, figure 3.1). The two 
molecular weight species are not affected by precipitation and resolubilisation (UF lane, 
figure 3.1). In contrast, caveolin-3 is unaffected by heating at any time during the 
heating protocol. Addition of NEM to caveolin-3 results in slightly smudged appearance 
on western blots, due to the size of the modification. These results suggest that NCX1 
aggregates if unreduced prior to heating.  
 
3.2 NCX1 Is Sensitive To Temperature And Reducing Agent 
 
Heating NCX1 above 40°C alters electrophoretic mobility of NCX1. ARVM lysates 
were heated to different temperatures for 10 minutes. Room temperature (RT), 37°C 
and 60°C were selected to determine the effect of temperature on NCX1. In addition, 
the effect of routinely used reducing agents on detection of NCX1 by western blotting 
was investigated. 
 
 
 
Figure 3.2: NCX1 Is Sensitive To Temperature And Reducing Agent. Following 
incubation for 10 minutes at various temperatures, in the presence and absence of 
reducing agent, visualisation of NCX1 via western blotting was reduced following 
heating above 37°C and further reduced by the presence of β-mercaptoethanol. RT – 
room temperature, DTT – Dithiothreitol, β-me - β-mercaptoethanol. 
 
2mg of ARVM were solubilised in 500µl 2 X SDS-Loading buffer (see Table 2.7), then 
subdivided into different treatment groups indicated in Figure 3.2. Samples were heated 
at the respective temperature for 10 minutes then subjected to SDS-PAGE gel 
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electrophoresis followed by western blotting. At RT, under all conditions, NCX1 was 
observed as 120kDa band (Figure 3.2). 37°C had no distinguishable effect on NCX1, 
regardless of reducing agent present. At temperatures above 60°C, NCX1 started to 
appear as a double band in samples without reducing agent (Figure 3.2), although a 
higher molecular weight band was more prominent. β-mercaptoethanol reduced 
visualisation of NCX1 on western blots at 60°C. This suggests that β-mercaptoethanol 
has an effect on aggregation of NCX1 or masks the epitope of antibody at high 
temperatures. At 60°C, in the presence of DTT, NCX1 was observed as 120kDa band. 
Despite NCX1 not adversely being affected by DTT, this was not sufficient to rescue 
the effect occurring in the presence of β-mercaptoethanol. Based on these results, NCX1 
can only be heated to 37°C. Since a reducing agent is required for elution at the end of 
the acyl rac protocol, 100mM DTT was selected as β-mercaptoethanol had a detrimental 
effect on detection of NCX1. 
 
3.3 NCX1 Is Palmitoylated In Adult Rat Ventricular Myocytes 
 
Acyl rac was used to capture palmitoylated proteins from isolated ARVM in order to 
assess NCX1 palmitoylation. Two different alkylating agents to block free cysteine 
residues were evaluated. MMTS is a reversible alkylating agent, whereas NEM is an 
irreversible alkylating agent. These two different agents were compared to determine 
the most suitable agent to use in acyl rac protocol. In addition, the ability to use an 
irreversible alkylating agent at non-palmitoylated cysteine residues will allow 
differential labelling of previously palmitoylated cysteine residues once proteins are 
eluted from thiopropyl sepharose (see section 2.6.2 for details of acyl rac). Differential 
labelling of cysteine residues will allow identification of potential palmitoylation sites 
by mass spectrometry. 
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Figure 3.3: NCX1 Is Palmitoylated In ARVM. A. NCX1 can be purified by acyl rac 
from isolated ARVM. As a marker for the assay efficiency, the constitutively 
palmitoylated caveolin-3 (cav3) was also investigated. B. Mean data revealed no 
significant difference between NCX1 purification between MMTS (79% ± 10.7, n=6) 
and NEM (67% ± 6.5, n=6). UF – unfractionated, Ha – hydroxylamine, MMTS - S-
Methyl methanethiosulfonate, NEM – N-Ethylmaleimide. Representative of 6 
independent replicates. 
 
As shown in figure 3.3, NCX1 is palmitoylated, as it is observed in acyl rac fractions 
treated with hydroxylamine, which cleaves thioester bonds and reveals previously 
palmitoylated cysteine residues, allowing capture via thiopropyl sepharose. 
Additionally, caveolin-3 is a constitutively palmitoylated protein identified via acyl rac, 
confirming the effectiveness of this assay to capture palmitoylated proteins. 
Comparison of MMTS and NEM revealed that there is no significant difference using 
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either as a blocking agent prior to acyl rac to capture palmitoylated NCX1. The graph in 
figure 3.3 shows the mean palmitoylation data from 6 independent replicates for MMTS 
and NEM treated experiments. This is calculated as mean bound as a percentage of 
mean starting material. These results suggest that NEM is suitable for alkylating free 
cysteines, therefore making it a suitable alkylating agent for analysing palmitoylated 
proteins by mass spectrometry following acyl rac. 
 
3.4 NCX1 Is Sub-Stoichiometrically Palmitoylated In ARVM 
 
Caveolin-3 is known to be constitutively palmitoylated protein. This was utilised to 
estimate the extent of NCX1 palmitoylation. In addition to analysing the unfractionated 
(UF) and bound (B) fractions of the Acyl Rac protocol, the unbound (UB) fraction was 
analysed to determine if all NCX1 and caveolin-3 were being captured by the assay 
(figure 3.4). The double band corresponding to NCX1 was observed in UB fraction 
from acyl rac, suggesting acyl rac did not purify all of NCX1 present. Conversely, no 
caveolin-3 was observed in UB fractions, suggesting that acyl rac purified all of 
palmitoylated caveolin-3. Both NCX1 and caveolin-3 were observed in the bound 
fractions treated with hydroxylamine. This supports evidence suggesting caveolin-3 is 
100% palmitoylated (Dietzen et al. 1995). In contrast, in the absence of hydroxylamine, 
NCX1 and caveolin-3 are not purified by acyl rac (bands present in UB NaCl fraction) 
confirming the specificity of capture. Normalised to caveolin-3 palmitoylation, acyl rac 
is able to purify approximately 60% of NCX1 from ARVM. This suggests that NCX1 is 
sub-stoichiometrically palmitoylated in ARVM. 
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Figure 3.4: NCX1 Is Sub-Stoichiometrically Palmitoylated In ARVM. A. NCX1 was 
purified by acyl rac. Not all NCX1 was captured using this technique, suggesting it is 
not 100% palmitoylated. Acyl rac is able to purify all of palmitoylated caveolin-3. B. 
Estimating stoichiometry against caveolin-3, which is 100% palmitoylated, reveals 
NCX1 to be approximately 60% palmitoylated. Cav3, 100% ± 0, n=6, NCX1, 56.7% ± 
4.9, n=6. UF – unfractionated, UB – unbound, B – bound, Ha – hydroxylamine, NaCl – 
sodium chloride. Representative of 6 independent replicates. 
 
3.5 Palmitoylation Of NCX1 Is Not Splice Variant Specific 
 
As NCX1.1 can be purified by acyl rac, it was investigated whether this was specific to 
the cardiac splice variant. NCX1 is subject to alternative splicing within the intracellular 
loop, which are expressed in a tissue specific manner (Quednau, Nicoll & Philipson 
1997b). To determine whether palmitoylation was confined to the NCX1.1 splice 
variant, whole brain or whole kidney lysates were subjected to acyl rac. The 
predominant splice variants in brain are NCX1.4, NCX1.5 and NCX1.6, whereas 
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NCX1.3 and NCX1.7 are predominant in kidney. The NCX1 monoclonal antibody, 
R3F1, was originally raised against the cardiac NCX1 (Porzig et al. 1993), however 
there is evidence to suggest that this antibody is capable of recognising other splice 
variants (Hurtado et al. 2006; Ander et al. 2007). Therefore NCX1 monoclonal 
antibody, R3F1, was used to detect brain and kidney NCX1 palmitoylation. 
 
 
 
Figure 3.5: Palmitoylation Is Not Specific To The Cardiac Splice Variant Of NCX1. 
Splice variants of NCX1 expressed in brain and kidney are also targets of protein 
palmitoylation. NCX1 splice variants in these tissues are successfully captured by acyl 
rac. UF – unfractionated, Palm. – palmitoylated, Ha – hydroxylamine, NaCl – sodium 
chloride, Flot2 – flotillin 2. n=3. 
 
Shown in figure 3.5, NCX1 splice variants are detected by R3F1 NCX1 monoclonal 
antibody, bands corresponding to NCX1 are observed in UF samples from brain and 
kidney. Additionally, brain and kidney lysates reveal that NCX1 is palmitoylated in 
these tissues as NCX1 is purified by acyl rac in the presence of hydroxylamine. This 
interaction is specific since no NCX1 is detected when acyl rac is performed in the 
presence of NaCl. Flotillin-2 is also palmitoylated in all tissues examined, and is also 
captured during acyl rac in the presence of hydroxylamine. These results suggest that 
palmitoylation is not specific to the cardiac splice variant but occurs on other splice 
variants, regardless of expression within excitable and non-excitable cell types. 
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3.6 SDS Is Essential For Elution Of Palmitoylated Proteins Captured By Acyl Rac 
 
Routinely, proteins captured by acyl rac were eluted using 2 X SDS-Loading Buffer 
containing 100mM DTT. In order to characterise the cardiac palmitoyl proteome, mass 
spectrometry was utilised to identify proteins captured during acyl rac. However, SDS 
is not compatible with mass spectrometry, therefore an alternative method of elution 
from the thiopropyl sepharose was required. Proteins are digested with trypsin prior to 
mass spectrometry. Digestion would be inhibited with SDS present, however urea is 
more compatible. Elution from thiopropyl sepharose was done using alternative 
reagents. Two different concentrations of urea were used to determine if proteins could 
be solubilised. Additionally, temperature was also investigated, with room temperature 
and 37°C since some proteins can be subject to temperature dependent aggregation 
effects (Section 3.2). Acyl rac was used to purify palmitoylated proteins from isolated 
ARVM. During the last wash step of acyl rac protocol, the sample was split into 3. 
Thiopropyl sepharose was recovered by centrifugation and proteins were eluted with 
100mM DTT plus 2 X SDS-Loading Buffer lacking bromophenol blue, 0.8M Urea or 
8M Urea. Samples were analysed by SDS-PAGE gel electrophoresis followed by 
western blotting. Membranes were probed for NCX1 and caveolin-3 to investigate 
efficiency of elution. 
 
 
Figure 3.6: SDS Is Essential For Elution Of Proteins From Thiopropyl Sepharose. 
Samples taken and analysed throughout the acyl rac protocol then assessed for the 
ability of SDS and 2 different concentrations of Urea to solubilise proteins reveal that 
SDS is required to elute from sepharose. SM – starting material, DTT – Dithiothreitol, 
NEM – N- Ethylmaleimide, UF – unfractionated, UB – unbound, RT – room 
temperature. Representative of 3 independent experiments. 
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NCX1 and caveolin-3 were detected in fractions eluted with SDS. There was no 
difference between level of proteins eluted between room temperature and 37°C. No 
bands corresponding to NCX1 or caveolin-3 were observed in samples eluted in the 
presence of 0.8M Urea, regardless of temperature used. Despite increasing the 
concentration of urea to 8M, NCX1 was not eluted to the same extent as with SDS. A 
small amount of caveolin-3 was eluted in the presence of 8M Urea, but not to the same 
level as SDS. Based on these results, proteins were solubilised with SDS, thus aiding 
elution with 100mM DTT, which was removed prior to mass spectrometry via filter 
aided sample preparation (FASP) (Section 2.11). 
 
3.7 PANTHER Analysis Reveals Functions Of Proteins In Cardiac Palmitoyl 
Proteome 
 
Mass spectrometry is capable of identifying large numbers of proteins through peptide 
recognition. To analyse a large data set, it is useful to determine functions of proteins 
identified. In order to generate a comprehensive overview of the cardiac palmitoyl 
proteome, 3 different data sets were pooled. Mass spectrometry data from acyl rac 
performed on isolated ARVM and whole heart were used. An additional data set from 
Dr Jacqueline Howie utilising acyl rac from isolated ARVM followed by iTRAQ, 
which determines amounts of proteins in a given sample via isobaric labelling followed 
by quantative proteomics by tandem mass spectrometry. Protein lists produced from the 
3 experiments were compared and only high confidence candidates (appeared in 2 data 
sets or more) selected for further analysis. Mitochondrial proteins were removed from 
the list using MitoMiner. The remaining proteins were then analysed using Protein 
ANalysis THrough Evolutionary Relationship (PANTHER) analysis, which classifies 
proteins and their genes (Mi et al. 2013). Resultant protein hits were classified 
according to family and subfamily, molecular function, biological process and pathway.  
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Figure 3.7: PANTHER Analysis Reveals Respective Functions Of Palmitoylated 
Proteins Identified By Mass Spectrometry. PANTHER analysis revealed that 
palmitoylated proteins in cardiac tissue have a variety of different functions. 
 
PANTHER analysis revealed that a large number of the proteins identified by mass 
spectrometry are associated with membranes. Shown in Figure 3.7, proteins possessing 
catalytic activity, structural molecule activity and binding activity are most abundant in 
this data set. Additional functions of proteins identified by mass spectrometry are ion 
channel, transporter activity, translation regulator activity, transcription regulator 
activity, enzyme regulator activity, antioxidant activity, receptor activity and motor 
activity. The functions of proteins identified by mass spectrometry are wide-ranging, 
indicating that palmitoylation is an important post-translational modification in cardiac 
tissue for a variety of different proteins. For a full list of proteins that were identified by 
mass spectrometry, see Appendix 1.  
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3.8 DAVID Analysis Indicates Functional Pathways That Are Palmitoylated In 
Cardiac Tissue 
 
In addition to analysing the proteomic dataset identified by mass spectrometry using 
PANTHER analysis, DAVID analysis was also employed. DAVID bioinformatics 
resources are designed to enable users to extract biological meaningful data from large 
proteomic data sets (Huang et al. 2008). This analysis maps identified genes associated 
biological annotation (gene ontology terms) and then statistically determines the most 
represented (enriched) biological annotation out of thousands of linked terms and 
contents. The enrichment analysis allows users to identify biological processes that are 
most relevant to their biological phenomenon. The 287 UniProt Accession IDs 
remaining following MitoMiner analysis were uploaded to DAVID Bioinformatics 
Resources Version 6.7. Once generated, the results were functionally clustered at high 
classification stringency.  
!
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Figure 3.8 details a selection of functional clusters identified by DAVID analysis. As 
previously shown by PANTHER analysis, a wide variety of functions of proteins were 
identified by mass spectrometry. Functional clustering reveals proteins involved in 
membranes scaffolding, glycolysis, GTP binding, macromolecular complex assembly 
and ion homeostasis. 122 functional clusters were identified within cardiac muscle. A 
number of proteins found within each of these functional clusters have been described 
previously, in other tissues and cell types as being palmitoylated (Dietzen et al. 1995; 
Morrow et al. 2002; Linder et al. 1993; Howie et al. 2013). Identification of these 
proteins within the cardiac palmitoyl proteome confirms that mass spectrometry is 
capable of identifying palmitoylated proteins and the efficiency of acyl rac to capture 
palmitoylation proteins. 
 
3.9 Verification Of Specific Targets Identified By Mass Spectrometry 
 
A major disadvantage of using mass spectrometry to identify proteins within a sample is 
the possibility of false positives. Proteins that are abundant in the sample can 
contaminate the final sample. Due to their high abundance, these proteins may not be 
removed during wash steps completely and have a tendency to appear on mass 
spectrometry identification lists as positive hits. To ensure only positive hits were 
investigated further, we subjected isolated ARVM to acyl rac and analysed by SDS-
PAGE gel electrophoresis followed by western blotting. 
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Figure 3.9: Verification Of Proteins Identified By Mass Spectrometry. Acyl rac was 
performed on isolated ARVM and resultant samples immunoblotted for proteins of 
interest. Representative members of functional clusters identified by DAVID analysis 
were selected. UF – unfractionated, + - with hydroxylamine, - - without hydroxylamine, 
UB – unbound, B – bound. 
 
Representative members of select functional clusters identified by DAVID analysis 
(Section 3.8) were selected for investigation. Flotillin-1, the alpha subunit of Gi, 
GAPDH and caveolin-3 have been previously described to be palmitoylated (Morrow et 
al. 2002; Linder et al. 1993; Yang et al. 2005; Dietzen et al. 1995). Shown in Figure 3.9, 
flotillin-1, Gialpha subunit, GAPDH, caveolin-3 and NCX1 were captured by acyl rac 
due to their visualisation in bound fractions following western blot analysis. Given that 
these targets have been previously described to be palmitoylated confirms the 
specificity of acyl rac in capturing palmitoylated proteins.  Interestingly, the level of 
palmitoylation observed varies between targets, suggesting they are palmitoylated to 
differing levels. GAPDH, for instance, is much less palmitoylated compared to the 
constitutively palmitoylated caveolin-3 and flotillin-1. The P value shown is the 
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DAVID enrichment P value (Huang et al. 2008). Flotillin-1, Gialpha subunit and 
GAPDH are well enriched in this sample, suggesting that acyl rac has captured a greater 
proportion of these proteins, or that they are simply more abundant in cardiac tissue 
compared to caveolin-3 and NCX1. 
 
3.10 Mass Spectrometry Reveals Cys557 Is Not A Potential Palmitoylation Site 
 
As previously described, non-palmitoylated cysteine residues were alkylated with NEM, 
and following elution from thiopropyl sepharose, palmitoylated proteins were 
differentially alkylated with iodoacetamide. All proteins captured were digested with 
trypsin and analysed using mass spectrometry. Differential alkylation of cysteine 
residues allows identification of previously palmitoylated cysteine residues and non-
palmitoylated residues (Forrester et al. 2011). Mascot was used to match peptides 
identified by mass spectrometry to proteins and produce a coverage map of proteins 
identified. 
 
 
Figure 3.10: Coverage Map Of NCX1. Coverage map produced by Mascot following 
mass spectrometry. Residues shown in red were covered by mass spectrometry. 
Resultant coverage was approximately 27%. 
 
Since NCX1 is a large protein, achieving full coverage by mass spectrometry is 
difficult. As a result, coverage of NCX1 was approximately 27%. Of this 27%, only 1 
cysteine residue out of a possible 15 was covered (Figure 3.10). Nevertheless, despite 
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the poor coverage of cysteine residues, Cys557 was identified as not being a 
palmitoylation site. Shown in Figure 3.11, the presence of N-ethylmaleimide on Cys557 
(highlighted by the black box) suggests that this cysteine residue was not previously 
palmitoylated. Since NCX1 is not 100% palmitoylated, palmitoylation sites could be 
labelled with both NEM and IAA, making site identification tricky. 
!
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The ion score of Cys557 is 46. In Mascot, the ion score is based on calculated 
probability, P, that the observed match between the experimental data and the database 
sequence is a random event. Therefore, if 1500 peptides fall within the tolerance 
window about precursor mass, and the significance level was 0.05, this would translate 
as an ion score of 45 or greater. Based on this, Cys557 is a genuine hit. However, 
Cys557 is 1 of 15 possible sites, therefore mass spectrometry has only eliminated one 
potential site. This is disappointing, given the high number of cysteines present, it was 
hoped that mass spectrometry could have eliminated more than 1 site. 
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3.11 Discussion 
 
One of the major aims from this work was to determine NCX1 palmitoylation status and 
stoichiometry in cardiac muscle. As described previously, NCX1 plays an important 
role in the removal of Ca2+ from the cytosol during diastole (Bers 2002). Although the 
structure-function relationship of NCX1 is well studied, less is known about its post-
translational regulation. An appreciation is growing that palmitoylation is important in 
the regulation of protein function (Linder & Deschenes 2007). Of particular interest is 
recent evidence to suggest a role for palmitoylation in the regulation of ion transport 
(Shipston 2011; Howie et al. 2013).  
 
Temperature Sensitivity Of NCX1 
 
During the course of this work, it became evident that NCX1 appeared as a double band 
when analysed by SDS-PAGE gel electrophoresis followed by western blotting. 
Philipson and colleagues previously described that NCX1 forms a disulphide bond 
between Cys 14 or 20 and Cys792 (Santacruz-Toloza et al. 2000). They report that 
under reducing conditions NCX1 appears as two bands of 120kDa and 70kDa molecular 
masses respectively following SDS-PAGE gel electrophoresis. Conversely under non-
reducing conditions, NCX1 appears as a higher molecular weight band of 160kDa. 
Band shifts occurring in the presence and absence of reducing agents is suggestive of 
the presence of a disulphide bond. Given that DTT reduces the disulphide bond, 
samples were pre-reduced prior to cysteine alkylation. Prior treatment with DTT had no 
effect on the appearance of NCX1 as a double band. This suggests that the appearance 
of NCX1 as a double band is not dependent on the presence of a disulphide. Previous 
publications from Philipson and colleagues indicate that molecular mass of NCX1 
varies dependent on SDS-PAGE conditions (Philipson et al. 1988). Interestingly, the 
double band only appears after heating at temperatures above 37°C, indicating that 
NCX1 forms aggregates as a result of heating. This would indeed result in a molecular 
weight band shift, as the higher molecular weight species would not migrate as easily 
through polyacrylamide gels. 
 
Inclusion of different routinely used reducing agents had an effect on the appearance of 
NCX1 analysed by SDS-PAGE gel electrophoresis and western blotting (Figure 3.2). 
Without reducing agent, NCX1 appears as a higher molecular weight species following 
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exposure to 60°C. Including DTT in the sample prior to SDS-PAGE gel electrophoresis 
reduced this species to a lower molecular weight. Interestingly, β-mercaptoethanol has a 
profound detrimental effect on visualisation of NCX1 by western blotting by almost 
reducing its appearance completely. This suggests that β-mercaptoethanol facilitates 
temperature dependent aggregation of NCX1 at temperatures above 37°C. Furthermore, 
DTT appears to be more efficient at maintaining protein stability at higher temperatures. 
Despite being more efficient at stabilising NCX1 at higher temperatures, DTT did not 
prevent the detrimental effect of β-mercaptoethanol. DTT was used at 100mM, whereas 
β-mercaptoethanol was used at 700mM. This may explain why the effect of β-
mercaptoethanol on NCX1 visualisation was not rescued by adding DTT as β-
mercaptoethanol is in excess. 
 
NCX1 Palmitoylation Status In Cardiac Muscle 
 
Enriching palmitoylated proteins from isolated ARVM revealed that NCX1 is 
palmitoylated. Additionally, the constitutively palmitoylated caveolin-3 was captured 
by acyl rac. This confirms the specificity of this assay to capture palmitoylated proteins 
as caveolin-3 has previously been shown to be palmitoylated (Dietzen et al. 1995). 
Assessing compatibility of different alkylating agents revealed no significant difference 
between each agent for use in acyl rac as palmitoylated proteins can be purified to 
approximately the same extent. To estimate NCX1 palmitoylation stoichiometry, i.e. 
how much of NCX1 is palmitoylated, enrichment of NCX1 following acyl rac was 
compared to the constitutively palmitoylated caveolin-3 (Dietzen et al. 1995). As a 
result, NCX1 palmitoylation stoichiometry was estimated to be approximately 60%. 
Therefore NCX1 is sub-stoichiometrically palmitoylated in cardiac muscle. If NCX1 
was 100% palmitoylated, this may suggest that palmitoylation is obligatory for cellular 
functions of NCX1 (e.g. membrane targeting), which is an established regulatory 
mechanism (Linder & Deschenes 2007). Given that NCX1 palmitoylation is estimated 
to be 60%, this suggests that palmitoylation may play a role in the regulation of NCX1, 
potentially in a dynamic way. There is increasing evidence for dynamic palmitoylation 
of targets, in contrast to the historical opinion that palmitoylation was a stable 
modification (Martin et al. 2011).  
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Palmitoylation Status Of Alternatively Spliced Variants Of NCX1 
 
The canine sarcolemmal NCX1 was first cloned in 1990 and designated NCX1.1 (Nicoll 
et al. 1990). Since this point, NCX1 has been cloned from multiple species and tissues 
(Komuro et al. 1992; Low et al. 1993; Schulze et al. 1996). The wide expression profile 
of NCX suggests that it plays an important physiological role in various cell types. 
NCX1 is most abundant in the heart but is found in many other tissues and cells, such as 
brain, kidney, skeletal muscle, smooth muscle, lung and spleen(Quednau, Nicoll & 
Philipson 1997b). The C-terminus of the large intracellular loop domain contains a 
variable region of 110 amino acids that is subject to alternative splicing. The genomic 
structure within this region contains a cluster of 6 exons, designated A, B, C, D, E and F 
(Quednau, Nicoll & Philipson 1997b). Exons A and B are mutually exclusive, whereas 
C, D, E and F are cassette exons (Kofuji et al. 1994). Presently, there are 12 known 
splice variants of NCX1 (Quednau, Nicoll & Philipson 1997b), which are thought to 
convey functional diversity amongst the different splice variants. To investigate whether 
palmitoylation was restricted to the cardiac splice variant, NCX1.1, we subjected brain 
and kidney lysates to acyl rac. Brain predominantly expresses NCX1.4, 1.5 and 1.6, 
whereas kidney expresses NCX1.3 and 1.7 (Quednau, Nicoll & Philipson 1997b). The 
results revealed that NCX1 splice variants expressed in brain and kidney are 
palmitoylated. This is unsurprising, given that alternative splicing of NCX1 does not 
remove any cysteine residues (Figure 3.12). 
 
! 121 
 
Figure 3.12: Clustal Alignment Of NCX1 Splice Variants. Comparison of sequences 
of 6 splice variants of NCX1. Alignment performed using Clustal Omega. 
 
The alternative splicing of NCX1 only results in changes C terminal to the Ca2+ binding 
domains (CBDs). Shown in figure 3.12 is a clustal alignment of NCX1 splice variants 
expressed in heart (NCX1.1), brain (NCX1.4, 1.5 and 1.6) and kidney (NCX1.3 and 
1.7). Alternative splicing results in dramatic differences in amino acid sequences, but 
regulation of NCX1 by alternative splicing is largely uninvestigated to date. Expression 
of the cardiac splice variant and a kidney splice variant in oocytes revealed differential 
sensitivities to regulation by voltage, intracellular Ca2+ and phosphorylation (Ruknudin 
et al. 2000). In addition, isoform-specific regulation by protein kinase A (PKA) has also 
been demonstrated (S. He et al. 1998). Investigation into the ionic regulatory properties 
of splice variants of NCX1 may provide insight into whether NCX1 is tailored for 
specific Ca2+ handling requirements in different tissues. Na+-dependent inactivation is 
more pronounced in NCX1.3 than NCX1.4 (Dyck et al. 1999). Furthermore, regulatory 
Ca2+ only modestly affected Na-dependent inactivation of NCX1.3, whereas 
inactivation of NCX1.4 could be completely overcome by intracellular Ca2+.  
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Although differences exist in the regulation of NCX1 splice variants, given that no 
cysteine residues are removed as a result of splicing suggests that palmitoylation still 
occurs. Interestingly, alternative splicing of NCX1 results in introduction of a new 
cysteine residue in NCX1.4, 1.5, 1.6 and 1.7. However, whether this cysteine is a site of 
palmitoylation within these different splice variants is beyond the scope of this 
investigation. Palmitoylation may potentially contribute to the differential regulation of 
splice variants by Na+, Ca2+, voltage and phosphorylation. 
 
Requirement Of SDS For Elution Of Palmitoylated Proteins 
 
Somewhat surprisingly, proteins captured during the acyl rac protocol cannot be eluted 
from thiopropyl sepharose in the absence of SDS in the elution buffer. Substituting urea 
at two different concentrations did not result in elution. However a small amount of 
caveolin-3 was observed following elution with 8M urea, but not same amount as SDS. 
The mode of binding of SDS to proteins and how the protein is denatured is dependent 
upon the concentration of SDS used (Bhuyan 2010). At submicellar concentrations of 
SDS, below 1mM, SDS monomers bind to proteins via hydrophobic interactions and 
causing unfolding of the tertiary structure. This would allow DTT access to bond 
between the protein and the thiopropyl sepharose, thus allowing elution of the proteins. 
In contrast, although high concentrations of urea are capable of denaturing proteins to a 
similar extent as SDS, this has shown to be dependent on heating the sample to 
temperatures above 60°C (Bennion & Daggett 2003). Since NCX1 does not tolerate 
high temperatures, samples were not heated above 37°C. If the denaturing effect of urea 
largely depends upon heating to higher temperatures; this may explain why proteins 
could not be eluted. To try and ensure high coverage of NCX1 by mass spectrometry, 
temperature dependent aggregation was avoided; hence samples were not exposed to 
high temperatures. 
 
Functional Analysis Of Palmitoylated Proteins In Cardiac Muscle 
 
Mass spectrometry is capable of generating a large amount of information regarding 
proteins present in a particular sample. Therefore, to extract meaningful data from lists 
of protein IDs generated, the ability to analyse a large dataset is important. Two 
methods of analysing the data were used, PANTHER analysis and DAVID analysis.  
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PANTHER analysis groups proteins into their respective functions to facilitate high-
throughput analysis. This is particularly useful as it allows the functions of identified 
proteins to be determined. PANTHER is a comprehensive system that combines gene 
function, ontology, pathways and statistical analysis allowing analysis of large scale 
dataset (Mi et al. 2013). Functions of identified genes are classified in different ways; 
families and subfamilies annotated with ontology terms and sequences assigned to 
PANTHER pathways. Using genes classified into families and subfamilies allows an 
overview of functions identified within the dataset. The palmitoylated proteins 
identified by mass spectrometry revealed a plethora of functions of proteins identified. 
Unsurprisingly, a number of these proteins are associated with functions that are 
typically carried out at the cell membrane such as ion channel activity, transport 
activity, binding, structural membrane activity and catalytic activity. A role in 
membrane targeting is a well-established role for protein palmitoylation, as well as 
direct regulation of activity (Linder & Deschenes 2007; Linder & Deschenes 2003; 
Blaskovic et al. 2013; Blaskovic et al. 2014).  
 
DAVID Analysis was also used to generate information regarding the functions of 
proteins identified by mass spectrometry. DAVID bioinformatics resources consists of 
an integrated biological knowledge database and analytical tools that extract biological 
meaning from large protein/gene lists (Huang et al. 2008). Proteins analysed by DAVID 
analysis can be functionally clustered into bio-pathways, giving information regarding 
biological pathways that proteins identified may play a role in. As a useful addition, 
enriched functionally related gene groups and enriched annotation terms can be 
identified by this analysis. This provides information regarding how well represented 
particular proteins are within the protein list. Analysing protein lists in this manner, 
supports the activities of proteins identified by PANTHER analysis. A number of 
proteins identified as palmitoylated in cardiac muscle are involved in the same 
signalling cascades, as shown by the functional clusters such as membrane fraction, 
glycolysis, GTPase activity, macromolecular complex assembly and ion homeostasis. 
Functional clusters group proteins involved in the same biological pathway together, 
providing insight into pathways potentially regulated by protein palmitoylation. Proteins 
involved in scaffolding of proteins or are integral to the membrane were identified as 
being palmitoylated, such as flotillin-1 and caveolin-3. Based on the emerging evidence 
that a number of ion transport mechanisms are regulated by protein palmitoylation, it is 
not surprising that a diverse range of ion transporters and channels were identified by 
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mass spectrometry (Shipston 2011). Somewhat surprisingly, all major routes of Ca2+ 
and Na+ entry and exit across the sarcolemmal membrane were identified as 
palmitoylated. This suggests that palmitoylation could be as important as 
phosphorylation in the regulation of excitation-contraction coupling and thus cardiac 
function. The regulation of these ion transport mechanisms by palmitoylation is 
relatively unexplored. One transport mechanism that has been studied with regards to 
protein palmitoylation is the cardiac Na+/K+ ATPase and its accessory protein, 
phospholemman (Howie et al. 2013; Tulloch et al. 2011). Palmitoylation of 
phospholemman inhibits the Na+/K+ ATPase, which is relieved by the non-specific 
DHHC inhibitor, 2-BP. In addition, phosphorylation of phospholemman, which 
activates Na+/K+ ATPase, promotes palmitoylation. The interaction between these two 
post-translational modifications on the ability of phospholemman to modulate Na+/K+ 
ATPase remains to be investigated fully.  
 
Verification Of Targets Identified By Mass Spectrometry 
 
A drawback of using affinity chromatography followed by mass spectrometry to 
identify proteins within a given sample is the possibility of false positives. The datasets 
shown as a result of this work have had all mitochondrial proteins removed, as cysteine 
thioesters exist within mitochondria as a result of fatty acid metabolism. Mitochondrial 
proteins were abundant in the samples analysed, due to the relative abundance of 
mitochondria within cardiac tissue. Evident from proteins identified by mass 
spectrometry were large structural proteins that may not be palmitoylated but are highly 
abundant in cardiac tissue. Large proteins will also generate large numbers of peptides, 
resulting in high MASCOT scores. To verify that other proteins within the sample that 
were relatively abundant are true positive hits, a small selection were verified by 
performing acyl rac followed by SDS-PAGE gel electrophoresis and western blotting. 
Representative members from different functional groups that had well characterised 
antibodies raised against them were selected for analysis. All protein targets selected for 
verification were identified by acyl rac, supporting the proteins identified by mass 
spectrometry. Additionally, not all targets selected were palmitoylated to the same 
extent. Given the diverse range of functional effects of palmitoylation on protein 
function, differential levels of palmitoylation would potentially regulated proteins in 
different ways, depending on their respective functions. For instance, structural and 
scaffolding proteins such as flotillin-1 and caveolin-3 are palmitoylated to a high 
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degree, suggesting that their palmitoylation is involved in anchoring these proteins to 
the membrane or targeting them to membrane compartments (Dietzen et al. 1995; 
Morrow et al. 2002). GAPDH, whose palmitoylation has been described previously 
(Yang et al. 2005), is only palmitoylated to a low extent, as acyl rac captured a small 
amount of the protein. GAPDH has a reactive cysteine residue within its active site, 
which plays a role in its activity. This could potentially generate a false positive as acyl 
rac relies on thioesters to purify palmitoylated proteins (see following section for 
discussion). Additionally, Giα subunit was also identified in the mass spectrometry 
screen as well as verified by acyl rac analysis. This supports evidence previously 
described that G-protein subunits are subject to protein palmitoylation (Linder et al. 
1993). For all proteins analysed, NaCl treated fractions revealed no bands, suggesting 
that none of these proteins bind to the thiopropyl sepharose used in the acyl rac protocol 
non-specifically. The positive verification of selected targets supports that proteins 
identified by mass spectrometry are genuine hits. Additionally, analysing high 
confidence targets from the pooled data from 3 separate experiments further supports 
the authenticity of identified proteins. 
 
Identification Of Palmitoylation Sites By Mass Spectrometry 
 
During the acyl rac protocol, irrelevant or non-palmitoylated cysteine residues are 
alkylated. This can be exploited to determine palmitoylation sites by mass spectrometry. 
Non-palmitoylated cysteine residues were labelled with N-ethylmaleimide (NEM), an 
irreversible alkylating agent as part of the acyl rac protocol. Following elution of 
captured proteins, during the FASP protocol used to remove the SDS from the sample 
previously palmitoylated cysteine residues were labelled with iodoacetamide. Peptides 
were digested with trypsin and submitted for mass spectrometry analysis. Peptides 
identified by mass spectrometry are matched to proteins via MASCOT. A coverage map 
is generated resulting from the number of peptides mapped to its respective sequence. 
Peptides containing amino acids with modifications are shown as a list following the 
coverage map. Cysteine residues labelled with NEM are designated as non-
palmitoylated, given that NEM was used prior to thioester bond cleavage to label 
irrelevant cysteine residues. Conversely, peptides labelled with iodoacetamide (shown 
in MASCOT list as Carbamidomethyl) identify cysteines previously palmitoylated. 
Unfortunately, despite using an inclusion list for proteins of interest, mass spectrometry 
generated poor coverage of NCX1. As a result, the majority of the cysteine residues 
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present within NCX1 were not represented. Nevertheless, one cysteine residue was 
mapped within the sequence. Cys557 showed the addition of NEM, which suggests that 
this cysteine residue is not palmitoylated. Cys557, is located close to Ca2+ binding 
domain 2 (CBD2) of NCX1 (Besserer et al. 2007). Palmitoylation of this residue would 
lead to a large change in secondary structure, presumably altering the Ca2+ sensitivity 
and binding of these domains. NCX1 possesses 14 other cysteine residues. Two of these 
residues are known to be involved in forming a disulphide bond (Santacruz-Toloza et al. 
2000). The precise location within the protein of the other cysteines is predicted but not 
proven. At present, there is no crystal structure available for mammalian NCX1.  
 
Summary 
 
Taken together, these results suggest that NCX1 is palmitoylated within cardiac muscle, 
and acyl rac captured approximately 60% of NCX1. NCX1 cannot tolerate prolonged 
exposure to temperatures above 37°C without aggregating. This aggregation is not 
caused by the presence of the disulphide within NCX1. In addition to palmitoylation of 
NCX1, vast arrays of proteins were identified as palmitoylated within cardiac tissue by 
mass spectrometry. This suggests that palmitoylation has the potential to regulate many 
different cellular processes. With a number of ion transport mechanisms across the 
sarcolemmal membrane found to be palmitoylated, this points toward palmitoylation 
being a significantly important post translational modification within cardiac muscle. 
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Chapter 4: Mapping Palmitoylation Site(s) In 
NCX1.1 
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4.1 Comparison Of NCX1 Palmitoylation In BHK, HeLa and HEK293 Cell Lines 
 
Culturing of cardiac myocytes can be challenging. In culture following isolation, 
myocytes isolated show gradual loss of subcellular structure (Pavlovic et al. 2010). In 
addition, ability to maintain contractile responses is diminished. Transfection of isolated 
ARVM is difficult using routine transfection techniques, with transfection rates varying 
between 0-15% (Djurovic et al. 2004). Using isolated cardiac myocytes would provide 
physiological palmitoylation stoichiometry of NCX1, but this would be extremely labor 
intensive. As a result, cell lines were selected for ease of use and transfection. As NCX1 
is approximately 60% palmitoylated in cardiac tissue, the following cell lines were 
analysed for NCX1 palmitoylation; Baby Hamster Kidney (BHK), HeLa and Human 
Embryonic Kidney (HEK) 293 cell lines. These cell lines express no endogenous 
NCX1. Cell lines were transfected with canine NCX1. Palmitoylated proteins were 
purified from cell lysates using acyl rac followed by SDS-PAGE gel electrophoresis and 
western blotting to analyse degree of palmitoylation of transfected NCX1.  
 
 
 
Figure 4.1: NCX1 Is Palmitoylated To A Greater Extent In HeLa And HEK293 Cell 
Lines. Comparison of acyl rac performed on NCX1 transfected BHK, HeLa and 
HEK293 cell lines revealed that HeLa and HEK293 cell lines show the highest 
palmitoylation. 
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NCX1 palmitoylation in transiently transfected cells was compared to cardiac lysates. 
NCX1 palmitoylation is variable between cell lines. BHK cell line transfected with 
NCX1 show the lowest extent of palmitoylation (figure 4.1). NCX1 is palmitoylated to 
a greater level in transfected HeLa cells. In addition, NCX1 shows significant 
palmitoylation in transfected HEK293 cells. Flotillin-2 is palmitoylated in all cell lines 
investigated, however BHK cells show the lowest level of palmitoylation. These results 
suggest that HeLa and HEK293 cell lines palmitoylate NCX1 to a higher level, 
compared to BHK cell lines. However, HeLa and HEK293 cell lines do not palmitoylate 
NCX1 to the same extent as cardiac myocytes. Therefore, HeLa and HEK293 cell lines 
were used to investigate NCX1 palmitoylation. 
 
4.2 Expression And Palmitoylation Of NCX1 Site Mutations In HeLa And 
HEK293 Cell Lines 
 
As mass spectrometry did not definitively elucidate site(s) of palmitoylation on NCX1, 
a mutational approach was adopted. Mass spectrometry showed C557 was not 
palmitoylated, however given that NCX1 is not 100% palmitoylated in ARVM, this 
does not rule it out, as NCX1 exists in palmitoylated and non-palmitoylated states. A 
number of cysteine residues were excluded based on their predicted location. Cysteines 
at position 20 and 792 are experimentally determined to form a disulphide bond 
(Santacruz-Toloza et al. 2000). Additionally, recent reexamination of NCX1 predicted 
topology excluded C938 as it is predicted to lie on the extracellular side of the 
membrane. As a starting point, cysteine residues located within the large intracellular 
loop domain, which is known to be involved in regulation, were selected for mutational 
analysis. Using site-directed mutagenesis, cysteines at positions 383, 387, 485, 557, 
731, 739 were mutated to alanine. In addition, cysteine at position 914, located within 
an intracellular loop domain between transmembrane domains 9 and 10, was also 
mutated to alanine. Single and double-site mutations were engineered to increase the 
probability of mapping the palmitoylation site(s). Following confirmation by DNA 
sequencing, mutant NCX1 constructs were transfected into either HeLa or HEK293 cell 
lines. Wild-type NCX1 and an empty vector control were transfected alongside. 
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Figure 4.2: Site-directed Mutagenesis Reveals Cys739 As The Principal 
Palmitoylation Site In NCX1. A. NCX1 mutants C383A, C387A, C485A, C557A, 
C731A and C914A are palmitoylated when expressed in HEK293 cell lines. Mutation of 
Cys739 to alanine results in complete abolition of NCX1 palmitoylation. B. Mutation of 
Cys739 to alanine results in abolition of NCX1 palmitoylation in HeLa cell lines, 
consistent with HEK293 cell line data. 
 
Following transfection and expression of cysteine to alanine mutant NCX1 constructs, 
palmitoylation was assessed using acyl rac. Analysis of UF analytical samples taken 
during the acyl rac protocol revealed that all mutant NCX1 proteins express and are the 
expected size, compared to a positive control (Figure 4.2). Measuring palmitoylation of 
NCX1 mutants reveals that all constructs are palmitoylated, except C739A. Flotillin-2 
was analysed as a quality control for acyl rac. Flotillin-2 was present in the absence of 
NCX1 C739A palmitoylation, suggesting acyl rac has captured palmitoylated proteins. 
Flotillin-2 is evenly expressed therefore differences in palmitoylation of NCX1 mutants 
result from differences in expression. This suggests that Cys739 is not palmitoylated 
when mutated to alanine. Inability to visualise C739A suggests that it is the principal 
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palmitoylation site. Both HeLa and HEK293 cell lines yield the same results, 
confirming that there is no difference in the processing and expression of NCX1 
mutants between cell lines of different origins. 
 
4.3 Expression And Palmitoylation Of NCX1 Intracellular Loop Site Mutants In 
HeLa And HEK293 Cell Lines 
 
As a proof of principal approach, additional mutagenesis was performed to further 
verify the palmitoylation site of NCX1. A cysless intracellular loop was engineered 
using site-directed mutagenesis, to replace 6 endogenous cysteine residues within the 
large intracellular loop domain of NCX1 with alanine. Each cysteine residue was re-
introduced one by one into the cysless intracellular loop background. This resulted in 7 
different NCX1 mutant constructs, as follows, 
 
1  Cysless 
    2  C383 Only 
3  C387 Only 
    4  C485 Only 
    5 C557 Only 
   6 C731 Only 
   7 C739 Only. 
 
All mutants were transfected alongside wild-type NCX1, as well as an empty vector 
control.  
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Figure 4.3: Cys739 Is Necessary And Sufficient For Palmitoylation Of NCX1. A. 
Mutational analysis revealed that only when Cys739 is present is NCX1 palmitoylated 
in HEK293 cell line. B. C739 is required for NCX1 palmitoylation in HeLa cell line. C. 
C383 has not expressed well in representative blots shown, but is palmitoylated to the 
same degree in other experiments. 
 
Palmitoylation of mutant NCX1 was assessed by acyl rac. Visualisation of NCX1 in UF 
suggests that all constructs are processed and expressed normally, regardless of cell 
line. Acyl rac reveals that when Cys739 is present, NCX1 is palmitoylated. In the 
absence of Cys739, NCX1 is poorly palmitoylated. These results support previous data 
that Cys739 is the principal palmitoylation site. Additionally, the results suggest that the 
presence of Cys739 is sufficient for NCX1 palmitoylation. When Cys739 is absent, 
palmitoylation does not occur at another cysteine residue. Analysis of flotillin-2 
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confirms the efficiency of acyl rac. Flotillin-2 is evenly expressed across both cell lines, 
suggesting differences observed are due to differences in NCX1 expression. C383 only 
has not expressed well in the experiments shown, however it has expressed in other 
experiments and is palmitoylated to the same level (panel C, figure 4.3) as other mutant 
NCX1 proteins in the absence of C739. 
 
4.4 Expression And Palmitoylation Of NCX-YFP Fusion Mutants In HEK293 Cell 
Line 
 
To elucidate the role of palmitoylation in NCX1, cDNAs encoding only the intracellular 
loop constructs were cloned into a YFP expression vector to generate YFP fusion 
proteins. The 3 constructs selected for further study were wild type (WT), cysless and 
C739 only containing NCX1 intracellular loop mutants. This results in fusion proteins 
with an N-terminal YFP tag. Fusion to YFP would allow visualisation by confocal 
microscopy to determine cellular localisation, providing insight into enzymes 
responsible for NCX1 palmitoylation. The impact of YFP tag on palmitoylation of 
NCX1 intracellular loop was addressed by acyl rac. Full length NCX1 containing 
cDNAs with wild type, cysless or C739 intracellular loops (Section 4.3) were amplified 
by PCR and cloned into pEYFP-C1 expression vector. Following verification by 
sequencing and restriction enzyme digest, constructs were transfected into HEK293 cell 
line. Palmitoylation was assessed by acyl rac followed by SDS-PAGE gel 
electrophoresis and western blotting. 
 
Figure 4.4: NCX-YFP Fusion Proteins Are Palmitoylated In HEK293 Cell Line. Acyl 
rac revealed that only wild type and C739 intracellular loop YFP-fusion proteins are 
palmitoylated in HEK293 cell lines. Cysless, containing no cysteine residues within its 
intracellular loop, is not palmitoylated. 
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The presence of cysteine residues within intracellular loop domains is important for 
capture by acyl rac. WT-YFP and C739ONLY-YFP are captured by acyl rac in the 
presence of hydroxylamine, suggesting they are palmitoylated. Conversely, Cysless-
YFP is not captured by the thiopropyl sepharose in the presence of hydroxylamine, 
suggesting that it is not palmitoylated. Cysless-YFP consistently expressed less well 
compared to WT-YFP and C739ONLY-YFP. These results suggest that a single cysteine 
residue is sufficient for NCX1 palmitoylation within the intracellular loop domain. 
Flotillin-2 was used as a loading control. Shown in figure 4.4, flotillin-2 expression and 
palmitoylation is consistent across different samples, suggesting differences observed 
are due to NCX1-YFP processing and expression. 
 
4.5 Localisation Of WT NCX, Cysless And C739 Intracellular Loop Domains 
Fused to YFP 
 
To address localisation of YFP-fusion proteins, cells were fractionated into membrane 
and cytosolic fractions based on detergent solubility. WT, Cysless or C739ONLY NCX-
YFP fusion constructs were transfected into HEK293 cells. Cell lysates were 
fractionated into membrane and cytosolic fractions. Fractions were analysed by SDS-
PAGE gel electrophoresis and western blotting. Anti-GFP antibodies were used to 
detect NCX-YFP mutants. Additionally, to confirm each fraction contained membranes 
and cytosol, samples were probed for Na+/K+ ATPase and GAPDH respectively. 
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Figure 4.5: WT And C739ONLY YFP Fusion Proteins Are Anchored To Membranes In 
HEK293 Cell Line. Fractionation of cellular membranes and cytosolic components 
reveal that WT and C739ONLY YFP fusion proteins are anchored to membranes. 
Conversely, cysless YFP fusion protein is not anchored to membranes and remains in 
the cytosol. Numbers represent molecular weights in kDa. 
 
Analysis of cystosolic fractions reveal that all 3 YFP-fusion proteins are present, but 
WT-YFP and C739Only-YFP are less abundant than Cysless-YFP (figure 4.5). Only WT-
YFP and C739ONLY-YFP are present in the membrane fraction. This suggests that 
palmitoylation anchors the intracellular loop to membranes. GAPDH is present within 
cytosolic fractions, confirming that cytosolic proteins were purified successfully. In 
addition, the membrane fraction was probed for α1 Na+/K+ ATPase subunit, which is 
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resident at the plasma membrane. Na+/K+ ATPase was successfully identified in 
membrane containing fractions, confirming the validity of the fractionation protocol 
used.  
 
The crude fractionation protocol does not distinguish between plasma membrane and 
membranes from intracellular compartments or organelles. Direct visualisation of YFP-
fusion protein localisation was investigated. WT-YFP, Cysless-YFP and C739ONLY-YFP 
were co-transfected into HEK293 cell lines grown on glass coverslips with either 
DSRED-ER or Grasp65-mCherry constructs, which label the Endoplasmic Reticulum 
(ER) and Golgi apparatus (Golgi) respectively. Following transfection, cells were fixed 
and stained with DAPI, a nuclear marker, mounted on glass slides and analysed by 
confocal microscopy.  
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Figure 4.6: Confocal Microscopy Of YFP-Fusion Proteins Do Not Localise To The 
ER. Co-staining of YFP-fusion proteins with DSRED-ER, an ER marker, show that all 3 
of the fusion proteins do not localise to the ER. 
  
WT-YFP shows distinct staining, which appears to be compartmentalised to an 
intracellular region. C739ONLY-YFP shows a similar pattern, suggesting that it is 
localised to an intracellular region similar to WT-YFP. Cysless-YFP in contrast shows 
diffuse cytoplasmic staining. Cell nuclei are depicted in blue following DAPI staining 
(Figure 4.6). DSRED-ER, which visualises the ER in living cells, shows little co-
localisation with YFP fusion proteins (Figure 4.6, merged images). This suggests that 
these proteins do not localise to the ER. As this is transient transfection, some staining 
observed may be an overexpression artifact. 
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To further determine the intracellular localisation of WT-YFP and C739ONLY-YFP, co-
localisation studies were performed using Grasp65-mCherry, which labels the Golgi 
apparatus in living cells. WT-YFP shows the same distinct staining, as well as 
C739ONLY-YFP (Figure 4.7). Cysless-YFP shows diffuse cytoplasmic staining, as 
before. Interestingly, WT-YFP and C739ONLY-YFP show co-localisation with Grasp65-
mCherry (merged image, figure 4.7). Co-localisation with Grasp65-mCherry suggests 
WT-YFP and C739ONLY-YFP localise to the Golgi apparatus in HEK293 cells. Cysless-
YFP shows no co-localisation with Grasp65-mCherry, the staining pattern is diffuse, 
indicating that Cysless-YFP is present throughout the cytoplasm. 
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Figure 4.7: Confocal Microscopy Of YFP-Fusion Proteins Reveal Localisation To 
The Golgi. Co-transfections of NCX-YFP fusion proteins with Grasp65-mCherry, a 
Golgi resident protein, reveal that WT-YFP and C739ONLY-YFP localise to the Golgi in 
HEK293 cells. 
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4.6 Discussion 
 
In order to identify and determine the functional effects of palmitoylation it was 
necessary to use genetic approaches. For many proteins that undergo palmitoylation, 
target cysteine residues are often located close to transmembrane domains (TMDs) 
(Bijlmakers & Marsh 2003). In some instances, the TMD has been shown to influence 
palmitoylation (Ponimaskin & M. F. G. Schmidt 1998). Mutation of non-hydrophobic 
residues within the TMD/cytoplasmic domain boundary of haemagglutinin to 
hydrophobic residues results in decreased palmitoylation. Additionally, palmitoylated 
cysteine residues are predominantly present within 10 residues of the TMD boundary, 
however this is not mutually exclusive as there is evidence for select proteins that their 
palmitoylation site(s) lie further than 10 amino acids away from the TMD boundary 
(Shipston 2014; Bijlmakers & Marsh 2003). Predicting site(s) of palmitoylation has 
been difficult, given there is no consensus sequence for directing palmitoylation 
towards particular residues. Prediction algorithms exist, such as CSS Palm 3.0 and the 
recently developed PalmPred (J. Ren et al. 2008a; Kumari et al. 2014). Historically, 
palmitoylation site(s) were identified using site-directed mutagenesis, which is time 
consuming and labour intensive. The development of techniques to analyse 
palmitoylation site(s) by mass spectrometry is becoming more prevalent, however 
sufficient coverage to provide bona fide palmitoylation site information is difficult. 
Therefore, there is an urgency to develop in silico prediction algorithms, which will be 
of great use to the palmitoylation field.  
 
Mapping The Site(s) Of Palmitoylation In NCX1 
 
As mass spectrometry did not yield definitive palmitoylation site(s), a site-directed 
mutagenesis approach was adopted. Prior to commencing mutagenesis, CSS Palm 3.0 
was used to determine if any cysteine residues were predicted to be palmitoylated. CSS 
Palm 3.0 predicted 3 residues to be targets of palmitoylation, Cys 14, Cys 122 and Cys 
768 with scores of 1.289, 0.371 and 1.364 respectively (J. Ren et al. 2008a). Since the 
completion of this work, a new prediction algrorithm was developed, PalmPred, which 
correctly identified the site determined here (Kumari et al. 2014). Cys14 was eliminated 
as it is predicted to be on the extracellular side of the membrane and is involved in 
formation of a disulphide (Santacruz-Toloza et al. 2000). Additionally, Cys122, located 
in TMD2 is predicted to be close to the extracellular membrane, furthest from the 
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cytoplasm, making it an unlikely target for palmitoylation. Finally, Cys768 is located 
within TMD6, which immediately follows the large intracellular loop domain (Figure 
4.8). TMD6 is predicted to begin at 762, with Cys768 modelled to be at the centre of 
TMD6 (X. Ren et al. 2006). Therefore, cysteine residues present within the large 
intracellular loop domain were selected for mutational analysis, with the addition of 
Cys914 which is predicted to lie within the intracellular loop joining TMD 9 and 10 (X. 
Ren & Philipson 2013).  
 
A single cysteine residue is the main palmitoylation site within NCX1. Cys739, located 
at the C-terminal end of the intracellular loop domain. In addition to being the principal 
palmitoylation site within NCX1, when Cys739 is unavailable, no other cysteine residue 
becomes palmitoylated. The abolition of palmitoylation in the absence of C739 suggests 
that there is a reason that this cysteine is preferentially palmitoylated. As mentioned 
previously, PalmPred, correctly predicts this residue as a palmitoylation site (Kumari et 
al. 2014). It is possible that it is simply the presence of the cysteine itself that is 
responsible for directing DHHCs. Further mutational analysis of residues surrounding 
C739 is required to determine which additional residues are important for 
palmitoylation. 
 
 
 
Figure 4.8: Schematic Of NCX1 Predicted Topology. Schematic showing positions of 
cysteine residues within NCX1. Generously provided by Dr Michela Ottollia. 
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NCX-YFP Localisation 
 
Using YFP-tagged fusion proteins of WT, Cysless and C739ONLY containing NCX1 
intracellular loops and determining their localisation, palmitoylation was found to 
anchor this domain to membranes. One palmitoylation site is sufficient to target and 
anchor this domain to the membrane, as C739ONLY-YFP fusion protein is present within 
membrane fractions. In the absence of cysteine residues, the intracellular loop domain is 
confined to the cytoplasm of the cell. These results suggest that a single cysteine residue 
is sufficient to anchor protein domains to membranes. It has been previously described 
that two lipid modifications lead to stable membrane association (Shahinian & Silvius 
1995; Salaun et al. 2010). Therefore, a single palmitoylation site could result in 
transient association of the intracellular loop domain with membranes. It is unlikely that 
a single palmitoylation site is required for targeting of a 10 TMD protein to the plasma 
membrane. Interestingly, this cysteine residue is preceded by a stretch of negatively 
charged amino acids (figure 4.9), which will repel the negatively charged inner face of 
the lipid bilayer. The addition of a palmitate moiety to this region will drastically alter 
the microenvironment surrounding those residues and force it into the membrane. As a 
result, this will induce a large change in secondary structure, due to the negatively 
charged residues wishing to point away from the membrane.  
 
 
Figure 4.9: Sequence Surrounding C739 Is Negatively Charged. Sequence from 720 
to 762, which is the start of TMD6, reveals negatively charged amino acids surrounding 
the palmitoylation site. 
 
As there is no crystal structure for the entire intracellular loop, determining how 
accessible C739 is to DHHCs is tricky. Using secondary structure prediction software 
can provide insight into accessible residues (Cole et al. 2008). The intracellular loop 
was analysed using Jpred 3, which can provide information on secondary structure and 
solvent accessibility. Shown in figure 4.10 is the secondary structure prediction of the 
intracellular loop of NCX1. C739 is predicted to be less than 25% solvent accessible, 
suggesting that it is not completely freely accessible, however it is must be still 
accessible. It is perhaps accessible enough to be palmitoylated by DHHCs. Residues 
upstream are completely free, which may play a role in interaction with DHHCs to 
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allow palmitoylation of C739. Downstream of the palmitoylation site, residues vary in 
their availability, with some residues completely buried.  The role in which the relative 
accessibility of residues play in palmitoylation remains to be determined. 
 
 
Figure 4.10: JPred3 Secondary Structure Prediction Of NCX1 Intracellular Loop. 
Secondary Structure Prediction of NCX1 intracellular loop domain from Residue 721 to 
the beginning of TMD6. C739 is less than 25% solvent accessible, as designated by the 
B (burial) in Jnet_25. This suggests that C739 shows some accessibility. Jnet_25 – less 
than 25% solvent accessibility, Jnet_5 – less than 5% exposure, Jnet_0 – 0% exposure, 
Jnet Rel – reliability prediction accuracy (Cole et al. 2008). Run using Jpred 3 on 
Human NCX1 sequence. 
 
Recently, a crystal structure for a prokaryotic NCX1 homolog was established (Liao et 
al. 2012). This prompted reexamination of mammalian NCX1 topology, originally 
proposed to have 9 TMDs. As a result, the predicted topology of NCX1 was revised 
based on cross-linking studies to contain 10 TMDs, the same as its prokaryotic 
homolog, NCX_Mj (Ren & Philipson 2013). Examination of the crystal structure of 
NCX_Mj revealed that TMD 6 is longer than the remaining 8 TMDs, with the exception 
of TMD1. Additionally, TMD6 is modeled to lie at a 45° angle to the membrane surface 
(Liao et al. 2012). TMD6 moves dramatically between outward-facing and inward-
facing conformations (Figure 4.10). C739 is located upstream of the start of TMD6, 
which starts at 762. Palmitoylation, anchoring this region to the membrane, may restrict 
the movement of TMD6. TMD6 is tilted compared in the outward-facing conformation, 
compared to the rest of the TMDs. During the inward-facing conformation, TMD6 
moves dramatically, becoming perpendicular to the membrane. Addition of a palmitoyl 
moiety to C739, which is located upstream of the beginning of TMD6 (which starts at 
762), may significantly impact the conformation changes of NCX1 during the exchange 
process. The effect of palmitoylation on the conformation of NCX1 during the reaction 
cycle remains to be examined.  
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Figure 4.11: Structural Comparison Of Outward-Facing And Inward-Facing 
Conformations. Outward-facing NCX_Mj (orange) and inward-facing NCX_Mj (green) 
structural comparisons reveal conformation changes during the reaction cycle. Core 
portion (grey) does not change between conformations. Modified from (Liao et al. 
2012).  
 
Confocal microscopy was used to elucidate where WT-YFP, Cysless-YFP and 
C739ONLY-YFP are localised within the cell. As the engineered intracellular loop 
constructs are tagged with YFP, this enables visualisation via microscopy. In addition, 
markers for different cellular components can be employed to determine the precise 
localisation of the YFP-fusion proteins. Based on initial confocal microscopy data, WT-
YFP and C739ONLY-YFP showed a distinct staining pattern, in contrast to the diffuse, 
cytoplasmic staining of Cysless-YFP. It appeared that WT-YFP and C739ONLY-YFP are 
localised to an intracellular compartment, within the secretory pathway. As result, two 
different cellular components were investigated, the ER and Golgi. Co-localisation 
studies of WT-YFP and C739ONLY-YFP with DSRED-ER revealed that these proteins 
are not anchored to ER membranes. This suggests that the intracellular loop domain is 
not palmitoylated in the ER. Additionally, a number of the PATs, the enzymes 
responsible for palmitoylation, reside within ER membranes, suggesting that this subset 
of DHHCs are not involved in the palmitoylation of Cys739. Given that there are 24 
known PATs, this narrows down the possible PATs that palmitoylate NCX1. 
Conversely, co-localisation studies with a Golgi marker revealed co-localisation with 
packed core and ion-binding sites but has different
packing between the peripheral helices (TMs 1,
2A, 6, and 7A) and the core (Fig. 4B and fig. S7).
Without obvious steric clash, the inward-facing
model retains similar hydrophobic-packing inter-
actions between these helices and the core. The
movement of TMs 1, 2A, 6, and 7A is hinged at
the bends between TMs 2A and 2B and TMs 7A
and 7B, and it may involve sliding across a central
flat hydrophobic patch that is centered about the
conserved Pro residues from the signature se-
quence motifs of the a repeats (Fig. 4C and fig.
S8). Consequently, this proposed conformational
change leads to the closure of the two outward-
facing ion passageways and the formation of two
inward-facing ones connecting the Sint and SCa
sites, respectively, to the intracellular side (Fig.
4D and fig. S5B). With a simple sliding motion
primarily involving two loosely packed helices,
the outward and inward conformations can rap-
idly interchange, coupling to the alternative access
of the four ion-binding sites from each side, con-
sistent with the mechanism of rapid consecutive
ion-exchange reaction in NCX (3, 8, 38, 39).
Na+/Ca2+-exchange mechanisms. The arrange-
ment of four central ion-binding sites with differ-
ing specificity and their alternating accessibility
from each side upon conformational change re-
veal the structural mechanism of Na+/Ca2+ exchange
in NCX. Among the four sites, only SCa is spe-
cific for Ca2+ binding, whereas the other three
are designed for Na+ binding under physiological
conditions, and their occupancy depends on the
Na+ concentration. Whereas SCa is alternatively
accessible from each side, the three Na+ sites are
aligned in a winding single file with only one end
being accessible in a given conformation: Sext
when facing outward and Sint when facing inward.
Positioning these two identical, Na+-specific sites
on both ends ensures the selective and bidirec-
tional Na+/Ca2+-exchange function in NCX.
The cluster of four sites in close proximity
and ligand-sharing features in NCX_Mj lead us to
propose a progressive antagonist effect of multi-
ple Na+ binding on Ca2+ affinity as depicted in the
Fig. 4. The outward-inward conformational change of NCX_Mj. (A) The surface-rendered NCX_Mj
structure shows two independent external passages (yellow) for ion access to the four central ion-
binding sites (colored spheres). The ion passageways are analyzed using the program CAVER (41).
(B) Side view for structural comparison of the outward-facing NCX_Mj (orange) and inward-facing
model (green). The core portion of the protein remains the same in both conformations and is
shown in gray. The light blue surface-rend red CPK models are r sidues f rming the central
hydrophobic patch. (C) The central hydrophobic patch (light blue) with TMs 1 and 2A and 6 and
7A removed for clarity. (D) Surface-rendered inward-facing model showing two independent
passageways (yellow) for intracellular ion access to the four central ion-binding sites. Stereo
views of all figures shown here are also presented in figs. S5, S7, and S8.
Fig. 5. Cartoon repre-
sentation of Na+/Ca2+
exchange of NCX in the
classical 3Na+:1Ca2+ ex-
trusion mode.
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Grasp65-mCherry, a Golgi marker. Based upon these results, it appears that WT-YFP 
and C739ONLY-YFP are anchored to membranes within the Golgi. Cysless-YFP shows 
weak co-localisation with Grasp65-mCherry, however the staining pattern is more 
diffuse throughout the cytoplasm. However, Cysless-YFP may still interact with 
DHHCs but is no longer palmitoylated. Co-immunoprecipitation studies would 
determine whether Cysless-YFP interacts with DHHCs that palmitoylated NCX1. This 
suggests that palmitoylation of C739 occurs within the Golgi. There are a number of 
Golgi located PATs (Ohno et al. 2006), making them likely candidates as responsible 
for NCX1 palmitoylation. Following the identification of responsible PATs, comparing 
the region of NCX1 and known substrates of those PATs could possibly elucidate a 
potential consensus sequence for proteins. To date, no consensus sequence has been 
found for palmitoylation (Salaun et al. 2010). Suggested characteristics of palmitoylated 
cysteine residues such as proximity to myristoylation and prenylation sites, basic or 
hydrophobic amino acids surrounding site and location to cytoplasmic regions flanking 
transmembrane domains have been suggested (Salaun et al. 2010; Shipston 2014). 
However, C739 only fulfills one of these criteria, proximity to a transmembrane 
domain. 
 
Summary 
 
This work has identified that NCX1 has a single palmitoylation site, located within the 
large intracellular loop domain. Removal of the palmitoylation site, through site-
directed mutagenesis, does not result in palmitoylation at another site, suggesting that 
PATs are directed to this site preferentially. Palmitoylation at this site anchors this 
domain to the membrane. Therefore, palmitoylation at this site will result in a large 
change in secondary structure. Given that this domain is involved in the regulation of 
NCX1 (Hilgemann, Collins & Matsuoka 1992b; Matsuoka & Hilgemann 1992; 
Hilgemann, Matsuoka, Nagel & Collins 1992d; Nicoll et al. 2006; Besserer et al. 2007), 
palmitoylation within this domain could potentially influence the activity of the 
exchanger. This may be achieved by changing the local microenvironment that the Ca2+ 
binding domains are exposed to, or influencing the PIP2 regulation or tilt of TMD6 of 
NCX (Shen et al. 2007; Yaradanakul et al. 2007). The effect of palmitoylation on 
NCX1 requires further investigation. 
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Chapter 5: Identification Of Protein Acyl 
Transferases That Palmitoylate NCX1.1 
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5.1 Expression Profile Of PATs In Adult Rat Heart 
 
To date, the expression profiles of the PATs or DHHCs within different tissues and 
cells have not been extensively studied. Shipston and colleagues published information 
regarding the expression profile of DHHCs expressed within the mammalian HEK293 
cell line (Tian et al. 2010). This only provides information regarding DHHC expression 
at the mRNA level, as antibodies against all 24 isoforms are not commercially available. 
To investigate DHHCs that may be functionally relevant to cardiac palmitoylation, 
Total RNA was extracted from cardiac tissue of 4 male adult Wistar rats. cDNA was 
synthesized from the resulting RNA and expression was quantified relative to the 
geometric mean of β-actin and GAPDH using Fast Start Universal SYBR 
GreenTaqMAN with primers specific for the 24 known DHHCs in Real-Time PCR 
machine.  
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Figur  5.1: DHHC Expression Profile In Cardiac Muscle. The expression profile of 
DHHCs in cardiac muscle is expressed as the geometric mean relative to β-actin and 
GAPDH (n=4). Each measured in duplicate. 
 
Figure 5.1 shows the expression profile of DHHCs expressed in cardiac muscle. 
DHHC2 was the most abundant in cardiac muscle. DHHCs 4, 5 and 7 are also expressed 
at a high level. DHHCs 1, 3, 8 and 20 are expressed at a similar level. DHHCs 11, 23 
and 25 are expressed at low levels. DHHCs 19 and 22 were undetectable by this assay. 
Expression levels of DHHCs are expressed as geometric mean relative to β-actin and 
GAPDH. 
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5.2 Co-Immunoprecipitation Of Candidate DHHCs With NCX1.1 
 
Confocal microscopy data (Figure 4.6 and 4.7) revealed that the intracellular loop of 
NCX1 is localised to the Golgi apparatus in HEK293 cells. This suggests that 
palmitoylation of this region occurs within the secretory pathway, most likely the Golgi. 
Thus, DHHCs that are expressed in cardiac muscle were cross-referenced with known 
Golgi-resident DHHCs. This generated a list of 8 DHHCs that are expressed in cardiac 
muscle, within the Golgi apparatus. DHHCs 3, 4, 7, 8, 9, 12, 17 and 18 were selected 
for protein-protein interaction analysis with NCX1. In addition, DHHC5, a cell surface 
resident DHHC, and DHHC6, an ER resident DHHC, were selected as controls for co-
immunoprecipitation experiments (Korycka et al. 2012). DHHCs were co-transfected 
into HEK293 cells with WT-YFP NCX1. Following transfection, HA-tagged DHHCs 
were immunoprecipitated and copurification of WT-YFP NCX1 assessed by 
immunoblotting for YFP.  
 
 
Figure 5.2: Co-Immunoprecipiation Of Candidate DHHCs With WT–YFP NCX1. 
Protein-protein interactions were assessed by co-immunoprecipitation with anti-HA 
affinity matrix. DHHCs 5, 9, 12 and 18 co-immunoprecipitated with WT-YFP NCX1. 
Arrowheads indicate DHHC proteins. 
 
Following co-immunoprecipiation, captured proteins were analysed by SDS-PAGE gel 
electrophoresis and western blotting. Figure 5.2 shows a representative blot from co-
immunoprecipitation experiments. DHHC constructs used all possess a haemagglutinin 
(HA) tag, enabling purification using Anti-HA affinity matrix (Section 2.6.4). DHHC9 
showed the highest interaction with WT-YFP NCX1. DHHC12 and DHHC18 show 
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weak interaction with WT-YFP NCX1 as shown by the faint bands detected. DHHC5 
co-purified a small amount of NCX, suggesting a weak interaction. Results were 
variable between co-immunoprecipitation experiments. Only high confidence 
candidates were selected for further study with full length NCX1 (Table 5.1). High 
confidence candidates are classified as DHHCs purified with WT-YFP NCX1 in at least 
3 experiments out of 4. 
 
 
 
Table 5.1: Summary Of DHHCs Purified By Co-Immunoprecipitation. DHHCs found 
to interact with NCX-YFP, assessed by co-immunoprecipitation experiments. 
 
5.3 Effect Of Candidate DHHCs On Full Length NCX1 Palmitoylation. 
 
Based on the data obtained from co-immunoprecipitation experiments, DHHCs 5, 9, 12 
and 18 were transfected into HEK293 cell lines stably expressing either full length WT 
NCX1 or C739A NCX1. DHHC8 and an empty vector control were transfected 
alongside as negative controls. Following transfection, palmitoylated proteins were 
purified from cell lysates by acyl rac and analysed by SDS-PAGE gel electrophoresis 
and western blotting. 
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Figure 5.3: Candidate DHHCs Have No Effect On Palmitoylation Of WT NCX1. A. 
Representative blot from DHHC overexpression in FT293 cells stably expressing WT 
NCX1. B. Mean data from acyl rac experiments show no significant changes in WT 
NCX1 palmitoylation. Analysis by one way ANOVA with post hoc Dunnett correction. 
UF – unfractionated, Palm. – palmitoylated, EV – empty vector, Ha – haemagglutinin. 
 
Shown in panel A of figure 5.4, WT NCX1 is expressed in all cell lysates analysed. 
DHHCs 5, 9, 12 and 18 are each expressed following transfection of the cell lines. 
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DHHCs are detected in bound fractions following acyl rac in the presence of 
hydroxylamine. This suggests that DHHCs are palmitoylated as well as palmitoylating 
specific targets. Shown in panel B of figure 5.3, compared to EV, there was no 
significant difference in WT NCX1 palmitoylation following transfection of candidate 
DHHCs. These results suggest that WT NCX1 palmitoylation is principally controlled 
by thioesterase activity, as palmitoylation is not increased with DHHC overexpression.  
 
 
 
Figure 5.4: Candidate DHHCs Do Not Increase C739A NCX1 Palmitoylation. A. 
Representative blot from DHHC overexpression revealing no palmitoylation of C739A 
NCX1. UF – unfractionated, Palm. – palmitoylated, EV – empty vector, Ha – 
haemagglutinin. 
 
Based on previous data, mutation of Cys739 to alanine abolishes palmitoylation of 
NCX1. To determine if DHHCs are able to palmitoylate alternative cysteine residues in 
the absence of C739, candidate DHHCs were transfected into HEK293 cells engineered 
to stably express C739A NCX1. Shown in figure 5.4, C739A NCX1 is expressed in cell 
lysates (UF samples). Interestingly, regardless of DHHC expressed, C739A NCX1 is 
not palmitoylated. All DHHCs examined expressed and were also found to be 
palmitoylated. These results suggest that DHHCs will only palmitoylate NCX1 when 
C739 is available. 
 
The effect of candidate DHHCs was assessed on known substrates, flotillin-2 and Ras. 
Shown in panel A of figure 5.5, overexpression of DHHC5 did not increase flotillin-2 
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palmitoylation. Mean flotillin-2 palmitoylation, expressed as fold change compared to 
EV show no significant increases in flotillin-2 palmitoylation. Panel B of figure 5.5, 
overexpression of DHHC9 did not increase Ras palmitoylation compared to EV. Mean 
data of Ras palmitoylation expressed as fold change compared to EV showed no 
statistical significant change in Ras palmitoylation. These results suggest that DHHC 
overexpression is not reliable as changes in palmitoylation of known substrates were 
unchanged. 
 
 
Figure 5.5: Flotillin-2 And Ras Palmitoylation In Response To DHHC 
Overexpression. A. Impact of DHHC overexpression on flotillin-2 palmitoylation. No 
significant differences observed. B. Impact of DHHC overexpression on Ras 
palmitoylation. No significant differences observed. Analysed by one-way ANOVA with 
post hoc Dunnett correction. UF – unfractionated, Palm. – palmitoylated, EV – empty 
vector, Flot2 – flotillin-2. 
 
5.4 Effect Of DHHS Mutants On Full Length NCX1 Palmitoylation. 
 
As DHHCs 5, 9, 12 and 18 did not increase full-length NCX1 palmitoylation, site-
directed mutagenesis was used to generate DHHC mutants, where cysteine residues 
within the conserved DHHC motif had been mutated to serine residues. The resultant 
DHHS proteins are predicted to be catalytically inactive (Mitchell et al. 2006) and act in 
a dominant negative manner. DHHS mutants of DHHC 5, 9, 12 and 18 were expressed 
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in FT293 WT NCX1 cell lines, palmitoylated proteins were purified from cell lysates by 
acyl rac then analysed by SDS-PAGE gel electrophoresis and western blotting. 
 
 
Figure 5.6: DHHS9 Significantly Decreases WT NCX1 Palmitoylation. A. Impact of 
DHHS overexpression on WT NCX1 palmitoylation. B. Mean data shows that DHHS9 
significantly decrease WT NCX1 palmitoylation. In addition, co-expression of DHHS9 
and 18 also results in decreases. DHHS9 mean, 0.71 ± 0.06, p<0.01, DHHS9+18 mean, 
0.74 ± 0.04, p<0.001, n=4. UF – unfractionated, Palm. – palmitoylated, EV – empty 
vector, Bds – beads, Ha – hemagglutinin. Analysed by one-way ANOVA with post hoc 
Dunnett correction. 
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Shown in panel A of figure 5.6, WT NCX1 is expressed in all cell lysates analysed. In 
addition, DHHS mutants express in FT293 cell line. The amount of palmitoylated 
NCX1 captured is decreased when DHHS9 is expressed. In addition, expressing 
DHHS9 and DHHS18 together also decreased NCX1 palmitoylation to a similar level 
as DHHS9 only transfections. Surprisingly, despite the lack of cysteine within the 
DHHC domain, DHHS mutants analysed are palmitoylated. This suggests that they are 
palmitoylated at cysteine residues outwith the DHHC domain. Panel B of figure 5.6 
shows mean palmitoylation data. DHHS9 significantly reduced NCX1 palmitoylation 
compared to EV. In addition, co-expression of DHHS9 and DHHS18 significantly 
decreased NCX1 palmitoylation compared to EV. Reduction of NCX1 palmitoylation 
following co-expression of DHHS9 and DHHS18 was not additive suggesting the 
decrease in palmitoylation is due to DHHS9.  
 
In order to determine whether DHHS mutants have an effect on established targets of 
DHHC proteins, acyl rac experiments were also examined for flotillin-2 and H-Ras. 
Panel A of figure 5.7 shows flotillin-2 palmitoylation detected by western blotting. 
Flotillin-2 palmitoylation was significantly decreased when co-expressed with 
DHHS9+18 compared to EV. Panel B of figure 5.7 shows Ras palmitoylation. Ras 
palmitoylation was decreased when cells were transfected with DHHS9, DHHS18 and 
DHHS9+18 compared to EV. DHHS18 decreased Ras palmitoylation to a greater 
degree than DHHS9. This suggests that DHHS proteins act in a dominant negative 
manner in this cell line, proven by their ability to negatively regulate palmitoylation of 
known targets. 
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Figure 5.7: Effect Of DHHS Overexpression On Flotillin-2 And Ras Palmitoylation. 
A. Representative blot of impact of DHHS overexpression on flotillin-2 palmitoylation. 
Significant decreases in flotillin-2 were observed in DHHS 9 + DHHS18. B. Impact of 
DHHS overexpression on Ras palmitoylation. Mean data shows significant decrease in 
Ras palmitoylation with DHHS9, DHHS18 and DHHS9+18 compared to EV. DHHS9 
mean 0.68 ± 0.09, p<0.01, DHHS18 mean 0.52 ± 0.09, p<0.001, DHHS9+18 mean 
0.49 ± 0.15, p<0.01. UF – unfractionated, Palm. – palmitoylated, EV – empty vector. 
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5.5 Discussion 
 
In order to gain insight into the regulation of NCX1, determining which DHHCs are 
responsible for NCX1 palmitoylation was a key aim of this work. The 24 mammalian 
DHHCs localise to different intracellular regions, with the majority localised to the 
Golgi apparatus or the Endoplasmic Reticulum (ER) (Korycka et al. 2012). Presently, 
there are only 2 DHHCs known to localise to regions out with these intracellular 
compartments, DHHC2 which has been shown to localise to plasma membrane, 
endosomes and other vesicular structures (Greaves et al. 2011). DHHC5 was also 
shown to localise to the plasma membrane (Ohno et al. 2006). Determining the DHHC 
protein responsible for palmitoylation of NCX1 will give insight into the location of 
NCX1 palmitoylation and when during its processing this occurs. 
 
DHHC Expression Profile In Cardiac Muscle 
 
To date, there are no commercial antibodies available to detect all 24 mammalian 
DHHCs. This makes determining relative protein levels of each DHHC difficult. 
Recently, the DHHC expression profile of HEK293 cell line was determined (Tian et al. 
2010). cDNA was synthesised from mRNA generated from adult rat heart and DHHC 
expression profiles were analysed by quantitative PCR. β-actin and GAPDH were used 
as internal reference controls. The results revealed that DHHC2 was the highest 
expressed in adult rat heart. DHHC4, 5 and 7 were expressed at relatively high levels. 
Recent data suggests that palmitoylation can be dynamic as well as stable (Martin et al. 
2011). The high expression of DHHC2 and DHHC5 in cardiac muscle may indicate that 
palmitoylation is occurring in a dynamic way at the sarcolemmal membrane. DHHCs 
that are expressed throughout the Golgi and ER are also expressed in cardiac muscle, 
such as DHHCs 1, 4, 7, 8 and 20. The expression profile of DHHCs within cardiac 
muscle varies from that found in HEK293 cell line. There is some evidence to suggest 
that DHHC proteins vary in expression level in a tissue-specific manner (Ohno et al. 
2006). To date, very few DHHCs have established substrates. To address this question, 
pulse-chase experiments, similar to that performed previously (Martin et al. 2011), will 
be required to address palmitoylation turnover within cardiac muscle. 
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DHHCs That Palmitoylate NCX1 
 
Based on confocal microscopy data, NCX-YFP localises to the Golgi apparatus within 
HEK293 cell line. DHHCs that are expressed within the Golgi apparatus and are 
abundant within cardiac muscle were selected to determine protein-protein interactions 
with NCX-YFP. DHHCs 3, 4, 7, 8, 9, 12, 17 and 18 were selected for co-
immunoprecipitation experiments. DHHCs 5 and 6 were transfected alongside as 
additional controls, as they localise to the plasma membrane and ER respectively 
(Korycka et al. 2012; Ohno et al. 2006). Co-immunoprecipitation experiments were 
used to detect protein-protein interactions that may occur. DHHC9 was found to interact 
with NCX-YFP in HEK293 cell line. DHHCs 12, 18 and 5 also showed weak 
interaction. These results suggest that the intracellular loop of NCX1 is palmitoylated 
within the Golgi apparatus by DHHC9. These experiments assume NCX1 forms a 
stable complex with its palmitoylating enzyme, which has recently been questioned 
(Lemonidis et al. 2014). 
 
Effect Of DHHS Mutants On WT NCX1 Palmitoylation 
 
Given the high level of WT NCX1 palmitoylation observed, catalytically inactive 
DHHC mutants were engineered. Mutation of cysteine within the DHHC domain to 
alanine or serine blocks enzymatic activity and is essential for function (Mitchell et al. 
2006). DHHS mutants of DHHC 5, 9, 12 and 18 were generated using a site-directed 
mutagenesis approach. Mutants were expressed in FT293 WT NCX1 cell line and 
palmitoylation of NCX1 was analysed by acyl rac followed by SDS-PAGE gel 
electrophoresis and western blotting. The results revealed that DHHS9 decreased WT 
NCX1 palmitoylation. Combining both DHHS 9 and 18 did not have an additive effect 
on decreasing NCX1 palmitoylation. Therefore, of those studied DHHC9 is the main 
palmitoylation enzyme responsible for the palmitoylation of NCX1. There is little to no 
information regarding the precise location of DHHCs within the Golgi apparatus, 
whether they are located in cis-, medial-, endo- or trans-Golgi regions.  Depending on 
the precise location within the Golgi apparatus of these DHHCs, NCX1 may encounter 
different DHHCs depending on whether it is the full-length or fusion protein that is 
being processed and palmitoylated.  
!
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Sequence alignment of NCX1 with two known substrates of DHHC9, H-Ras and N-Ras 
(Swarthout et al. 2005) shows significant sequence homology. Examination of the 
sequence immediately surrounding the palmitoylation sites shows that the residue 
immediately preceding are small amino acids (serine in the case of NCX1 and glycine 
in the case of H-Ras and N-Ras (Figure 5.8)).  Palmitoylation sites are on the C terminal 
side of negatively charged amino acids, glutamate and aspartate. These amino acids will 
be repelled by the phospholipid head groups of the lipid bilayer, as well as the negative 
membrane potential generated by K+ movement across the cell membrane. Interestingly, 
from position 660 to 720, NCX1 shares a large amount of homology with H-Ras and N-
Ras. There are a number of conserved residues (indicated by * underneath residues) as 
well as similarity in sequence (indicated by : underneath residues). This suggests that 
this region may be important for substrate recognition of DHHC9, given that 2 known 
substrates that share homology with a region of NCX1, demonstrated here to be 
palmitoylated by DHHC9. There is evidence that domains and residues distant from 
palmitoylation sites can influence specificity of substrate:DHHC interactions. Mutation 
of a proline residue  25 residues downstream of the palmitoylated cysteine-rich 
domain in SNAP25 results in its palmitoylation by DHHC3 and not DHHC17 (Greaves 
et al. 2009). In addition, regions outwith the palmitoylated domain of yeast substrates 
are important for governing interactions with DHHCs. Presence of SH4 domain within 
yeast proteins does not confer preferential palmitoylation by specific DHHCs (Nadolski 
& Linder 2009). Vac8, Meh1 and Yg1108 palmitoylation specificity was lost when SH4 
domains were analysed in isolation. Collectively, these results indicate that regions 
outwith the palmitoylated region of substrates may contribute to recognition by specific 
DHHCs and thus confer substrate specificity. 
 
The way in which DHHCs interact with and recognise their substrates is only becoming 
apparent for a limited number of proteins. Regions outwith the CRD-DHHC domain are 
involved in recognition of substrates. Huntingtin is palmitoylated by DHHC17 but not 
by DHHC3 (K. Huang et al. 2009). It was demonstrated that the ankyrin repeat domain 
of DHHC17 interacts with huntingtin (Singaraja et al. 2002). Chimeras of DHHC3 that 
contain the ankyrin repeat domain of DHHC17 is capable of palmitoylating huntingtin. 
In agreement with this, DHHC5 confers substrate recognition via its cytoplasmic tail 
(Howie et al. 2014). Truncation mutants of DHHC5, which lack the cytoplasmic tail, 
cannot palmitoylate its substrates flotillin-2 and phospholemman. These results suggest 
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that regions outwith the DHHC domain are important for governing substrate 
interactions.  
 
In a recent study in which DHHC9 was depleted, intracellular localisation of H-Ras was 
unchanged (Rocks et al. 2010). In addition, replacement of amino acids surrounding 
palmitoylation sites in Ras with their D-amino acid counterparts did not affect Golgi 
localisation of micro-injected proteins, which is used as a measure of efficient 
palmitoylation. Furthermore, depletion of five DHHCs from yeast resulted in a 
reduction in Vac8 palmitoylation (Hou et al. 2009). Overexpression of each individual 
DHHC in this yeast strain results in Vac8 palmitoylation, suggesting DHHCs have 
overlapping activity. Thus it remains unclear and more work is required to determine 
the specificity of DHHC-substrate interactions. 
 
DHHC Overexpression 
 
DHHCs 5, 9, 12 and 18 were selected for overexpression experiments based on the co-
immunoprecipiation with NCX-YFP. In addition to co-expression with WT NCX1, 
candidate DHHCs were co-expressed with C739A NCX1. This was to determine 
whether DHHCs are capable of palmitoylating other available cysteine residues. 
Surprisingly, no significant increases in WT NCX1 palmitoylation were observed 
(figure 5.5). DHHC9, DHHC12 and DHHC18 significantly decreased WT NCX1 
palmitoylation. This was somewhat surprising, given palmitoylation would be expected 
to increase in response to DHHC overexpression. It may be that overexpression of 
specific DHHCs negatively regulates endogenous DHHCs or activates thioesterases and 
leads to decreased palmitoylation. Overexpression may result in high levels of binding 
to common sites, thus overcoming regulation in terms of where they are expressed, 
preventing endogenous DHHC actions. The level of NCX1 palmitoylation may be 
controlled by thioesterase activity, rather than DHHCs. WT NCX1 is likely to be 
palmitoylated in the secretory pathway as it is processed, it would only be in proximity 
to DHHCs as it traffics through the biosynthetic pathway but will likely be continuously 
exposed to thioesterases, therefore thioesterase activity is likely to be the main 
determinant in NCX1 palmitoylation. The turnover rate of NCX1 palmitoylation has not 
been addressed, however it is entirely possible that blocking thioesterase activity by 
siRNA knockdown or pharmacological inhibition would reveal whether 
depalmitoylation of NCX1 is the major factor in determining palmitoylation. In 
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addition, as WT NCX1 is likely to be palmitoylated in the secretory pathway as it is 
processed, it would only be in proximity to DHHCs as it traffics through the 
biosynthetic pathway. Surprisingly, flotillin-2 and Ras palmitoylation was unchanged 
by overexpression of DHHC5 and DHHC9 respectively. In the case of DHHC9, it could 
be due to limiting levels of GCP16. DHHC9 requires GCP16 for acyltransferase activity 
and protein stability (Swarthout et al. 2005). In the model used in this thesis, DHHC9 
could be unstable when overexpressed in the absence of GCP16, which may account for 
why Ras palmitoylation is unchanged. However, DHHC5 has not been shown to require 
a co-factor for acyltransferase activity. Therefore, why DHHC5 overexpression does not 
result in increase flotillin-2 palmitoylation is unknown and unaccounted for in this 
model. 
 
Summary 
 
DHHCs 2, 4, 5 and 7 are the most abundantly expressed DHHCs within cardiac muscle, 
demonstrated by quantitative PCR. Co-immunoprecipitation experiments revealed 
protein-protein interactions between NCX-YFP and DHHCs 5, 9, 12 and 18. However, 
overexpression of candidate DHHCs identified by co-immunoprecipitation decrease 
full-length NCX1 palmitoylation. This may be due to an effect on the thioesterase 
activity. However, overexpression of one DHHC may adversely affect endogenous 
DHHCs and thus impact NCX1 palmitoylation. Finally, using DHHS mutants of 
DHHCs 5, 9, 12 and 18, DHHC9 was found to be responsible for NCX1 palmitoylation. 
Alignment of NCX1 with known substrates of DHHC9 revealed significant sequence 
homology upstream of palmitoylation sites, which may be important for DHHC9 
substrate recognition. Further study is required to determine regions of NCX1 that may 
be important for conferring DHHC specificity. 
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Chapter 6: Effect Of Palmitoylation On NCX1 
Function 
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6.1 Effect Of Pharmacological And Mutational Inhibition Of Palmitoylation On 
WT NCX1 
 
Few palmitoylation inhibitors exist, with 2-bromopalmitate (2-BP) commonly used to 
inhibit palmitoylation (Quednau, Nicoll & Philipson 1997b; Webb et al. 2000; B. C. 
Jennings et al. 2008). 2-BP has recently been documented to have off-target non-
specific effects, making its use less desirable (Davda et al. 2013). As a result, to assess 
functional effects of palmitoylation on NCX1, mutational and pharmacological 
inhibition of palmitoylation were used. FT293 cell lines stably expressing WT NCX1 or 
C739A NCX1 were engineered and treated with 2-BP (100µM, overnight treatment). 
Lysates were used in acyl rac followed by SDS-PAGE gel electrophoresis and western 
blotting to assess palmitoylation.  
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Figure 6.1: 2-BP Decreases WT NCX1 Palmitoylation. A. Treatment of FT293 WT 
NCX1 cells with 100µM 2-BP decreases WT NCX1 palmitoylation. No palmitoylation is 
observed in C739A NCX1 expressing cells. B. 2-BP significantly decreased WT NCX1 
palmitoylation. Flotillin-2 palmitoylation was unchanged by 2-BP treatment. C739A 
NCX1 was also not effected by 2-BP treatment. 
 
Shown in panel A of figure 6.1, WT NCX1 palmitoylation was reduced by 2-BP 
treatment. 2-BP had no effect on C739A NCX1 palmitoylation, which is completely 
abolished by mutation of C739. In addition, 2-BP did not reduce palmitoylation of 
flotillin-2. As previously shown, flotillin-2 is palmitoylated in both WT NCX1 and 
C739A NCX1 lysates, verifying the efficiency of acyl rac. The graph in panel B 
displays the mean data, showing that 2-BP significantly decreased WT NCX1 
palmitoylation, with no effect on C739A NCX1. There was no significant effect on 
flotillin-2 palmitoylation following 2-BP treatment. These results suggest that 2-BP 
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inhibits NCX1 palmitoylation. The lack of effect on flotillin-2 palmitoylation, this 
suggests that flotillin-2 palmitoylation turns over slower than NCX1 palmitoylation. 
 
6.2 Effect Of Pharmacological And Mutational Inhibition Of Palmitoylation On 
WT NCX1 Cell Surface Localisation 
 
It is well documented that palmitoylation targets proteins to subcellular compartments 
(Linder & Deschenes 2007). To measure WT NCX1 that is localised to the cell 
membrane, a cell surface labelling assay, cell surface biotinylation, was used. 
Incubating cells with cell impermeable amine reactive biotinylation reagent sulfo-NHS-
SS-biotin labels cell surface membrane resident proteins with extracellular primary 
amines (N-terminus or lysine residues). Biotinylated proteins were purified from cell 
lysates using streptavidin beads. Samples were analysed by SDS-PAGE gel 
electrophoresis and western blotting. 
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Figure 6.2: NCX1 Cell Surface Localisation Is Not Decreased By Inhibiting 
Palmitoylation. A. WT NCX1 cell surface localisation is not decreased by inhibiting 
palmitoylation with 2-BP. C739A NCX1 is also expressed at the cell surface membrane, 
which is not effected by 2-BP treatment. 2-BP also had no effect on Na pump cell 
surface localisation. B. Mean data shows no significant difference in WT NCX1, C739A 
NCX1 or Na pump cell surface localisation after 2-BP treatment. WT NCX1, 2-BP 80.3 
± 10.5, n=3, Na+/K+ ATPase 79.3 ± 4.8, n=3, C739A NCX1, 2-BP 73.0 ± 16.52 n=3, 
Na+/K+ ATPase 2-BP 74.7 ± 13.28 n=3.  
 
WT NCX1 was purified using cell surface biotinylation, shown in panel A of figure 6.2. 
Inhibition of palmitoylation using 2-BP did not decrease the amount of NCX1 localised 
to the cell membrane. As a control, samples were blotted for Na+-K+-ATPase α1 
subunit, whose localisation is not regulated by palmitoylation (Tulloch et al. 2011). The 
amount of Na+-K+-ATPase captured was not affected by 2-BP treatment. Mean data 
revealed that 2-BP did not significantly decrease the amount of NCX1 localised to the 
cell surface. Additionally, the level of Na+-K+-ATPase was not significantly changed by 
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2-BP treatment. These results suggest that palmitoylation is not required for targeting of 
WT NCX1 to the cell membrane. 
 
As 2-BP was recently shown to have non-specific and off-target effects (Davda et al. 
2013), mutational inhibition of palmitoylation is a more elegant method of determining 
its role in membrane targeting of NCX1. FT293 C739A cell line was used to determine 
if non-palmitoylatable NCX1 is trafficked to the membrane. In addition, cells were 
treated with 2-BP to inhibit palmitoylation. Biotinylation of cell surface proteins was 
performed as previously described and samples analysed by SDS-PAGE gel 
electrophoresis and western blotting. 
 
Shown in panel A of figure 6.2, C739A is present in cell surface fractions, indicating it 
is trafficked to the cell membrane. In addition, 2-BP has no effect on the amount of 
C739A NCX1 that is present at the cell membrane. The α1 subunit of Na+/K+ ATPase 
was purified using cell surface biotinylation, confirming the effectiveness of this assay 
to purify cell surface resident proteins. The amount of Na+/K+ ATPase at the cell 
membrane was not affected by 2-BP. The mean data (panel B, figure 6.2) shows that 
localisation of C739A NCX1 to the cell surface membrane is not significantly decreased 
by treatment with 2-BP. Na+/K+ ATPase shows no significant difference in the amount 
at the cell membrane after 2-BP treatment compared to control. These results suggest 
that for full-length NCX1, palmitoylation is not required to target the protein to the cell 
surface membrane. 
 
6.3 Targeting Of NCX1 To Ventricular Myocyte Caveolae By Palmitoylation 
 
There is evidence that suggests a role for palmitoylation in targeting proteins to 
microdomains within the cellular membrane (Brown 2006; Melkonian et al. 1999). 
Caveolae are flask-shaped invaginations of the plasma membrane (Stan 2005), which 
are rich in cholesterol and sphingolipids and present in multiple cell types. There is 
evidence to suggest various ion channels, exchanger and transporters, as well as other 
cell signalling molecules are concentrated in caveolae in cardiac muscle (Balijepalli & 
Kamp 2008). To determine whether palmitoylation is involved in targeting NCX1 to 
caveolae, acyl rac was used to assess amount of palmitoylated NCX1 present in sucrose 
gradient fractions of caveolin-enriched membrane prepared from ARVM. 
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Figure 6.3: Palmitoylation Is Not Involved In Targeting NCX1 To Caveolae. A. 
Representative sucrose gradient. NCX1 is found in fractions 4 and 5, as well as 
caveolin-3, consistent with purification of caveolar membranes. B. Palmitoylated NCX1 
is present in pooled fractions 4 and 5. However, NCX1 is also present in unbound 
fractions in the presence of hydroxylamine. Ha – hydroxylamine.   
 
Panel A of figure 6.3 shows a representative sucrose gradient. Using floatation on a 
discontinuous sucrose gradient, which isolates buoyant caveolin-enriched membranes 
from isolated cardiac myocytes, NCX1 was detected in buoyant membranes (fractions 4 
and 5). In addition, caveolin-3, involved in the formation of caveolae, was detected 
within the same fractions, suggesting that NCX1 and caveolin-3 are both present in 
caveolae within cardiac myocytes. Fractions following 8-12 represent bulk sarcolemmal 
membrane, indicated by the presence of clathrin heavy chain within these fractions 
(Howie et al. 2014). There is a low level of NCX1 present within these fractions. This 
suggests that in cardiac myocytes, NCX1 predominantly localises to caveolar domains.  
As previously discussed, fractions 4 and 5 of the sucrose gradient represent caveolae-
! 169 
enriched fractions, whereas fractions 8 – 12 represent non-caveolar membranes. 
Analysis of pooled fractions by acyl rac revealed palmitoylated NCX1 localised to 
caveolar domains with caveolin-3. NCX1 is not detected in pooled fractions from 8 – 
12. Analysis of unbound fractions from acyl rac from pooled sucrose gradient fractions 
revealed NCX1 in pooled 4 and 5 fractions, in the presence of hydroxylamine. This 
suggests that not all NCX1 that localises to caveolae is palmitoylated. All of caveolin-3 
present in fractions 4 and 5 is palmitoylated, as it was not detected in unbound fractions 
from acyl rac assays using pooled 4 and 5 fractions. Since non-palmitoylated NCX1 is 
found in buoyant membranes, these results suggest that palmitoylation is not required to 
target NCX1 to caveolar domains within cardiac myocytes. 
 
6.4 NCX1 Exchange Current In HEK293 Cell Line 
 
FT293 cell line expressing WT NCX1 and C739A was used to measure NCX1 current-
voltage (IV) relationships via whole cell electrophysiology. Following establishment of 
whole cell mode, cells were held at the calculated reversal potential (-30mV). IV ramps 
were performed by stepping the membrane potential from -30mV to +80mV followed 
by decreasing membrane potential to -100mV over 1800ms.  
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Figure 6.4: WT NCX1 And C739A NCX1 IV Relationship In FT293 Cell Line. A. 
Representative whole cell current (black trace) recorded from non-transfected HEK293 
cell line with no sensitivity to replacement of Na+ and Ca2+ with Li+ and Mg2+ 
respectively (grey trace), which block NCX1 current. Current was measured from the 
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same cell  prior to and following Li+ & Mg2+ treatment B. Representative whole 
cell current (black trace) recorded from FT293 cell lines expressing WT NCX1 shows 
sensitivity to replacement of Na+ and Ca2+ with Li+ and Mg2+ respectively (grey trace), 
which block NCX1 current. Current was measured from the same cell  prior to and 
following Li & Mg treatment. C. Representative whole cell current (black trace) 
recorded from FT293 stable cell lines expressing C739A NCX1 also shows sensitivity to 
application of Li and Mg (grey trace). Current was measured from the same cell prior 
to and following treatment. D. Voltage ramp protocol over 1800 milliseconds from 
+80mV to -100mV. I – current, pA – picoampere, Vm – membrane potential, mV – 
millivolt, s – seconds. 
 
Panel A of figure 6.4 shows whole cell current from the average of 5 consecutive ramps 
from +80mV to -100mV over a 1800ms protocol from a single non-transfected HEK293 
cell (black trace). Replacement of Na+ and Ca2+ with Li+ and Mg2+ respectively resulted 
in little to no change in current recorded, demonstrating the absence of NCX1 current 
within non-transfected cells. Panel B of figure 6.4 shows whole cell current from a 
single FT293 cell stably expressing WT NCX1 (black trace). Following measurement of 
WT NCX1 current, extracellular Na+ and Ca2+ were replaced with Li+ and Mg2+ 
respectively to determine current remaining following replacement (grey trace). FT293 
WT NCX1 cells showed large NCX1 currents, which were Li+ and Mg2+ sensitive. 
Panel C of figure 6.4 shows C739A NCX1 current from FT293 cells. C739A NCX1 
current is also sensitive to replacement of Na+ and Ca2+ with Li+ and Mg2+ respectively. 
These results show that NCX1 proteins stably expressed in FT293 cells are active and 
are sensitive to Li+ and Mg2+.  
 
Current from endogenous voltage gated ion channels and leak current can contaminate 
currents generated by voltage ramp protocols. To correct for this, Li+ and Mg2+ sensitive 
current, which represents NCX1 only current was calculated by subtracting current 
remaining after Li+ and Mg2+ treatment from the total measured current. Shown in 
figure 6.5 is comparison of corrected current from WT NCX1 and C739A NCX1 
expressing cells. The reversal potential was not significantly different between WT 
NCX1 and C739A NCX1 expressing cells, -28.9 ± 1.7 mV and -35.9 ± 2.9 mV 
respectively, p value = 0.6 (panel A, figure 6.5). Normalising for cell capacitance, there 
was a significant difference in the amplitude of recorded current between WT NCX1 
and C739A NCX1 (panel B, figure 6.5). C739A NCX1 current was significantly 
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decreased at positive voltages, +80, +70 and +60mV compared to WT NCX1. These 
results suggest that inhibition of palmitoylation results in decreased NCX1 outward 
mode exchange current. Calculation of the rectification index (inset in panel B, figure 
6.5) showed that there was no significant difference between WT NCX1 and C739A 
NCX1 expressing cells, suggesting that differences observed may be due to subtle 
differences in expression levels between cells. Expression was normalised wherever 
possible by analysing expression levels between cells by western blotting. 
 
 
Figure 6.5: C739A NCX1 Current Is Decreased Compared To WT NCX1 At Positive 
Voltages. A. Reversal potential between WT NCX1 and C739A NCX1 was not 
statistically different. B. C739A NCX1 current at +80, +70 and +60 mV is significantly 
decreased compared to WT NCX1. Insert shows rectification index for WT and C739A 
NCX1 expressing cells at +80mV normalised to current obtained at -80mV. Statistical 
significance was calculated using the Holm-Sidak method with alpha 5%. WT NCX1 – 
n=6, C739A NCX1 n=5. 
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6.5 Discussion 
 
Palmitoylation has been reported to have a number of different roles in the regulation of 
ion transport (Shipston 2014). Palmitoylation has been described to regulate cell surface 
expression of ion transporters and channels. In addition, palmitoylation has been 
described to regulate activity of ion channels, namely predominantly through altered 
voltage sensitivity, such as Kv1.1 (Gubitosi-Klug et al. 2005), ENaC (Mueller et al. 
2010) and α1BCa2+ (Stephens et al. 2000). Therefore, elucidating the effect of 
palmitoylation on NCX1 will provide insight into how this post-translational 
modification modulates activity. 
 
Membrane Targeting Of NCX1 By Palmitoylation 
 
As mentioned previously, palmitoylation regulates membrane targeting and cell surface 
localisation of a number of ion channels. Using FT293 cell lines stably expressing WT 
NCX1 or its non-palmitoylatable mutant, C739A, the cell surface localisation of NCX1 
was investigated. Cell impermeable reagents were used to label the cell surface proteins 
with biotin, which was exploited to affinity purify cell surface proteins using 
streptavidin. The results revealed that inhibiting palmitoylation either 
pharmacologically or using mutagenesis had no effect on trafficking of NCX1 to the 
cell surface membrane. C739A NCX1, which is non-palmitoylated, is trafficked to the 
cell surface membrane. This is somewhat unsurprising as NCX1 has 10 transmembrane 
domains (Ren & Philipson 2013); therefore it is unlikely that a single lipid modification 
would alter trafficking to the membrane. Indeed, single lipid modifications have been 
described to promote transient membrane association (Shahinian & Silvius 1995; 
Salaun et al. 2010). Evidence regarding palmitoylation of the BK channel, which is a 
multi-pass transmembrane protein, suggests that palmitoylation of multiple residues can 
govern surface membrane localisation (Jeffries et al. 2010). The BK channel is 
palmitoylated on S0-S1 linker domain on 3 cysteine residues (Jeffries et al. 2010), 
which regulates its cell surface expression. Steady state cell surface expression levels 
were reduced by ~55% in non-palmitoylatable BK channels. It appears that in order to 
regulate cell membrane targeting of large multi-pass transmembrane proteins, multiple 
palmitoylated cysteine residues are required.  
 
 
! 174 
Targeting Of NCX1 To Caveolae In Cardiac Muscle 
 
As palmitoylation does not appear to regulate cell surface expression of NCX1, 
influence on NCX1 targeting to lipid rafts was investigated. Few studies have 
determined whether NCX1 localises to caveolar domains and what the functional 
consequences of this localisation are. NCX1 was shown to associate with caveolin-3 in 
bovine cardiac sarcolemmal vesicles (Bossuyt et al. 2002). Additionally, evidence that 
annexin A5 interacts with NCX1 as part of a larger macromolecular complex, which 
includes caveolin-3 localised to caveolae in human ventricular myocytes (Camors et al. 
2006). In contrast, co-immunoprecipitation failed to detect NCX1 and caveolin-3 
interactions from rat ventricular myocardium or co-localisation using immunolabelled 
rat ventricular myocytes (Cavalli et al. 2007). The same study reported a large majority 
of NCX1 present in cardiac myocytes does not localise to caveolae (Cavalli et al. 2007). 
In order to determine whether NCX1 is found in caveolae within cardiac muscle, 
buoyant caveolin-enriched microdomains were prepared from isolated ARVM by 
floatation on a discontinuous sucrose gradient. NCX1 was found in caveolin containing 
fractions isolated from sucrose gradients. Moreover, palmitoylated NCX1 localised to 
caveolae in rat ventricular myocytes. Surprisingly, non-palmitoylated NCX1 was found 
in pooled fractions 4 and 5 fractions from sucrose gradients. These results suggest that 
palmitoylation is not required to target NCX1 to caveolae in cardiac muscle, as non-
palmitoylated NCX1 is also present in buoyant caveolin-enriched fractions. NCX1 
contains five possible caveolin-binding motifs (Bossuyt et al. 2002), therefore 
localisation to caveolae is most likely dependent on the interaction between NCX1 and 
caveolin-3 and not its palmitoylation.  
 
Palmitoylation may not be involved in targeting to cell surface membranes in HEK293 
cells or caveolae in cardiac myocytes, however it may serve as a signal to target NCX1 
to t-tubules. Cardiac t-tubules are branched invaginations of cardiac myocyte 
sarcolemma (figure 6.7). T-tubules are highly involved in initiation of Ca2+ transients 
and many of the proteins involved in Ca2+ cycling appear to be concentrated at the t-
tubule (Brette & Orchard 2003). Indeed, NCX1 has been described to localise to the 
sarcolemmal and t-tubular membrane within cardiac myocytes (Frank et al. 1992). 
Approximately 60% of NCX1 is localised to the t-tubular membrane (Despa et al. 
2003), although other studies have reported higher levels (Z. Yang 2002). However, the 
mechanism by which proteins are targeted to t-tubules is unknown. L-type Ca2+ 
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channels are also targeted to t-tubules, which has in part been described as due to 
subunits which form the channel as well interaction with the scaffolding protein BIN1 
(Shaw & Colecraft 2013). It is proposed that BIN1 may act as a membrane anchor to 
target L-type Ca2+ channels to t-tubules. If a membrane anchor is required to target ion 
channels and transporters to t-tubules, palmitoylation may be involved. However, direct 
measurement of targeting of palmitoylation to specific microdomains within cells has 
not been achieved. If NCX1 exits the Golgi fully palmitoylated as previous data 
suggests, upon reaching the cell surface membrane, NCX1 may then be depalmitoylated 
that may lead to its lateral diffusion to other subdomains.  
 
 
Figure 6.6: T-Tubule Network And Protein Organisation. A. 3D structure of t-tubular 
system in rat ventricular myocyte, reconstructed from a stack of images of dextran-
linked fluorescein fluorescence within t-tubules. Bar = 5µm. B. Schematic 
demonstrating protein distribution between t-tubules and sarcolemmal membrane based 
on immunohistological data. Both modified from (Brette & Orchard 2003). 
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NCX1 Exchange Current 
 
Inhibition of palmitoylation did not affect cell surface localisation of NCX1, nor was 
palmitoylation involved in targeting to caveolae. This suggests that palmitoylation may 
be involved in modulation of NCX1 activity. To address this, the current-voltage (I-V) 
relationship of WT NCX1 and its non-palmitoylated mutant C739A NCX1 was 
determined using whole cell electrophysiology. I-V relationships were determined using 
a voltage ramp protocol from +80mV to -100mV. NCX1 current measured from WT 
NCX1 and C739A NCX1 expressing cells showed sensitivity to Li+ and Mg2+, used to 
inhibit NCX1 current. In addition, a significant difference was observed in NCX1 
current measured at positive potentials. NCX1 current was significantly decreased in 
C739A NCX1 expressing cells at +80mV, +70mV and +60mV compared to WT NCX1. 
NCX1 measured at positive potentials is indicative of outward exchange current. 
Additionally, lack of NCX1 palmitoylation has no effect on the reversal potential at the 
ion concentrations used. These results suggest that palmitoylation has a regulatory role 
in NCX1 current.  
 
A potential reason for the decreased exchange current observed in C739A NCX1 
expressing cells may be due to a change in Ca2+ sensitivity. Experimental solutions 
were designed so NCX1 was not maximally Ca2+ activated (free Ca2+ = 2µM). Ca2+ 
regulates NCX1 through binding to regulatory domains, CBD1 and CBD2 located 
within the intracellular loop domain. Recently, Ca2+ regulation was described to feature 
a dual electrostatic switch mechanism (Hilge et al. 2009). Ca2+-binding increases the 
electrostatic potential at the Ca2+ binding sites and increases the attraction to negatively 
charged areas. As a result, Ca2+ induced changes in electrostatic potential are regarded 
as switches that promote structural rearrangements (Shao et al. 1997). Following a rise 
in cytoplasmic Ca2+, Ca2+ ions bind to CBD1, increasing the electrostatic potential of 
CBD1. This results in CBD1 and CBD2 reorientation and thus a more compact 
conformation is adopted (figure 6.8, B). This initial activation step is termed Ca2+-
dependent activation and is the responsible for the initiation of Na+/Ca2+ exchange 
(Hilgemann, Collins & Matsuoka 1992b). In order to maintain activation and counteract 
Na+-dependent inactivation, CBD2 must also bind Ca2+ ions, thus inducing a change in 
electrostatic potential for CBD2 (figure 6.8, C). Following a decrease in cytoplasmic 
Ca2+ below the CBD1 Ca2+ affinity, this reverses the activation steps and NCX becomes 
inactive (figure 6.8, A). Based on the solutions used in these experiments, it may be the 
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second step (panel B) of Ca2+-dependent activation that is modulated by palmitoylation. 
CBD2 is closer to the palmitoylation site, which may govern the influence of 
palmitoylation to regulate the conformation change in response to Ca2+.  
 
 
Figure 6.7: Hypothetical Dual Electrostatic Switch Mechanism In NCX Regulation. 
A. Inactive, Ca2+-free NCX in an extended conformation. B. Submicromolar Ca2+ 
concentrations induce conformation change in CBD1 via the electrostatic switch. C. 
Binding of Ca2+ to CBD2 results in sustained Na+-Ca2+ exchange and removes Na+-
dependent inactivation. CBD1 is shown in red, CBD2 is shown in green. CLD - catenin-
like domain. Modified from (Hilge et al. 2009).  
 
Palmitoylation of NCX1 may result in a change in the secondary structure. This could 
lead to a change in the Ca2+ sensitivity required for activation, potentially an increase in 
the Ca2+ affinity for CBD1 (Hilge et al. 2009). However, more likely is the ability of 
CBD2 to overcome Na+-dependent inactivation. Introduction of a membrane anchor 
may promote the ability of Ca2+ to bind to CBD2 and induce the second electrostatic 
switch that is required to overcome Na+-dependent inactivation. To address whether it is 
Ca2+ sensitivity that is adversely affected in the absence of palmitoylation, further 
electrophysiological experiments are required. Additionally, whether Na+-dependent 
inactivation is more pronounced in C739A NCX1 required further investigation, which 
is beyond the scope of this thesis. 
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NCX1 has also been described to be regulated by PIP2 (Hilgemann & Ball 1996; 
Yaradanakul et al. 2007; Shen et al. 2007). In excised patches, exogenous application of 
PIP2 results in stimulation of NCX1 current, which inactivates upon removal of Ca2+ or 
increasing cytoplasmic Na+. This is modulated by direct interaction of PIP2 and the XIP 
domain, located within the intracellular loop domain (Matsuoka et al. 1997), which is 
proposed to be at the N-terminal end of the intracellular loop. In addition to modulation 
by PIP2, NCX1 was also demonstrated to be regulated by intracellular acyl CoAs 
(Riedel et al. 2006), as acyl CoA activated outward exchange current. These results 
suggest that anionic lipids regulate NCX1 exchange activity, predominantly the outward 
exchange current. However, the majority of these studies were performed in excised 
patches and applying exogenous PIP2 or acyl CoAs. Further investigation will be 
required to determine whether PIP2 or indeed acyl CoAs are capable of modulating 
exchange current in a physiological setting. It is possible that palmitoylation may 
influence the regulation by anionic lipids. The addition of a lipid anchor towards the C-
terminal end of the intracellular loop may impact protein-protein interactions or 
interactions with mediators. Further work is required to determine whether C739A 
NCX1 would be regulated by PIP2 in the absence of palmitoylation. 
 
Summary 
 
These results suggest that palmitoylation is not involved in membrane trafficking or 
indeed targeting to lipid rafts such as caveolae. Palmitoylation, does however, appear to 
regulate exchange activity of NCX1, predominantly the outward mode. The mechanism 
by which palmitoylation influences regulation by secondary messengers like PIP2, if 
that indeed is the case, remains to be explored. The observed decrease in outward 
NCX1 current in the absence of palmitoylation may point to a change in regulation of 
the exchanger by Ca2+ and Na+. Further experiments are required to tease out the 
mechanism by which palmitoylation regulates NCX1 activity. 
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Chapter 7: NCX1 Palmitoylation In Disease 
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7.1 NCX1 Palmitoylation In Left Ventricular Heart Failure 
 
Contractile abnormalities during the development of left ventricular hypertrophy and 
heart failure are a result of an imbalance between SERCA2a and NCX1. This ultimately 
leads to more Ca2+ removal from the cytosol (via overactive NCX1), resulting in 
decreased Ca2+ being sequestered back into intracellular stores (via reduced SERCA2a 
activity) and ultimately leading to decreased contractility (Pogwizd et al. 1999; Hobai & 
O'Rourke 2000). The role of palmitoylation in cardiovascular disease has not been 
investigated. As NCX1 is often upregulated in heart failure, it was investigated whether 
NCX1 palmitoylation was changed in a model of heart failure. Heart failure was 
induced in adult rats via aortic banding, in which the ascending aorta was constricted 
with a titanium clip. Animals were allowed to recover and monitored by 
echocardiography. Once ejection fraction decreased to below 45%, animals were 
sacrificed and tissue collected. Prior to tissue collection, cardiac function measurements 
were recorded using Millar pressure-conductance catheters, which provide direct 
measurements of LV pressure-volume relationships and is the gold standard method for 
ejection fraction measurements. Compensated hypertrophy, evident at 16-20 weeks, 
progressed to heart failure by approximately 25 weeks. Heart tissue, which was 
normalised by assessing protein concentration, was used in acyl rac to determine 
palmitoylation of specific targets followed by SDS-PAGE gel electrophoresis and 
western blotting. Both sham operated and banded animals were investigated. 
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Figure 7.1: NCX1 Expression and Palmitoylation Are Unchanged In A Rat Model Of 
Heart Failure. A. NCX1 palmitoylation is not affected by heart failure. B. Statistical 
analysis revealed no significant difference between sham and banded animals. n=4-5, 
sham mean 1.215 ± 0.2864, banded mean 0.9123 ± 0.1810. UF – unfractionated, Palm. 
– palmitoylated, S – sham, B – banded. 
 
UF samples in figure 7.1 reveal that NCX1 expression is variable between banded 
hearts, sham 418545 ± 67340 A.U and banded 455282 ± 154744 A.U. Despite 
inconsistencies in NCX1 expression, palmitoylation of NCX1 is consistent between 
sham and banded hearts. Statistical analyses revealed that there is no significant 
difference between NCX1 palmitoylation in sham and banded hearts. These results 
suggest that NCX1 palmitoylation is unaffected by left ventricular heart failure in this 
model. 
 
In addition to NCX1 upregulation, SERCA2a is downregulated in heart failure 
(O'Rourke et al. 1999; Hasenfuss & Schillinger 2004). To validate the heart failure 
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model used in this study, SERCA2a expression was determined. Shown in figure 7.2, 
banded hearts show decreased SERCA2a expression compared to sham hearts (panel A, 
figure 7.2). Statistical analysis revealed that the difference in SERCA2a expression 
observed on western blotting is not significant (panel B, figure 7.2). The results suggest 
that in this model of heart failure, SERCA2a expression does not change. However, post 
hoc power analysis revealed power to be 55.1%, suggesting that this study is 
underpowered to see an effect of banding on SERCA2a expression. 
 
 
 
Figure 7.2: SERCA2a Expression Is Unchanged In Heart Failure. A. SERCA2a 
expression shows a decrease in banded samples on western blots. B. Statistical analysis 
revealed that differences observed on western blots are not significant between sham 
and banded hearts. n=4-5, sham mean 154186 ± 76009, banded mean 74763 ± 34138. 
UF – unfractionated, S – sham, B – banded, A.U – arbitrary units. 
 
An underlying cause of contractile abnormalities in cardiac disease is the balance of 
Ca2+ removal from the cytosol by SERCA2a and NCX1. During development of heart 
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failure, there is a shift towards NCX1, as has been demonstrated by increased activity in 
models of heart failure (Hobai & O'Rourke 2000; Pogwizd et al. 1999). To determine 
whether the ratio between SERCA2a and NCX1 was favouring NCX1, the ratio of 
SERCA2a expression was calculated against NCX1 expression. Shown in figure 7.3, 
the SERCA2a:NCX1 ratio is unchanged in banded animals compared to sham operated 
animals. However, SERCA2a:NCX1 ratio is slightly decreased in banded animals 
compared to sham, suggesting that the ratio is shifting towards NCX1, despite no 
statistical significance. 
 
 
Figure 7.3: SERCA2a:NCX1 Ratio In Heart Failure. Ratio between SERCA2a and 
NCX1 expression in heart failure is unaffected by heart failure. 
 
Changes in caveolin-3 protein expression have been reported in models of heart failure 
(Woodman et al. 2002; Feiner et al. 2011; Ohsawa et al. 2003; Y. I. Lee et al. 2006). 
However, these reports are controversial. In a murine model of heart failure and in 
human failing heart, caveolin-3 was decreased (Feiner et al. 2011). In contrast, 
caveolin-3 knockout mice developed progressive cardiomyopathy (Woodman et al. 
2002). In order to determine whether caveolin-3 expression and palmitoylation was 
affected in this rat model of heart failure, acyl rac samples from sham and banded hearts 
were investigated. In contrast to reports that find differences in caveolin-3 expression 
between failing and non-failing hearts, there was no difference between caveolin-3 
expression between sham and banded hearts detected by western blotting (panel A, 
figure 7.4). Determining palmitoylation of caveolin-3 in sham and banded hearts 
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revealed no significant difference (panel B, figure 7.4). In this model of heart failure, 
caveolin-3 palmitoylation is unchanged. 
 
 
Figure 7.4: Caveolin-3 Expression And Palmitoylation Is Unchanged In Heart 
Failure. A. Caveolin-3 expression is not significantly affected by heart failure. B. 
Palmitoylation of caveolin-3 is comparable between sham and banded hearts. n=4-5, 
sham mean 0.7526 ± 0.04620, banded mean 0.8465 ± 0.07535. UF – unfractionated, 
Palm. – palmitoylated, S – sham, B – banded, Bds – beads. 
 
As caveolin-3 expression and palmitoylation is unchanged in this model, it was used to 
normalise the amount of NCX1 palmitoylation, to establish if NCX1 palmitoylation is 
altered in this model. Additionally, caveolin-3 palmitoylation serves as a control for 
acyl rac, as it is a constitutively palmitoylated protein and should be enriched during the 
assay. Shown in figure 7.5, NCX1 palmitoylation is unchanged following banding, 
compared to sham operated animals. This suggests that in this model, NCX1 
palmitoylation is unchanged following induction of heart failure. 
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Figure 7.5: NCX1 Palmitoylation Is Unchanged In Heart Failure When Normalised 
To Caveolin-3 Palmitoylation. NCX1 palmitoylation is unchanged when expressed 
relative to caveolin-3 palmitoylation.  
 
7.2 NCX1 Palmitoylation During Development Of Left Ventricular Hypertrophy 
 
NCX1 expression has been shown to increase during hypertrophy (Hobai & O'Rourke 
2000; Pogwizd et al. 1999; Hasenfuss et al. 1994) but whether palmitoylation is affected 
has not been investigated. To determine the effect of hypertrophy on NCX1 
palmitoylation, a rodent in vivo model of cardiac hypertrophy was used (Boguslavskyi 
et al. 2014). Myocardial hypertrophy was induced by pressure overload following 
suprarenal aortic constriction (banding) in 6-week old mice. Mice were sacrificed after 
3 days, 2 weeks, 4 weeks and 8 weeks following surgery. Tissue was harvested and 
used in acyl rac to assess changes in protein palmitoylation.  
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Figure 7.6: NCX1 Palmitoylation Does Not Change During Development Of Left 
Ventricular Hypertrophy. A. NCX1 palmitoylation is unchanged 3 days post banding, 
sham mean 1.00 ± 0.22 n=4, banded mean 0.90 ± 0.08 n=4. B. NCX1 palmitoylation 
does not change 2 weeks post banding, sham mean 1.00 ± 0.2 n=5, banded mean 0.96 ± 
0.18 n=6. C. 4 weeks of banding had no effect on NCX1 palmitoylation, sham mean 
1.00 ± 0.33 n=3, banded mean 1.13 ± 0.16 n=6. D. 8 weeks of banding had no effect on 
NCX1 palmitoylation, sham mean 1.00 ± 0.22 n=6, banded mean 0.70 ± 0.15 n=6. UF 
– unfractionated, Palm. – palmitoylated, S – sham, B – banded. 
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Figure 7.6 shows a timecourse of NCX1 palmitoylation following banding in mice. 
NCX1 palmitoylation was unchanged at any of the timepoints investigated (figure 7.6). 
Statistical analysis revealed that there is no significant change in NCX1 palmitoylation 
between sham and banded animals at any timepoint. These results suggest that in the 
samples analysed, there is no significant change in NCX1 palmitoylation in this model 
of cardiac hypertrophy. 
 
7.3 Changes In Caveolin-3 And SERCA2a During Development Of Left 
Ventricular Hypertrophy 
 
As previously discussed, changes in caveolin-3 expression have been reported in 
various models of cardiovascular disease. In order to determine whether caveolin-3 
palmitoylation was changed in hypertrophy, samples used in NCX1 palmitoylation 
analysis were used to assess changes in caveolin-3 palmitoylation between sham and 
banded animals. Additionally, caveolin-3 palmitoylation can determine how efficiently 
acyl rac captured palmitoylated proteins and can be used to normalise relative 
palmitoylation of other targets investigated. 
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Figure 7.7: Caveolin-3 Expression And Palmitoylation Does Not Change During 
Development Of Hypertrophy. A. Caveolin-3 expression or palmitoylation does not 
change 3 days post banding. B. 2 weeks post banding had no effect on caveolin-3 
palmitoylation. C. 4 weeks post banding had no effect on caveolin-3 palmitoylation. D. 
8 weeks post banding does not change caveolin-3 palmitoylation. UF – unfractionated, 
Palm. – palmitoylated, S – sham, B – banded. Graphs represent mean data ± sem. 
 
Shown in figure 7.7, caveolin-3 expression and palmitoylation following banding at 4 
time points. At all timepoints investigated, caveolin-3 expression and palmitoylation is 
unchanged during left ventricular hypertrophy development. Statistical analysis of the 
mean data revealed that palmitoylation of caveolin-3 does not change between sham 
and banded samples. Based on these results, caveolin-3 palmitoylation does not 
significantly change in response to cardiac hypertrophy. 
 
As described previously, normalising palmitoylation of targets to caveolin-3 can serve 
as an additional control to account for variability in acyl rac to capture palmitoylated 
proteins. Shown in figure 7.8 is mean NCX1 palmitoylation data expressed relative to 
palmitoylated caveolin-3. NCX1 palmitoylation is unchanged at 3 days; 2 weeks and 8 
weeks post surgery. Surprisingly, expressing NCX1 palmitoylation relative to caveolin-
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3 palmitoylation revealed a significant increase in NCX1 palmitoylation at 4 weeks. 
This indicates that the acyl rac was too variable at this time point to determine an effect 
of hypertrophy development on NCX1 palmitoylation. Normalising to caveolin-3 
palmitoylation accounts for the variability and allows effects of hypertrophy 
development to be observed. 
 
 
Figure 7.8: NCX1 Palmitoylation Is Significantly Increased At 4 Weeks Post Banding 
Relative To Caveolin-3 Palmitoylation. A. NCX1 palmitoylation is unchanged at 3 days 
post banding compared to sham operated animals when expressed relative to caveolin-
3 palmitoylation. B. NCX1 palmitoylation is unchanged at 2 weeks post banding 
relative to caveolin-3 palmitoylation. C. NCX1 palmitoylation is significantly increased 
at 4 weeks post banding relative to caveolin-3 palmitoylation. Sham mean 1.00 ± 0.30, 
banded mean, 2.55 ± 0.32. D. NCX1 palmitoylation is unchanged at 8 weeks post 
banding relative to caveolin-3 palmitoylation. 
 
Downregulation of SERCA2a is associated with cardiac dysfunction (O'Rourke et al. 
1999; Hasenfuss & Schillinger 2004). To determine whether SERCA2a expression was 
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downregulated in this model, heart samples from a timecourse of hypertrophy 
development were used to analyse expression. Shown in figure 7.9 is SERCA2a 
expression following banding for 3 days, 2 weeks, 4 weeks or 8 weeks. At 3 days 
following banding, SERCA2a expression is decreased slightly in banded heart, however 
this is not significantly different (panel A, figure 7.9). Following banding for 2 weeks, 
SERCA2a is significantly decreased in banded hearts compared to sham (panel B, 
figure 7.9). In some hearts examined, SERCA2a is virtually undetectable by western 
blotting. At 4 weeks post banding, the initial decrease in SERCA2a observed at 2 weeks 
is lost, with no significant difference in SERCA2a expression between sham and 
banded hearts (panel C, figure 7.9). By 8 weeks post banding, there is no significant 
difference in SERCA2a expression between sham and banded hearts, despite SERCA2a 
expression appearing decreased in some hearts analysed (panel D, figure 7.9). Taken 
together, these results suggest that SERCA2a is downregulated as early as 2 weeks 
following pressure overload. However this downregulation does not appear to be 
maintained during the development of left ventricular hypertrophy. 
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Figure 7.9: SERCA2a Is Downregulated At 2 Weeks Post Banding In Hypertrophy. 
A. SERCA2a is unchanged following 3 days post banding, sham mean 251561 ± 27348 
n=4, banded mean 204871 ± 17447 n=4. B. By 2 weeks post banding, SERCA2a is 
significantly decreased, sham mean 374069 ± 33373 n=5, banded mean 225761 ± 
34177 n=6, p<0.05. C. 4 weeks post banding, SERCA2a expression is unchanged 
following banding, sham mean 143048 ± 41045 n=3, banded mean 148778 ± 20301 
n=5. D. Following 8 weeks post banding, SERCA2a expression does not change, sham 
mean 245058 ± 10688 n=6, banded mean 183486 ± 69983 n=6. 
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As discussed previously, the balance of Ca2+ extrusion from the cytosol during diastole 
between SERCA2a and NCX1 is altered during cardiac hypertrophy (Boguslavskyi et 
al. 2014). The balance shifts towards NCX1, resulting in decreased Ca2+ within the 
sarcoplasmic reticulum, leading to decreased contraction. Using the data presented 
previously, the ratio of SERCA2a to NCX1 was determined. Shown in panel A of figure 
7.10, NCX1 expression gradually increased following banding. However this increase 
was not significant compared to sham operated animals. SERCA2a expression 
decreased significantly at 2 weeks in banded animals compared to sham operated 
animals (panel B, figure 7.10). In addition, the ratio of SERCA2a to NCX1 significantly 
decreased as early as 3 days compared to sham operated animals, and decreased further 
at 2 weeks (panel C, figure 7.10). This effect was then lost by 8 weeks. This suggests 
that in this model, the ratio of SERCA to NCX1 is shifting to favour Ca2+ extrusion by 
NCX1. 
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Figure 7.10: SERCA:NCX1 Ratio Significantly Decreased By 3 Days During 
Development Of Left Ventricular Hypertrophy. A. NCX1 expression is not significantly 
increased during development of left ventricular hypertrophy. B. SERCA2a expression 
is significantly decreased at 2 weeks following banding. C. SERCA:NCX ratio is 
significantly decreased by 3 days and continues to decline by 2 weeks. This effect is lost 
by 4 weeks. 
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7.4 Discussion 
 
NCX1 has a well-documented role in heart failure. NCX1 is upregulated at the mRNA 
and protein level in heart failure (Menick et al. 2007). Increase NCX1 activity is also 
associated with animal models of heart failure (Pogwizd et al. 1999; O'Rourke et al. 
1999). Despite evidence for increased expression and activity, whether regulation of the 
exchanger is affected is relatively unexplored. One group has demonstrated an increase 
in NCX1 phosphorylation in failing hearts (Wei 2003), however whether NCX1 is 
directly phosphorylated is controversial. To date, there is no published data regarding 
NCX1 palmitoylation in models of heart failure. In order to determine NCX1 
palmitoylation altered during cardiac dysfunction, a rat model of heart failure and a 
murine model of left ventricular hypertrophy were used. 
 
Left Ventricular Heart Failure 
 
The first model was established in Dr Sarah Calaghan’s group at University of Leeds. 
This is a rat model of left ventricular heart failure, induced by constricting the ascending 
aorta. Rats were monitored with echocardiography until ejection fraction dropped below 
45%. Prior to tissue collection, LV-pressure volume relationships were measured using 
Millar pressure-conductance catheters. Despite echocardiography indicating that rats 
were in established heart failure, pressure-conductance catheters provide more sensitive 
measures of cardiac function. As a result, some rats that echocardiography had indicated 
were in heart failure, were not, and as such were excluded from analysis. This resulted 
in lower n numbers for comparison between groups. NCX1 palmitoylation was 
unchanged in this model. In addition, NCX1 expression is not upregulated as is 
described in many other models (Pogwizd et al. 1999; Hobai & O'Rourke 2000; Menick 
et al. 2007). This indicates that the model needs developed further to recapitulate all the 
parameters associated with heart failure. There may also be an issue with protein 
degradation following harvest, which would impact any results drawn from these 
samples. Therefore, NCX1 palmitoylation may be affected, however this experiment 
would need to be repeated following establishment of the model and with fresh tissue.  
 
In addition to NCX1 palmitoylation, SERCA2a expression was examined. As 
previously discussed, decrease in SERCA2a expression is associated with heart failure 
(Hasenfuss et al. 1994; Hobai & O'Rourke 2001). SERCA2a expression was 
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investigated in UF lysates from acyl rac. Surprisingly, SERCA2a expression is not 
significantly different between sham and banded hearts. Mean data (panel B, figure 7.2) 
indicates a decrease in SERCA2a expression, as well as decreases in SERCA2a 
expression in banded samples detected by western blotting. In addition, the ratio of 
SERCA2a to NCX1 was unchanged in banded animals compared to sham operated, 
suggesting that in this model, there is not a shift to favour Ca2+ extrusion via NCX1. 
The number of animals subjected to this procedure is small, with sham animals at n=4 
and banded animals at n=5. To increase statistical power, increased sample number 
would be required. However, this is a labour-intensive and expensive experiment, with 
some rats taking over 25 weeks to progress to established heart failure following aortic 
banding. 
 
Caveolin-3 is a scaffolding protein, integral to the formation of caveolae in cardiac 
myocytes. Mice lacking caveolin-3 develop progressive cardiomyopathy (Woodman et 
al. 2002). This phenotype is characterised by myocytes hypertrophy. Therefore, the 
authors argue that loss of caveolin-3 expression and cardiac myocyte caveolae is 
sufficient to induce activation of a hypertrophic program in cardiac myocytes 
(Woodman et al. 2002). In agreement with this, data from an overexpression model of 
caveolin-3 indicates that caveolin-3 overexpression confers protection from cardiac 
ischemia, similar to ischemic preconditioning (Tsutsumi et al. 2008). Using 
spontaneous hypertensive rat (SHR) model, Lee and colleagues demonstrated a decrease 
in caveolin-3 in non-exercised SHR compared to Wistar-Kyoto (WK) rats, which was 
increased upon exercising SHR (Y. I. Lee et al. 2006). These studies suggest that 
caveolin-3 is downregulated in heart disease, and when overexpressed, conveys 
protection against ischemic insults. In contrast, overexpression of a mutant caveolin-3 
associated with autosomal dominant limb-girdle muscular dystrophy 1C (LGMD1C) 
results in hypertrophic cardiomyopathy and enhanced contractility (Ohsawa et al. 2003). 
This hypertrophic cardiomyopathy is associated with increased endothelial nitric oxide 
synthase activity. Feiner and colleagues show that left ventricular dysfunction in both 
murine models of heart failure and failing human heart is associated with a decrease in 
the expression of caveolin-3 (Feiner et al. 2011).  
 
In contrast, dogs with pacing induced heart failure demonstrated increased levels of 
caveolin-3 (Hare et al. 2000). In agreement with these results, failing human heart 
obtained during placement of a left ventricular assist device showed increase caveolin-3 
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mRNA when compared to non-failing heart, however caveolin-3 mRNA levels increase 
further following left ventricular unloading (Uray et al. 2003). Although the role of 
caveolin-3 in heart failure is still under investigation, the role of post-translational 
modifications of caveolin-3 in heart failure is unexplored. Examining palmitoylation of 
caveolin-3 in a model of left ventricular heart failure revealed no significant difference 
in palmitoylation between sham operated and banded hearts. Caveolin-3 expression is 
consistent between sham and banded hearts in this model, resulting in comparable 
palmitoylation between each group. Therefore, in this model of heart failure, caveolin-3 
is unchanged, which directly contrasts previous reports of increased and decreased 
expression. If caveolin-3 expression was increased, an increase in palmitoylation may 
be expected. However, the role of DHHCs in heart failure is unknown, and differential 
regulation of palmitoylation may determine degree of palmitoylation for different 
targets.  
 
Taken together, these results suggest that this particular model needs to be further 
developed to establish basic changes in SERCA2a expression, which is consistent with 
heart failure. Increasing statistical power with more biological and technical replicates 
will also enable detection of changes in expression and palmitoylation of target proteins 
associated with heart failure. 
 
Cardiac Hypertrophy 
 
 To further determine the role of palmitoylation in heart disease, palmitoylation was 
assessed in hearts from a mouse model of left ventricular hypertrophy. Hypertrophy was 
induced in these animals by pressure overload, achieved through suprarenal aortic 
constriction (banding) in wild-type C57BL/6J mice (Boguslavskyi et al. 2014). 
Reproducibility of aortic constriction was assessed post-mortem by measurement of 
residual luminal area (RLA) and constrictions outwith predefined limits were excluded 
(see supplementary material for (Boguslavskyi et al. 2014) for further explanation). 
Following surgery, mice were allowed to recover for 3 days, 2 weeks, 4 weeks and 8 
weeks, after which heart tissue was collected, homogenised and snap frozen. 
Palmitoylation of NCX1 and Caveolin-3 was assessed at all time points. No significant 
differences in palmitoylation between sham and banded hearts were observed for either 
NCX1 or caveolin-3. Normalising NCX1 palmitoylation to caveolin-3 palmitoylation at 
4 weeks results in a significant increase in NCX1 palmitoylation in banded animals 
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compared to sham operated animals. This suggests that palmitoylation may be an 
important post-translational modification in the regulation of NCX1 during 
development of hypertrophy. The increase in NCX1 palmitoylation at 4 weeks may also 
indicate a decrease in thioesterase activity. However, activity of thioesterase has not 
been measured from this model, nor the level of thioesterase present. Contrastingly, 
NCX1 palmitoylation does appear to be decreasing by 8 weeks, however this change 
was not statistically significant. Caveolin-3 palmitoylation is consistently unchanged at 
all time points investigated. In addition, a significant decrease in SERCA2a expression 
was observed at 2 weeks post-banding. However this effect was lost at 4 weeks. 
However, only 3 sham hearts were available for 4 week timepoint, which may explain 
the variability in SERCA2a expression observed. By 8 weeks, SERCA2a appears to be 
decreased, however this did not reach statistical significance. Significant decreases in 
SERCA2a expression was observed in this model previously (Boguslavskyi et al. 2014), 
which validates the model. The ratio of SERCA2a to NCX1 is significantly decreased in 
banded animals compared to sham operated animals at 3 days and 2 weeks post surgery. 
This suggests that changes in the balance between SERCA2a and NCX1 to remove Ca2+ 
from the cytosol are altered as early as 3 days during development of hypertrophy. The 
samples used here have undergone freeze-thaw cycles, which may explain the lack of 
significant decreases in SERCA2a expression at other timepoints. The protein may have 
degraded through proteolysis. Therefore, to elucidate a role for palmitoylation in this 
model, acyl rac should be performed on freshly isolated tissue. 
 
Summary 
 
These results suggest that palmitoylation of NCX1 does not change in two clinically 
relevant models of chronic disease. A more in-depth study of NCX1 palmitoylation in 
heart disease is required. Perhaps measurement of NCX1 palmitoylation in failing 
human heart may give indication of the role of palmitoylation in heart failure. In 
agreement with data from left ventricular heart failure, caveolin-3 palmitoylation is 
unchanged in hypertrophy. This suggests that in these particular models, caveolin-3 
palmitoylation does not contribute to cardiac remodelling. Quantitative proteomic 
analysis of palmitoylated proteins isolated from control and failing hearts could provide 
insight into whether palmitoylation does change. Given the role of palmitoylation in 
membrane targeting of proteins, changes in palmitoylation following cardiac 
remodelling may occur. However, as palmitoylation regulates protein function in a 
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variety of different ways depending on substrate, changes in palmitoylation may vary 
from target to target. This would make it difficult to make a blanket hypothesis that 
palmitoylation is beneficial or detrimental to heart failure progression. 
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Chapter 8: Concluding Remarks And Future 
Work 
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8 Concluding Remarks 
 
The aim of this work was to analyse the biochemical and functional effect of 
palmitoylation on the cardiac Na+/Ca2+ exchanger (NCX1) using mass spectrometry, 
affinity chromatography, site-directed mutagenesis and whole cell electrophysiology. 
 
Key Findings 
 
This work has identified that NCX1.1 is palmitoylated in cardiac muscle. In addition, 
the site of palmitoylation was identified and was shown to be within the large 
intracellular loop of NCX1. This domain has been documented to be involved in the 
regulation of NCX1 (Matsuoka & Hilgemann 1992; Hilgemann, Collins & Matsuoka 
1992b; Hilgemann, Matsuoka, Nagel & Collins 1992d). Co-immunoprecipitation of the 
intracellular loop domain of NCX fused to YFP with DHHCs identified protein-protein 
interactions with DHHC5, DHHC9, DHHC12 and DHHC18. Overexpression of 
catalytically inactive DHHC5, DHHC9, DHHC12 and DHHC18 revealed that DHHC9 
is the major protein acyl transferase that palmitoylates NCX1. DHHC9 is predominantly 
expressed in the Golgi apparatus (Ohno et al. 2006), suggesting that NCX1 
palmitoylation occurs within the secretory pathway. Finally, genetic ablation of NCX1 
palmitoylation results in decreased outward current, indicated by I-V relationship 
analysis using whole-cell electrophysiology.  
 
Palmitoylation Site Conservation In Na+-Ca2+ Family 
 
NCX1 is a member of the Ca2+-cation exchanger superfamily, characterised by presence 
of α-repeats in hydrophobic domains separated by a hydrophilic loop (Philipson & 
Nicoll 2000). The Na+-Ca2+ exchanger family shares a large amount of sequence 
homology (figure 8.1), particularly in the transmembrane domains. In addition to the 
Na+-Ca2+ exchanger family, another family also part of the superfamily is Na+-Ca2+-K+ 
exchangers. These exchangers share homology within their transmembrane domains 
and also contain α-repeats (Philipson & Nicoll 2000), however there is little sequence 
similarity between NCX and NCKX exchanger families within their N-terminal and 
cytoplasmic loop domains. Alignment of NCX1, NCX2, NCX3 and NCKX1 reveals 
that the palmitoylation site is conserved in NCX family members (figure 8.1, red box), 
but not other Ca2+-cation family members. 
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Additionally, an NCX1 orthologue from Drosophila Melanogaster, Calx was also 
aligned with NCX and NCKX family members. NCX proteins expressed in Drosophila 
Melanogaster and higher organisms show conservation of the palmitoylated cysteine 
residue (figure 8.1, red box), as C.elegans NCX1 and NCX2 isoforms and Arabidopsis 
thaliana do not have this cysteine residue. The conservation of the cysteine suggests 
that palmitoylation is an important post-translational modification in the regulation of 
NCX family members. Previous data presented in this thesis (Chapter 3 results) 
revealed that the palmitoylated cysteine is conserved within splice variants of NCX1, 
which are also palmitoylated. Functional analysis of NCX1, NCX2 and NCX3 did not 
reveal major differences (Linck et al. 1998). NCX1 is regulated by Ca2+ (Hilgemann, 
Collins & Matsuoka 1992b), increases in intracellular Ca2+ results in activation of 
NCX1. Calx shares 49% amino acid homology with NCX1. In addition, Calx show 
similar Na+-dependent inactivation, current-voltage relationships and regulation by the 
peptide XIP (Hryshko et al. 1996) and like NCX1, Calx is regulated by Ca2+. In contrast 
to NCX proteins, cytoplasmic Ca2+ in the micromolar range inhibits Calx. Chimeric 
transfer of CBD1 from NCX1 to Calx results in Ca2+ stimulation of Calx (Dyck et al. 
1998). It is possible that the conserved palmitoylation site of NCX and Calx may play a 
role in Ca2+ regulation as NCKX proteins do not possess this conserved palmitoylation 
residue (figure 8.1). Palmitoylation may influence the electrostatic mechanism that 
regulates Ca2+ binding to CBDs within the intracellular loop domain as discussed 
previously. Whether palmitoylation influences Ca2+ regulation of NCX1 remains to be 
determined experimentally. 
 
TMD Tilting Of NCX1 
 
The crystal structure of NCX_Mj, a prokaryotic NCX1 homolog, revealed that TMD6 is 
significantly longer than other TMDs within NCX1 (Liao et al. 2012). As a result, this 
TMD is modelled to be at a 45° angle to the membrane. TMD6 is proposed to move 
significantly during the conformation change from outward-facing to inward-face 
conformations (figure 8.2). In the outward-facing conformation, TMD6 is parallel to the 
rest of the molecule, allowing access to the ion binding sites. However in the inward-
facing conformation, TMD6 moves to occlude the ion binding sites on the extracellular 
side (Liao et al. 2012). Movements of TMD6 is hinged at bends between TMD2A and 
2B and TMD7A and TMD7B and may involve sliding across a central flat hydrophobic 
patch that is centred around conserved proline residues from the α-repeats (Liao et al. 
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2012). C739 is located upstream of TMD6, within the large intracellular loop. It is 
possible that the addition of palmitate at this position would serve as an additional 
membrane anchor, and influence titling of the transmembrane domain (Nyholm et al. 
2007; Shipston 2014). Such an addition at this site would also confer conformational 
constraints on the protein. Indeed, this precise mechanism has been proposed to control 
ER exit of the regulatory β4 subunits of BK channels (Chen et al. 2013). 
Depalmitoylation of a cysteine residue located near TMD2 may result in hydrophobic 
mismatch at the ER, resulting in reduced ER exit and may also yield a conformation 
that is not favourable for interaction with BK channel α subunits and thus decreasing 
BK channel α subunits cell surface expression (Chen et al. 2013). It has been proposed 
that palmitoylation may result in structural rearrangement. Evidence from the BK 
channel also supports this hypothesis. The large C-terminal domain of the BK channel 
is cytosolic, which is palmitoylated (Tian et al. 2008). Palmitoylation of this domain 
results in association with the membrane, however in the absence of palmitoylation, this 
domain remains cytosolic. Palmitoylation in this region is thought to cause a structural 
rearrangement of the channel, impacting its activity. Upstream of the palmitoylated 
cysteine residues is a polybasic domain. Mutation of this domain results in inhibition of 
palmitoylation and a right-shift in channel half-maximal voltage for activation (Jeffries 
et al. 2012). PKA-dependent phosphorylation of a single serine residue within the 
polybasic region results in channel inhibition and reduced palmitoylation. This data 
suggests that the polybasic region in control palmitoylation of the cytosolic domain and 
that phosphorylation of this region acts as an electrostatic switch (Jeffries et al. 2012). 
Therefore it appears that palmitoylation can alter conformation of ion channels, thus 
resulting in regulation of their activity.  
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Figure 8.2: TMD6 Moves Considerably During NCX1 Transport. A. Surface rendered 
structure of NCX1 in the outward-facing conformation. TMD6 is parallel to the ion 
permeation pathway, whereas TMD1 is tilted at a 45° angle. B. Surface rendered 
structure of NCX1 in the inward-facing conformation. TMD6 is now at a 45° angle to 
the ion permeation pathway, occluding the outward-facing binding sites. Modified from 
(Liao et al. 2012). 
 
Although the recent crystal structure of NCX_Mj provides structural insight into TMDs 
of NCX, insight into the regulatory intracellular loop domain is lacking as NCX_Mj 
does not contain this domain. This suggests that NCX1 and NCX_Mj must be regulated 
through different mechanisms. Recently, evidence that NCX_Mj transports Ca2+ slower 
than its mammalian counterpart was published (Almagor et al. 2014). The authors 
suggest that the large intracellular loop controls the intrinsic equilibrium and rates of 
bidirectional Ca2+ in NCX proteins. NCX_Mj does not have a regulatory domain like 
the mammalian NCX proteins, meaning that 6 of the cysteine residues predicted to lie 
within this domain are not represented in this structural homolog. It may be that 
palmitoylation is involved in stabilising the outward-facing (extracellular) access, given 
that Ca2+ movement from the cytosol to the extracellular side is faster than the opposite 
direction (Almagor et al. 2014) in NCX_Mj chimeras possessing the intracellular loop 
domain. During the exchange cycle, NCX1 undergoes significant conformation changes 
(Liao et al. 2012). TMD6 moves significantly during this cycle. Inhibition of 
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palmitoylation may result in this domain being less anchored and more flexible. This 
may result in less ordered movements of TMD6 during the exchange cycle, potentially 
impacting the efficiency of this cycle.  
  
Thioesterase Activity Mediating NCX1 Palmitoylation 
 
Overexpression of DHHCs results in decreased NCX1 palmitoylation. This suggests 
that in the presence of increased DHHC expression, depalmitoylation of NCX1 is 
increased. Protein depalmitoylation is predominantly mediated by acyl thioesterases, 
which belong to the serine hydrolase superfamily (Zeidman et al. 2009; Bachovchin et 
al. 2010). However the thioesterase responsible for the depalmitoylation of NCX1 has 
not been identified to date. The extent to which serine hydrolases exhibit thioesterase 
activity towards different ion channels and transporters is unknown (Shipston 2014). 
Control of depalmitoylation of proteins is largely affected by a family of cytosolic 
thioesterases, which includes APT1 (Yeh et al. 1999; Devedjiev et al. 2000) and APT2 
(Tomatis et al. 2010).  APT1 and APT2 do show selectivity for different palmitoylated 
peptides (Tomatis et al. 2010). The depalmitoylation of the S0-S1 loop of BK channels 
is mediated by APT1 but not APT2 (Tian et al. 2012). Depalmitoylation of BK channels 
results in Golgi retention, which may indicate that reversible palmitoylation provides a 
checkpoint to regulate exit from the Golgi, thus controlling cell surface expression (Tian 
et al. 2012). However, mechanisms that determine whether proteins are depalmitoylated 
remain to be determined. Regulation of thioesterases themselves by palmitoylation is 
important for their association with membranes (Kong et al. 2013; Vartak et al. 2014). 
Additionally, APTs have been described to regulate the spatial organisation of 
palmitoylated membrane proteins (Vartak et al. 2014). Depalmitoylated APTs were 
found to be soluble and depalmitoylated substrates on all membranes. Palmitoylated 
APTs localise to the Golgi, which serves as a homeostatic regulatory mechanism that 
ensures partitioning of APT substrates between the plasma membrane and the Golgi 
(Vartak et al. 2014). The depalmitoylating activity of APTs serves as a release factor for 
mislocalised palmitoylated proteins. It is possible that APTs regulate the spatial 
organisation of NCX1 within the cell surface membrane. Furthermore, lysosomal 
degradation of protein often results in their depalmitoylation mediated by PPT1 
(Verkruyse & Hofmann 1996). In the absence of PPT1, total expression and surface 
membrane abundance of GluA4 AMPA receptor subunit was decreased, but no effect 
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was observed on GluA1 or GluA2 AMPA subunits or NMDA receptor subunits (Finn et 
al. 2011). For the majority of ion transporters and channels, the wherebouts 
depalmitoylation occurs within the cell and the time course of palmitoylation-
depalmitoylation cycles is unknown (Shipston 2014). Whether depalmitoylation of 
NCX1 plays a role in the regulation of its activity or spatial organisation remains to be 
determined. 
 
Site-Recognition By DHHCs 
 
Overexpression of catalytically inactive DHHCs (Mitchell et al. 2006) revealed that 
DHHC9 is responsible for palmitoylation of NCX1 (Chapter 5 results). To date, no 
consensus sequence has been identified for palmitoylation (Salaun et al. 2010). 
Palmitoylation prediction algorithms are being constantly developed to aid in the 
identification of palmitoylation sites. Using PalmPred (Kumari et al. 2014), a recently 
developed palmitoylation prediction algorithm, palmitoylation sites of specific proteins 
can be identified. Indeed, PalmPred correctly identifies C739 as the NCX1 
palmitoylation site. Examining other known DHHC9 substrates can generate insight 
into potential sequence features that may be involved in directing the DHHC to the 
appropriate site. As a result of clustal alignment, it was revealed that DHHC9 substrates 
have a proline residue at the -2 position relative to the target cysteine residue (Chapter 
5, discussion). Performing in silico mutation of the proline residue results in loss of the 
palmitoylation predicition by PalmPred (Figure 8.3). Panel A of figure 8.3 shows WT 
human NCX1. The prediction algorithm correctly predicts Cys739 (note: analysis run 
without removal of signal peptide, so numbering is +35 to account for signal peptide) as 
palmitoylated. However, shown in panel B of figure 8.3, changing the proline at the – 2 
position results in loss of the palmitoylation prediction of Cys739. This suggests that the 
sequence surrounding the target cysteine may be important for its palmitoylation. In 
addition, the proline residue at the -2 position is highly conserved among Na+-Ca2+ 
exchanger family members, even in NCKX1, which does not possess the palmitoylation 
site (figure 8.1). This suggests that this proline may not only be important for 
palmitoylation but for overall function of these proteins. DHHC9 substrates share a 
large amount of homology with NCX1 upstream of the palmitoylation site, suggesting 
that areas outwith this region may confer substrate specificity for DHHC9.  
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Figure 8.3: In Silico Mutagenesis Of Proline At Position 737 (771) to Alanine Results 
In Loss Of Palmitoylation Prediction. A. PalmPred predicts Cys739 is palmitoylated in 
WT NCX1. B. In silico mutagenesis reveals that proline at position 737 may be 
important for palmitoylation of NCX1, as palmitoylation prediction is lost when 
mutated to alanine. 
 
NCX1 Palmitoylation And Cardiovascular Disease 
 
As previously discussed, during development of cardiac dysfunction as a result of heart 
failure or cardiac hypertrophy, the balance of Ca2+ extrusion from the cytosol during 
diastole shifts to favour extrusion by NCX1. This can also be accompanied by an 
increase in NCX1 expression. As NCX1 is electrogenic, increased outward mode 
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exchange during diastole can result in arrhythmogenic delayed afterdepolarisations 
(Voigt et al. 2012; Venetucci et al. 2007). In ischemia reperfusion, outward mode 
exchange is responsible for Ca2+ overload and ultimately necrotic cell death (Ohtsuka et 
al. 2004). Shown in this thesis, outward mode of NCX1 is decreased in the absence of 
palmitoylation. As palmitoylation of NCX1 most likely occurs in the Golgi, changes 
within NCX1 palmitoylation would be expected to occur over a longer time scale, such 
as in the case of hypertrophic remodelling. However, as Ca2+ overload is caused by 
NCX1 outward mode, targeting this mode of NCX1 could be a potential therapeutic 
target for ischemia reperfusion. Altering NCX1 exchange has been demonstrated 
previously to be associated with less ischemia damage (Sipido et al. 2002; Hobai et al. 
2004). As outward mode appears to be enhanced by palmitoylation, selectively targeting 
NCX1 palmitoylation may serve as a potentially promising therapeutic target for 
ischemia reperfusion. NCX1 palmitoylation may increase during ischemia reperfusion, 
which may lead to a stabilisation of the outward mode, thus leading to greater Ca2+ 
influx into the cell and perpetuating Ca2+ overload and eventually cell death. However, 
further work is required to determine the role of NCX1 palmitoylation in ischemia 
reperfusion, and indeed cardiac dysfunction in general.  
 
Conclusions And Future Work 
 
The work presented in this thesis demonstrated that palmitoylation is important in the 
regulation of NCX1 activity. Although NCX1 shows a decrease in outward current of 
C739A NCX1 compared to WT NCX1, whether Ca2+ sensitivity or Na+-dependent 
inactivation is affected is unknown. Further electrophysiological studies are required to 
determine whether non-palmitoylatable NCX1 has altered Ca2+ sensitivity. Using 
excised patch or pipette-perfusion techniques would allow for a throughout assessment 
of Ca2+ sensitivity (Hilgemann, Collins & Matsuoka 1992b). Using this technique 
would also allow investigation of the effect of palmitoylation on Na+-dependent 
inactivation modulation by cytoplasmic Ca2+. Furthermore, PIP2 has previously been 
reported to regulate NCX1 activity (Hilgemann 2007). NCX1 has previously been 
described to be within close proximity of PIP2 within the membrane (Ottolia et al. 
2006). Palmitoylation may influence the interaction between PIP2 or subcellular 
localisation of NCX1 relative to PIP2.  
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Although palmitoylation did not control membrane localisation or caveolar localisation 
of NCX1, the mechanism targeting of proteins to t-tubular domains present within 
cardiac myocytes is unknown. Direct imaging of palmitoylated NCX1 would be 
required to determine whether this influences its localisation to t-tubular membranes. 
Furthermore, viral infection of cardiac myocytes with C739A NCX1 or a knock-in 
mouse possessing the same mutation may also provide insight into membrane targeting 
of NCX1. Generation of a cardiac specific NCX1 knockout resulted only a mild 
phenotype (Henderson et al. 2004). Mice show decreased contractility by 7.5 weeks of 
age. However no adaptation of the myocardium was detected. In addition, L-type Ca2+ 
channel current is decreased by 50%, with the number of channels unchanged 
(Henderson et al. 2004). Cardiac-specific ablation of NCX1 confers protection against 
ischemia/reperfusion injury (Imahashi et al. 2005). Therefore, it appears that NCX1 
contributes significantly to ischemic injury during reperfusion. Generation of a knock-in 
C739A NCX1 expressing mouse would provide insight into whether palmitoylation has 
an observable effect of NCX1 function within cardiac muscle or contributes to NCX-
mediated pathologies in other tissues. NCX1 palmitoylation stoichiometry is higher in 
myocytes than in HEK293 cells (chapter 4). Reducing palmitoylation from 60% to 0% 
rather than 30% to 0% would likely result in a greater observable difference in NCX1 
activity in the absence of palmitoylation compared to wild-type. 
 
Finally, as discussed previously, regions outwith the target cysteine residues of 
substrates may be important for directing DHHCs. Extensive mutational analysis of 
regions within the intracellular loop region that are conserved between NCX1 and other 
known DHHC9 substrates would elucidate which regions are important for 
DHHC9:NCX1 interactions. Additionally, mutational analysis of DHHC9 could also 
provide insight into functional domains important for substrate interaction. Recently, a 
similar study was conducted for DHHC5 and its interaction with phospholemman 
(Howie et al. 2014). It is clear more work is required to build upon the results presented 
here on the regulation of NCX1 by palmitoylation. !
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